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Resume 
RNA-binding proteins of the IMP family (IGF2 mRNA-binding proteins 1-3) are conserved 
oncofetal proteins, regulating transport, stability and decay of multiple mRNAs. IMPs are 
involved in embryonic development and tumorigenesis by controlling cell proliferation, 
differentiation, migration, polarization and many other important aspects of cell function. 
IMP-3 is hardly detectable in normal adult tissues, but is overexpressed in many cancers, 
where it has been reported as a marker of tumor aggressiveness, rapid growth, and bad 
prognosis for patients. In our research we utilized a rhabdomyosarcoma (RMS) cell line RD, 
where IMPs were first described as IGF-2 mRNA regulating proteins. We aimed to elucidate 
the mechanism by which IMP3 regulates the expression of cyclins D1 and D3, thereby 
contributing to the understanding of oncogenic processes in RMS.	  
In this study, we show that IMP3 regulates the expression of cyclin D1 and D3 in a significant 
manner in vivo. We also demonstrate that in the absence of IMP3, the mRNAs of the cyclins 
are exported to the cytoplasm and associated with polyribosomes, but not translated. IMP3 
inhibition does not influence the stability of cyclin mRNAs. We demonstrate that in human 
cancer cells, IMP3 interacts with multiple RNA-binding proteins, and that a number of these 
IMP-3 partners impacts on the expression of cyclins D1 and D3. These observations suggest 
the existence of a regulatory IMP-3 containing RNP complex on the 3’UTR of mRNAs of 
cyclin D1 and D3. Our results show that an inhibition of two key proteins of RNA-induced 
silencing complex (RISC) (AGO2 and GW182/TNRC6) rescues the expression of cyclin D1 
and D3 proteins, which is significantly decreased in the absence of IMP3 or its protein 
partners ILF3/NF90 and PTBP1. Therefore, IMP3 and RISC complexes can compete for 
cyclin mRNAs translational repression/activation. We also identified a number of  miRNAs 
that can be involved in this process, and characterized functionally important regions within 
3’ UTRs of the cyclins, where the competition between IMP-3 and RISC complexes takes 
place. 
Our results are consistent with the existence of IMP3 - containing  multiprotein complex, 
which is associated with 3’UTRs of the cyclins and  regulates their translation by protecting 
them from miRISC-dependent translational repression.	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Résumé 
Les protéines se liant à l’ARN de la famille IMP sont les protéines oncofoetales 
conservées, qui régulent le transport, la stabilité et la traduction de plusieurs ARNm cibles. 
Les IMPs sont impliqués dans la tumorigenèse et dans le développement embryonnaire par le 
contrôle de la prolifération cellulaire, la différenciation, la migration, la polarisation et 
d`autres processus cellulaires. IMP-3 est difficilement détectable dans des tissus adultes 
normaux, mais il est surexprimé dans les nombreux cancers, où il a été caractérisé comme un 
marqueur d’agressivité et de la croissance tumorale rapide, ainsi que d’un pronostic 
défavorable pour les patients. Dans notre étude, nous avons utilisé une lignée cellulaire RD de 
rhabdomyosarcome (RMS), où IMPs étaient initialement décrits comme des protéines 
régulatrices de l`ARNm de IGF-2. Nous avons essayé d'élucider le mécanisme par lequel 
IMP3 régule l’expression des cyclines D1 et D3, contribuant ainsi à la compréhension des 
processus oncogéniques dans les RMS et autres cancers.	  
Nous avons montré que IMP3 régule l'expression des cyclines D1 et D3 d'une manière 
significative in vivo. Nous avons également démontré, qu'en absence de IMP3, les ARNm des 
cyclines sont exportés vers le cytoplasme et s’associent avec les polyribosomes, mais ne sont  
pas traduits. En outre, l'inhibition d`IMP3 n'a pas d'influence sur la stabilité des ARNm des 
cyclines. Nous démontrons que dans des cellules cancéreuses humaines, IMP3 interagit avec 
plusieurs protéines se liant à l'ARN, et que nombre de ces protéines a un effet sul l’expression 
des cyclines, ce que suggère l'existence d'un complexe régulateur multiprotéique sur les 
3'UTR des cyclines D1 et D3. Nos résultat montrent que l'inhibition de deux protéines clés de 
RNA-induced silencing complex (RISC) (AGO2 et GW182/TNRC6), rétablit les niveaux 
d'expression des cyclines D1 et D3, qui ont été considérablement diminués en l’absence 
d’IMP3 ou de ses partenaires protéiques ILF3/NF90 et PTBP1. Nous concluons que les 
complexes d`IMP3 et RISC peuvent concourir pour la régulation des ARNm des cyclines. 
Nous avons également identifié les miARNs qui peuvent être impliqués dans ce processus, 
ainsi que les domaines fonctionnellement importants dans les 3 'UTR des cyclines, où se 
passe la competition entre les complexes d’IMP-3 et RISC.	  
  Nos résultats sont compatibles avec l'existence de IMP3 - contenant complexe 
multiprotéique, qui est associé à 3'UTRs des cyclines et régule leur traduction en les 
protégeant contre la répression traductionnelle par miRISC.	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Introduction 
1. The insulin-like growth factor-2 mRNA-binding protein family (IGF2BPs). 
1.1. The discovery of IMPs. 
The insulin-like growth factor-2 (major fetal growth factor) mRNA-binding protein family 
comprises three mRNA-binding proteins : IGF2BPs/IMPs 1-3, which, as their name suggests, 
can bind RNAs and influence their cellular fate : localization, turnover, and translational 
control. 
The nomenclature of the IGF2BP protein family remains confusing. It includes many 
synonyms: IMP, CRD-BP, VICKZ, ZBP1, Vg1RBP/Vera or KOC. In order to simplify the 
nomenclature of IMP family members, Dr. Yisraeli proposed the acronym VICKZ. The V is 
the first identified protein that binds Vg1 mRNA (Vg1RBP or VERA) [Zhang Q et al., 1999]. 
The I defines IMPs. C comes from the CRD-BP, K corresponds to KOC, Z to ZBP1. The 
human IMP1 (huIGF2BP1) has two orthologs : CRD-BP (muIGF2BP1) with an almost 
perfect homology in mice and ZBP1 (chIGF2BP1) with 95% homology in chicken. Moreover, 
IMP3 (huIGF2BP3) is identical to KOC and has 83% of homology with its ortholog in 
Xenopus, termed Vg1RBP/Vera. There is no ortholog described for IMP2. The closest to 
IMP2 is a protein, lacking the N-terminal RRM domain but comprising four KH-domains, 
that was identified in Drosophila, and is known as Drosophila IGF2BP (dIMP). Thus, 
multiple studies over the years have referred to these proteins with a variety of names (Fig. 1), 
and this Introduction will attempt to remain faithful to the original publications with regard to 
the nomenclature. However, in my own work in human cancer cells, I mostly used the 
abbreviation « IMP 1-3» or « IMP/IGF2BP 1-3» for these proteins, following the pioneering 
studies of Nielsen and Christianssen (discussed below).  
Evolutionally conserved IGF2BP family members and their orthologs are involved in many 
important processes during development and cancer, such as cell polarization, migration, 
changes in morphology, metabolism, proliferation and differentiation. The first described 
mammalian family member was IGF2BP1, which was initially identified  in 1999, when 
Bernstein and colleagues searched for factors that bind to specific regions of polysome-
associated c-myc mRNA and thereby alter its half-life. By UV-cross-linking experiments, 
IGF2BP1 was detected as a 75-KD polysome-associated protein bound to the 182-nucleotide 
fragment of c-myc mRNA in a coding region (c-myc-coding region determinant, CRD) and 
involved in protection of these region of c-myc mRNA from endonuclease attack  [Bernstein 
PL et al., 1992]. 
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Figure 1. Phylogenetic tree indicating amino acid substitutions of distinct IGF2BP paralogs 
from different species (hu human, mu murine, ch chicken, xoXenopus, dDrosophila) [Bell JL 
et al., 2013].  
 
IGF2BP1 prevents c-myc mRNA degradation and thereby promotes tumor cell proliferation 
and survival in various cancer contexts [reviewed in Bell JL et al., 2013]. Later on, Ross and 
Singer have isolated and cloned the 68-KDa ZBP1 (zipcode-binding protein 1, IGF2BP1 
ortholog in chicken) that was found to control the subcellular localization of ?-actin (ACTB) 
mRNA in primary fibroblasts and neurons. ZBP1 binds to conserved elements within ACTB 
mRNA 3`UTR, and notably to a 54-nucleotide element, which has been termed the 'zipcode' 
[Ross AF et al., 1997]. ZBP1 was proposed to play an essential role in subcellular localization 
of ?-actin mRNA to the sites of active actin polymerization, enhancing neurite outgrowth 
and axonal guidance [Huttelmaier  S et al., 2005].  
Human IMP2/IGF2BP2 was first described in 1999 as an insulin-like growth factor II mRNA 
binding protein, overexpressed in liver cancers [Nielsen J et al., 1999]. Later, this protein, also 
termed p62, was identified as an auto-antigen in hepatocellular carcinoma [Zhang JY et al., 
1999]. Some time later, single nucleotide polymorphisms (SNPs) were found within the 
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second intron of the human IGF2BP2 gene. IGF2BP2 gene variants with such SNPs were 
correlated with an elevated risk of developing type 2 diabetes [Christiansen J et al., 2009]. 
Recently, IGF2BP2 was identified as a positive regulator (enhancer) of cap-independent IGF2 
mRNA translational initiation after mTOR-dependent phosphorylation in the linker region 
connecting the RRM and KH domains. IGF2BP2 was also identified as a modulator of mTOR 
signaling [Dai N et al., 2011].  
Human IGF2BP3, that is highly overexpressed in pancreatic cancer cell lines and in 
pancreatic cancer tissue as compared to normal pancreas and chronic pancreatitis tissue, was 
initially termed KOC (KH domain containing protein overexpressed in cancer) [Mueller-
Pillasch F et al., 1997]. Since this first identification,  high levels of its expression were also 
found in tissue samples of other human tumors [Findeis-Hosey JJ et al., 2011]. 
 
1.2. Structure of IGF2BPs. 
In mammals, all three IGF2BP proteins show a high level of amino acid sequence identity 
(79–84%) and are strikingly similar in order and spacing of domains [reviewed in  Bell JL et 
al., 2013] (Fig. 2).  
All three human IGF2BP proteins contain two RNA-recognition motifs (RRMs) in their N-
terminal part, four hnRNP-K homology (KH) domains in the C-terminal part, and linker 
regions between conserved domains. The C-terminal KH domains of the IGF2BPs are 
essential for RNA-binding and thereby determine the subcellular localization of all three 
human family members, which is typically characterized by a mainly cytoplasmic, granular 
distribution [Wachter K et al., 2013]. Recent structural analyses as well as NMR studies of 
human IGF2BP1 (also termed ZBP1) KH-domains 3 and 4 suggests an anti-parallel pseudo-
dimer structure formation, where KH3 and KH4 each specifically recognize the targeted RNA 
in two appropriately spaced RNA motifs [Chao JA et al., 2010 ; Patel VL et al., 2012]. 
Forming IGF2BP-RNA complexes in vitro, IGF2BPs can change a conformation of 
associated transcripts and keep it with surprisingly long half-life (in vitro half-life of such 
complexes is greater than 2 h). Thus, IGF2BPs play an essential role in the formation of stable 
protein–RNA complexes. According to in vitro studies, RNA-binding is mainly facilitated by 
the KH domains, whereas the RRMs promote the stability of protein–RNA complexes and 
mediate the association with other RBPs [Wachter K et al., 2013 ; Nielsen J et al., 2004]. 
Despite the high degree of sequence identity in the KH and RRM domains, all three paralogs 
associate with the IGF2 mRNA but apparently exhibit distinct RNA-binding properties, and 
show differences in biological functions. These differences can be explained by the highly 
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variable linker regions [Wachter K et al., 2013].  
 
 
 
 
Figure 2. Domain structure of IGF2BPs [Bell JL et al., 2013]. 
 
1.3 Expression profile of IMPs. 
IGF2BP/IMP family members are highly expressed during the period between zygote and 
embryo stages [Hansen TV et al., 2004]. A sharp peak in expression occurs around embryonic 
day 12.5 (E12.5) before a decline in expression towards birth in mice [Hansen TV et al., 
2004 ; Hammer NA et al., 2005]. At E12.5, IGF2BPs are highly expressed in the brain, limb 
buds, muscle and epithelia of many organs in mice. In Xenopus embryo, Vg1RBP/Vera is 
highly expressed in neural cells. It plays a role in neural crest migration and is required for the 
migration of cells forming the roof plate of the neural tube [Yaniv K et al., 2003]. 
IGF2BP1 and IGF2BP3 are highly expressed during embryogenesis, but their expression 
levels in adult tissues are negligible, with the exception of reproductive tissues [Hammer NA 
et al., 2005]. In contrast, IGF2BP2 is largely expressed in different adult tissues, except 
pancreas, with an up-regulated expression in 80-week-old mice [reviewed in : Yaniv K et al., 
2002; Yisraeli JK, 2005; Christiansen J et al., 2009]. Huttelmaier group performed a semi-
quantitative RT-PCR to analyze the expression of IGF2BPs in various adult tissues in mouse. 
They confirmed previous reports and showed that IGF2BP1 expression in adult life is almost 
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absent, with a modest expression observed in the brain, lung and spleen of 16-week-old male 
mice. IGF2BP3 also demonstrates minor expression levels in the lung, spleen, kidney, and gut 
of male mice. Consistent with previous studies, largely age-independent expression of 
IGF2BP2 was observed by Huttelmaier in all adult mouse tissues, except pancreas. Hence, 
looking at expression patterns of IGF2BP1 and IGF2BP3, we can classify these proteins as 
‘oncofetal’, meaning their almost complete absence in adult tissues, but de novo synthesis or 
upregulation in various tumors and tumor-derived cells [reviewed in : Yaniv K et al., 2002; 
Yisraeli JK, 2005]. It seems that IGF2BP2 is the only family member to regulate mRNA fate 
in non-transformed adult tissues, probably with a specific role in metabolic control [reviewed 
in Christiansen J et al., 2009]. 
 
1.4 Control of IGF2BP/IMPs expression at transcriptional level. 
The regulation of IMPs expression at transcriptional level is an almost unexplored area. 
Activation of beta-catenin/TCF4 signaling is implicated in the development of human 
cancers. The Noubissi group showed that in HEK293 cells, β-catenin (CTNNB1) induces 
transcription of IGF2BP1 in a TCF4-dependent manner, promoting IGF2BP1-dependent 
stabilization and translation of BTRC and MYC mRNA [Noubissi FK et al., 2006]. However, 
this observation remains controversial, since the authors propose that without CTNNB1/TCF4 
overexpression, IGF2BP1 is barely detectable in HEK293 cells, whereas multiple other 
studies indicate that IGF2BP1 is highly abundant in HEK293 cells [Huttelmaier  S et al., 
2005; Jonson et al., 2007; Mayr C et al., 2009]. Noubissi shows that c-myc enhances 
IGF2BP1 transcription by binding to its promoter [Noubissi FK et al., 2010], while IGF2BP1 
stabilizes the myc mRNA by protecting the transcript from endonucleolytic attack [Lemm I et 
al., 2002], suggesting a positive feedback loop. IGF2BP1 was also proposed to prevent miR-
182 - dependent BTRC degradation, but BTRC promotes the degradation of CTNNB1, 
suggesting a negative feedback regulation of IGF2BP1. Taken together, these observations 
provide evidence for CTNNB1/TCF4 and MYC-dependent transcriptional activation and 
stabilization of IGF2BP1, and support the idea of an oncogenic role of IGF2BP1.  
Little is known about transcriptional regulation of other IGF2BPs, and especially, of 
IGF2BP3. With regard to IMP2/IGF2BP2, Brants JR and colleagues clearly indicate that 
architectural transcription factor HMGA2 (high mobility group A2) regulates its expression  
during embryogenesis. This report shows that IGF2BP2 expression, but not that of two other 
family members, is downregulated in two HMGA2-deficient mouse strains [Brants JR et al., 
2004]. HMGA2 binds to the AT-rich region in the first intron with enhancer elements of the 
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IGF2BP2 gene both in vitro and in vivo [Cleynen I et al., 2007]. Furthermore, they show that 
a nuclear factor-kappaB (NF-kappaB) cooperates with HMGA2 to positively regulate the 
transcription of IGF2BP2/IMP-2.  
 
1.5 Control of IGF2BP/IMP family expression at post-transcriptional level. 
In addition to transcription, IMPs expression is subjected to a posttranscriptional control. 
Bartel laboratory observed an interesting phenomenon in cancer cells, where the protein 
products of oncogenes are sometimes overexpressed without alteration of the proto-oncogene. 
They found that cancer cell lines often express large amounts of mRNA isoforms with shorter 
3' untranslated regions (3’UTRs) [Mayr C and et al., 2009]. Several short isoforms of IMP1 
are found in HEK293 cells. These shorter isoforms usually resulted from alternative cleavage 
and polyadenylation (APA). Authors believe that 3`UTR shortening provide escaping strategy 
from miRNA-dependent repression, illustrating this hypothesis by the fact that expressing the 
shorter but not the full-length isoform of the proto-oncogene IMP1 led to oncogenic 
transformation.  
Peter ME’s group, with the help of comparative bioinformatics, have identified 12 conserved 
oncofetal genes regulated by the heterochronic microRNA let-7. These mRNAs include IMP-
1/CRD-BP, which was experimentally confirmed to be a direct target of let-7 [Boyerinas B et 
al., 2008]. Taking into account the tumor suppressive role of the let-7 microRNA family, 
these data support the view that IGF2BP1 enhances tumor cell aggressiveness. Targeting of 
dIMP by let-7 has also been shown in Drosophila [Toledano H et al., 2012].  
Recent studies indicate that two isoforms of the mRNA-binding protein IGF2BP2 are 
generated by alternative translational initiation [Le HT et al., 2012]. Huttelmaier group found 
at least three protein isoforms of IGF2BP2, expressed in several tumor-derived and 
transformed cells [Bell JL et al., 2013]. 
Finally, no studies have demonstrated post-transcriptional regulation of IGF2BP3/IMP3. 
 
1.6. Nuclear roles of IGF2BPs. 
IGF2BPs are predominately cytoplasmic, usually with an ability to form or to be included 
within different RNP granules. Their nuclear role remains controversial, but there are reports, 
where IGF2BPs were shown to form complexes with newly transcribed mRNA in the 
nucleus. This mRNA-protein association can be essential for subsequent cytoplasmic mRNA 
localization [Oleynikov Yet al., 2003; Huttelmaier S et al., 2005; Pan F et al., 2007].  
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A nuclear role for IMP orthologs was also described using Xenopus laevis as a model system. 
Indeed, a protein called B3.65 was isolated through its ability to bind a cis-regulatory DNA 
sequence of the TFIIIA gene (transcription factor IIIA), essential for transcription of the 5S 
rRNA gene. The B3.65  protein has 97% of identity with Vg1 RBP/VERA, ortholog of 
huIGF2BP3/IMP3. Interestingly, the activation of the TFIIIA transcription corresponds to a 
nuclear localization of B3.65/Vg1RBP/VERA [Zhang Q et al., 1999]. 
In the same organism, during spermatogenesis, nuclear accumulation of IMP1 and IMP3 was 
observed [Zhang Q et al., 1999]. For IMP orthologs in chicken and mouse, two putative NLS 
signals (Nuclear Localization Signal) were described : a first one between RRM1 and RRM2 
domains, and a second one between RRM2 and KH1 domains [Doyle GA et al., 1998; Zhou Z 
et al., 2002]. However, these two sequences were not experimentally validated to induce 
nuclear import and it was subsequently suggested that a nuclear localization of IMPs depends 
on their protein partners [Nielsen FC et al., 2002]. Moreover, a sequence analysis of the IMPs 
identified two NES (Nuclear Export Signal) within RNA-binding KH domains 2 and 4 
[Nielsen J et al., 2003]. In addition, the NES motif within the KH4 domain is was described in 
dIMP in Drosophila. 
Other important observations suggest a role for IMPs in the events of splicing within the 
nucleus. Indeed, in HeLa cells, IMP3 was found in complex with the spliceosome [Zhou Z et 
al., 2002]. In addition, IMPs can be associated with nonsense-mediated decay (NMD) factors 
and exon junction complex factors (EJC). It is probable that IMPs bind their target mRNAs in 
the nucleus and form RNPs complexes before nuclear export [Huttelmaier S et al., 2005; 
Nielsen J et al., 2003 ; Oleynikov Yet al., 2003]. Once in the cytoplasm, these mRNPs 
associate with different macromolecular machines of mRNA translation, transport and/or 
degradation. Therefore, even though the functional part of the IMP - dependent regulation of 
RNA fate occurs in the cytoplasm, the initial, critical event of protein-RNA binding must take 
place in the nucleus (see examples below). 
 
1.7. Cytoplasmic roles of IMPs. 
IMPs are mainly cytoplasmic and ‘cage’ their target mRNAs, forming large mobile 
ribonucleoprotein (RNP) granules, dispersed in the peri-nuclear region and in cellular 
protrusions. These RNP granules, or ‘locasomes’, are unique RNPs, which differ from the 
neuronal Staufen and/or fragile X mental retardation protein granules, processing bodies (P- 
bodies) and stress granules. 
Within IMP1 granules, we can find the 40S ribosomal subunit and proteins that bind RNA 
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and poly(A) tail [Huttelmaier S et al., 2005]. Moreover, IGF2BP granules contain CBP80 and 
factors belonging to the exon-junction complex. Suprisingly, they lack eIF4E, eIF4G, and 60S 
ribosomal subunits. This observation suggests that mRNAs in these bodies are translationally 
repressed or have never been translated. 
Cytoplasmic IMP1-containing mRNPs were characterized by a proteomic approach, revealing 
association of IMP1 with various RNA-binding proteins [Jonson L et al., 2007]. Generally, 
IMPs interact with RBPs in RNA-dependent manner [Jonson L et al., 2007; Weidensdorfer D 
et al., 2009]. For example, IMP1 with other RBPs (HNRNPU, SYNCRIP, YBX1, and DHX9) 
stabilizes c-myc mRNA by associating with coding region instability determinant (CRD). 
However, some RNA-independent interactions have been identified for some family 
members. In Xenopus, Vg1RBP/VERA interacts with RBP60/HNRNPI in a RNA-
independent manner in the nucleus of oocytes [Lewis RA et al., 2008]. Curiously, in the 
cytoplasm, this interaction becomes RNA-dependent. This observation suggests that the IMPs 
containing RNP complexes are dynamic complexes that are revised during nuclear export. 
In humans, numerous protein partners and a large number of target RNAs indicate that IMPs 
are able to form a variety of complexes with many protein-protein and protein-RNA 
interactions. Furthermore, different IMP-interacting RBPs are involved in mRNA stability 
control (for example, AUF and HuD1), in the regulation of translation (FMRP) and in the 
control of mRNA localization (HuD and FMRP). It should also be noted that IMPs interact 
with many proteins of the cytoskeleton. In Xenopus, for example, Vg1/VERA interacts with 
microtubules [Elisha Z et al., 1995]. Human and Drosophila IMP1 granules are often found in 
well-organized rows, suggesting an association with the cytoskeleton [Christiansen et al., 
2002].  
It is estimated that about 3% of the mRNA transcriptome is found in IMP1 granules [Jonson L 
et al., 2007]. Most often, these mRNAs are involved in the protein degradation pathway via 
proteasome, such as those encoding for E3 ubiquitin ligases of the RING finger family 
(RNF4, RNF26, RNF130 and others). There are also mRNAs encoding the quality control 
proteins of endoplasmic reticulum and protein secretion.  
According to in vitro studies [Nielsen J et al., 2004], IGF2BPs form a stable protein-RNA 
association that can prevent the premature decay and promiscuous translation of specific 
target transcripts, for example, CD44, MYC, PTEN or BTRC, supposedly by limiting a 
release of these transcripts from associated proteins [Lemm I et al., 2002; Kobel M et al., 
2007; Stohr N et al., 2012 ; Vikesaa J et al., 2006 ; Noubissi FK et al., 2006]. IGF2BPs seem 
to be essential for controlling both mRNA localization and translation via directed recruitment 
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of targeted transcripts to cytoplasmic mRNPs. This stable IGF2BP-mRNAs association 
(mRNP) promotes ‘long-distance’ transport of the transcripts and their impermanent storage. 
Vg1 RNA-binding protein (Vg1RBP/Vera), an IMP3 ortholog in Xenopus, associates with 
Vg1 mRNA via specific VLE domain and directs its transport to the vegetal pole of the 
oocyte during oocyte maturation. During transport, the translation of Vg1 mRNA is inhibited 
[Deshler JO et al., 1997; Schwartz SP et al., 1992]. The injection of anti-Vg1 antibodies 
inhibits correct localization of Vg1 mRNAs by 50% [Kwon et al., 2002]. 
IMP1 ortholog in chicken, the chicken zipcode-binding protein (ZBP-1), participates in the 
localization of ?-actin mRNA to the leading edge of embryonic fibroblasts and neurons.  
ZBP1 co-localizes with mRNA of ?-actin in the lamellipodia of chicken embryo fibroblasts 
(CEFs). The localization of ?-actin mRNA in the lamellipodia is important to maintain the 
polarity and cell motility [Farina KL et al., 2003]. With the help of KH3 and 4 domains, 
which directly bind the zipcode region of ?-actin mRNA, ZBP1 promotes the formation of 
RNPs granules containing ?-actin mRNAs [Ross AF et al., 1997]. After the removing of the 
N-terminal domain of ZBP1, RNP granules can be observed, but they are not accumulated at 
the extremities of CEFs. This N-terminal domain seems to be important to target the 
destination of RNP granules. On the other hand, KH3 and KH4 domains also promote 
association of these granules with microfilaments of actin.  
Chicken ZBP1 was also observed in discrete foci in the nucleus, coinciding with the ?-actin 
mRNA transcription sites, indicating that ZBP1 binds to newly synthesized ? -actin 
transcripts. After the nuclear export, ZBP1 can act as a translational regulator of ?-actin 
mRNA in the cytoplasm, preventing premature translation by blocking translational initiation. 
When  ZBP1–RNA complex reaches its destination at the periphery of the cell, Src kinase 
phosphorylates a key tyrosine residue in ZBP1, required for RNA binding. This event 
decreases  ZBP1 affinity to the mRNA of ?-actin [Huttelmaier S et al., 2005]. The 
subsequent release of mRNA promotes translation. These findings confirm that ZBP1 plays a 
major role in temporal and spatial control of ?-actin mRNA translation. 
In neuroblastoma cells (NG 108-15), ZBP1 binds mRNA of ?-actin co-transcriptionally in 
the nucleus [Singer RH, 2003]. Once in the cytoplasm, ZBP1 does not only ensure the 
transport of the mRNA of ?-actin, but also appears to prevent premature translation. This 
hypothesis is confirmed by the ability of ZBP1 to inhibit translation initiation of ?-actin 
mRNA in vitro. Indeed, ZBP1 prevents the formation of the 80S ribosomal complex. 
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Translation, therefore, starts when the mRNA reaches its destination at the periphery of the 
cell, after phosphorylation of ZBP1 by Src protein kinase [Huttelmaier S et al., 2005]. 
In Drosophila, dIMP binds oskar mRNA at the IBE sites (UUUAY). At the oocyte posterior, 
IMP colocalizes with oskar mRNA in IBEs-dependent manner. After the mutation of subset 
or all IBE sites, oskar mRNA doesn’t translate and localize to the posterior pole of oocyte 
[Munro TP et al., 2006]. However, in the absence of dIMP, oskar mRNA translates normally 
and still have a ‘posterior’ mRNA localization. These observations suggest that activation of  
oskar translation may occur under the influence of another unknown IBE-binding factor, 
redundant to dIMP in its action. Alternatively, the unknown IBE-binding factor can 
exclusively activate oskar translation, and dIMP can compete with its binding by masking 
IBE sites [Munro TP et al., 2006].  
 
1.8. IMPs in the control of mRNA translation and stability. 
By ‘Caging’ their target transcripts in mRNPs, IGF2BPs increase their stability and inhibit 
their translation [Lemm I et al., 2002; Noubissi FK et al., 2006]. Indeed, IMP1 and IMP3 
stabilize CD44 mRNA [Vikesaa J et al., 2006], which has five IMPs binding sites within its  3 
'UTR. After HeLa cells treatment with actinomycin D (a transcriptional inhibitor), the absence 
of IMP1 or IMP3 causes a significant decrease in the half-life of CD44 mRNA. 
Similarly, IMP1 seems to protect the mRNAs encoding c-myc and MDR1 from 
endonucleolytic cleavage and degradation [Lemm I et al., 2002; Sparanese D et al., 2007]. 
When IMP1 binds c-myc mRNA in the coding region, it specifically recognizes with high 
affinity the CRD site (Coding Region Determinant instability), which is susceptible to be 
attacked by a polysome-associated endoribonuclease [Sparanese D et al., 2007 ; Bergstrom K 
et al., 2006]. Indeed, during the translation, the movement of ribosomes on the c-myc mRNA 
is slowed down at the beginning of CRD site which contains rare codons. The mechanism by 
which IMP1 stabilizes c-myc mRNA remains poorly understood, but it is possible that IMP1 
prevents the degradation of c-myc by impeding its co-translational cleavage in a way of 
protection of c-myc transcripts in mRNP complex [Weidensdorfer D et al., 2009]. IMP1 
works in a complex with four RBPs, which interact with each other in a CRD-dependent 
manner. Each of these proteins is essential for the stabilization of c-myc through the CRD. 
Indeed, a knock-down (KD) of IMP3 or of one of its four protein partners by siRNA leads to a 
two-fold decrease in c-myc mRNA half-life. Moreover, an association between IMP1 and c-
myc inhibits its rapid co-translational degradation. Interestingly, the expression of IMP1 in 
malignant tumors correlates with high expression of c-myc mRNA [Kobel M et al., 2007].  
	   18	  
Interestingly, a study of various lineages of human cancers suggests that IMP1 interferes with 
miRNA-dependent degradation of BTRC (beta-transducin repeat Containing E3 ubiquitin 
ligase protein) [Elcheva I et al., 2009]. miR-183 interacts with the coding region of BTRC. 
Curiously, BTRC also has a binding site (CRD) within the same region, which promotes 
stability by recruiting IMP1. This suggests that IMP1/CRD-BP competes with miR-183 for 
coding region binding, and that CRD-BP association prevents mRNA silencing by the 
miRNA pathway. Cytoplasmic IMP1 and 3 granules, locasomes, or « safe houses » also 
protect HMGA2 from AGO2/let-7 mediated repression, by impacting on the stability of 
HMGA2 mRNA [Nielsen FC et al., 2014]. 
The most prominent and frequently studied target of IGF2BPs is the IGF2 mRNA. The IGF-II 
gene generates overlapping primary transcripts that result in multiple mRNAs with identical 
coding regions and 3? UTRs, but distinct 5? UTRs, referred to as leader 1, 2, 3, 4. In K562 
cells (Leukemia cell line), IMP3 is capable to bind the 5`UTRs of IGF2 leader 3 and 4 and 
promote the translation of the mRNA IGF2 leader 3 [Liao B et al., 2005 ; Suvasini R et al., 
2011]. The inhibition of IMP3 by RNAi results in the reduction of endogenous protein level 
of IGF2 without decrease in mRNA leader 3 and 4 levels. In addition, the KD of IMP3 causes 
a dose-dependent translational repression of IGF-II leader 3–luciferase reporter construct. 
These results suggest that IMP3 promotes the translation of IGF2 leader 3. In contrast to 
IMP3, IMP1, being associated with 5`UTR, directs a repression of IGF-2 leader 3 at the 
translational initiation level [Nielsen J et al., 1999]. It was recently shown that 
phosphorylation of IGF2BP2 in the N-terminal linker region between RRM2 and KH1, by 
mTORC1, promotes the association with the 5`UTR of IGF2 leader 3, resulting in elevated 
IGF2 protein synthesis  [Dai N et al., 2011]. 
In conclusion, despite the high degree of sequence identity, the IGF2Bps can regulate the 
cellular fate of the same RNA in a different manner. These observations suggest that IGF2BPs 
are not absolutely redundant in their functions. Moreover, having a common set of targets, 
IGF2BPs associate with variable transcripts. For example, unlike IMP1, IMP3 does not bind 
to the c-myc and ?-actin mRNA [Liao B et al., 2005, Suvasini R et al., 2011].  
However, how to explain why some IGF2BP targets, being ‘caged’ in cytoplasmic mRNPs, 
are regulated in a opposite way ? At least two mechanisms can be proposed [Bell J et al., 
2013]. On the one hand, the mRNA fate can be determined by the exact protein composition 
of various cytoplasmic regulatory mRNPs. On the other hand, the cis-determinants of 
regulated transcripts can exclusively determine the final mRNA fate. IGF2Bps, in this  latter 
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case, can control the release of regulated transcripts from cytoplasmic mRNPs with different 
functions.  
 
1.9. Post-translational modifications of IMPs influence their roles in the cell. 
Phosphorylation-dependent modulation of the RNA-binding activity of RBPs is one of the 
essential mechanism regulating the cytoplasmic fate of mRNP-associated transcripts [Rudel S 
et al., 2011; Ostareck-Lederer et al., 2002]. These cytoplasmic signaling events modulate the 
release of mRNAs from IGF2BP granules, promoting their translation or decay. 
Phosphorylation of IGF2BP1 and Xenopus Vg1RBP (IGF2BP3) by the SRC-kinase 
(IGF2BP1) or MAPKs (IGF2BP3) regulates growth cone guidance [Huttelmaier  S et al., 
2005 ; Leung  KM et al., 2006 ; Yao J et al., 2006]. Phosphorylation of VgRBP/Vera by 
MAPKs promotes the release of the Vg1 mRNA from the vegetal cortex of Xenopus oocytes. 
In particular, it is suspected that IMP1 phosphorylation between KH2 and KH3 is responsible 
for the dissociation of ?-actin from mRNP complex with a subsequent activation of its 
translation [Noubissi FK et al., 2006]. Moreover, IMP1 and IMP2 phosphorylation by 
mTORC1 in the linker region between RRM and KH domains, promotes its association with 
the 5 'UTR of the IGF2 mRNA and a subsequent translation [Dai N et al., 2011]. For 
IGF2BP3, phosphorylation at a homologous residue was also reported, but the functional 
significance of this observation is not clear [Dai N et al., 2013]. Post-translational 
modifications of IMPs seem to modulate their role as regulators of cytoplasmic fate of 
specific transcripts. 
 
1.10. IMP target sites in RNAs. 
In order to determine the sequences within target mRNAs, bound by IGF2BPs, scientists use a 
variety of methods. RIP-ChIP was the first technique which allowed to study RNPs at large 
scale. RNA-binding protein precipitation with the antibodies was followed by the analysis of 
coimmunoprecipitated mRNAs by microarrays [Tenenbaum SA et al., 2000]. Later, in order 
to improve the detection power of this technology, researchers applied deep sequencing 
methods instead of microarrays (RIP-Seq). These two technologies identified single RBP 
associated with hundreds of mRNAs. The introduction of a UV cross-linking step, that ‘froze’ 
RNA-protein interactions, allowed the identification of RBP targets in living cells. This 
method was called cross-linking and immunoprecipitation (CLIP). CLIP is followed by 
sequencing or microarray analysis. Then, it was upgraded and gave rise to photoactivatable 
ribonucleoside enhanced CLIP (PAR-CLIP) and individual nucleotide resolution CLIP 
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(iCLIP). PAR-CLIP is consistent of the incorporation of photoreactive ribonucleoside analogs 
(4-thiouridine (4-SU) and 6-thioguanosine (6-SG)) into nascent RNA transcripts in living 
cells. UV irradiation of the cells induces cross-linking of photoreactive nucleoside-labeled 
cellular RNAs with interacting RBPs. Subsequent immunoprecipitation of the RBP is 
followed by the isolation of cross-linked and co-immunoprecipitated RNA. The isolated 
RNAs are converted into a cDNA library and deep sequenced using high-throughput 
sequencing technology. PAR-CLIP was used for identification of the transcriptome-wide 
binding sites for microRNA-containing ribonucleoprotein complexes (including AGO and 
TNRC6/GW182 proteins). iCLIP technique uses UV light to covalently bind RNA molecules 
with located in close proximity proteins. After, there is a purification of linked protein-RNA 
complexes step, including immunoprecipitation with SDS-PAGE and membrane transfer. The 
radiolabeled protein-RNA complexes are then cut out from the membrane, and treated with 
proteinase, resulting in one or two amino acids at the RNA cross-link site. The RNA is then 
reverse transcribed. Because reverse transcription stops prematurely at the cross-link site, we 
can identify binding site locations with high accuracy, which allows us to identify the 
sequence motifs for known RBPs and their locations within the transcript in vivo [Ule J et al., 
2003; Hafner M et al., 2010 ; Konig J et al. 2010, reviewed in Konig J et al., 2012]. Finally, 
SEQRS can be used to refine sequence motifs. This method is composed of in vitro selection, 
high-throughput sequencing of RNA and SSL (sequence-specificity landscapes). It is 
extremely useful to analyze the specificity of RBPs, and to study the modulation of RBP-
binding specificity by its protein partners and co-factors [Campbell ZT et al., 2012].  
Many RBPs bind structured elements within mRNA. This binding is based on the recognition 
of the mRNA structures rather than on nucleotide sequence identification. PARS and SHAPE-
Seq are recently developed genome-wide methods for RNA secondary structure identification. 
Using a wide range of described methods, we can discover novel RBPs, novel yet-unknown 
RNA-binding domains, create a catalog of protein–mRNA contact sites (‘mRNA 
interactome’), for each cell line [Castello A et al., 2012 ; Baltz AG et al., 2012].  
Many attempts were made to define the target sites of the IMPs, using a variety of methods. 
The Singer group searched for the IMP1/ZBP1 binding site within the 3 'UTR of ?-actin 
mRNA. With a help of band-shift mobility assays, UV cross-linking, and affinity purification 
experiments, they found that ZBP1 recognizes the conserved ACACCC sequence within 54-
nucleotide zipcode [Ross AF et al., 1997]. The same procedure used to show that 
Vg1RBP/VERA recognizes UUUCUA and UUCAC repeats in the 366-nucleotide VgLE 
	   21	  
from the 3?UTR of Vg1 mRNA in Xenopus [Havin L et al., 1998 ; Deshler JO et al., 1998]. 
In humans, IMPs recognize the UCACGUUCAC sequence of mRNA leader 3 of IGF2. That 
was demonstrated by mobility-shift assay [Nielsen J et al., 1999]. Drosophila dIMP binding to 
UUUAY motifs of oskar 3`UTR was demonstrated by SELEX method [Munro TP et al., 
2006].  
Further studies suggest that IMPs directly bind to secondary structures within mRNA via their 
KH3 and KH4 domains [Chao JA et al., 2010]. Indeed, as was shown by EMSA studies, that 
the sequence of the ‘zipcode’ ACACCC is not sufficient for IMP1 recognition. In 2009, 
Robert Singer lab identified two ‘zipcodes’ sequences: 5`element (5`-GGACU-3`), bound by 
KH4, and 3`element (5`-ACA-3`), bound by KH3. A mutation in one of these sequences 
results in the loss of mRNA binding by KH3 and KH4, indicating that these domains 
recognize a bipartite sequence within ‘zipcode’. It is interesting that a space between the two 
sequences, bound by individual KH3 and KH4, is consistent with the structure of domains 
KH3 and KH4 of IMP1, obtained by X-ray crystallography. However, KH domains do not 
bind mRNA with the same affinity as the whole protein [Nielsen J et al., 2004].  
In 2010, the Tuschl lab used the PAR-CLIP technique to identify the mRNA sequences 
recognized by the IMPs. They utilized HEK293 cells that stably express a tagged form of 
IMP1, 2 and 3 (FLAG-HA-IMP). 4-thiouridine-labeled transcripts were crosslinked to RBPs 
and partially digested by RNase. RNA-protein complexes were immunopurified and bound 
RNA was size-fractionated by SDS-PAGE. RNA molecules were eluted, associated RBPs 
were digested by proteinase K. RNA were converted into a cDNA library and deep 
sequenced. With PAR-CLIP method, authors showed that IMPs have a slight preference for 
the 3'UTR in comparison to coding sequence. They also determined that IMPs have more than 
1,000 targets and recognize their targets through a CAUH pattern (H = A, C or U) [Hafner M 
et al., 2010].  
Therefore, it is clear that despite the high degree of conservation between IMP orthologs, and 
high IMPs homology within the same species, particularly within canonical RNA-binding 
motifs, no generally accepted IGF2BP target site has been clearly defined so far. It also hard 
to explain why the three IGF2BPs often demonstrate different affinities for the same mRNA, 
and why they have a wide variety of  non-overlapping RNA targets [Yisraeli JK, 2005]. The 
study of interactions between IMPs and their targets is very complex in the ‘absence’ of a 
unique consensus sequence or pattern especially as the mRNA secondary structure also 
appears to play an important role in the recognition by IMPs [Nielsen FC et al., 2002]. In 
addition, IMPs are capable to form homodimers and heterodimers on their target mRNAs. 
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This dimerization further complicates the target identification but may explain the high 
stability of IMPs mRNPs-complex [Nielsen FC et al., 2002].  
 
1.11. Role of IGF2BP during development. 
The role of IMP proteins during development has been studied with the use of over-
expression and knock-down/knock-out experiments. 
Constitutive reexpression of KOC, the ortholog of IMP3, in transgenic mice under the control 
of metallothionine promoter, promoting its expression in the stomach, pancreas, liver and 
kidney, causes no any visible alterations, and mice demonstrate normal growth and behavior 
[Wagner M et al., 2003]. However, this overexpression leads to discrete changes in the micro-
architecture of the pancreas.  
In Drosophila, dIMP overexpression disrupts the dorsal/ventral polarity [Thomas Hays, 2008 ; 
Geng C et al., 2006]. In Xenopus, a down-regulation of Vg1RBP, an ortholog of IGF2BP 
family, was performed, using ‘antisense oligonucleotides’, called morpholinos (AMO). This 
led to many morphological defects : loss of lateral pigments, reduced or absent dorsal fin, 
impaired lens formation, abnormal morphology of the head (Yaniv et al., 2003). These defects 
are explained by inability of neural crest cells and neural tube roof plate cells to migrate and 
reach their destinations, although their differentiation markers are normal. After an injection 
of sense Vg1 RBP RNA, insensitive to AMO-directed degradation, a normal embryonic 
phenotype is restored with high efficiency. These experiments show the essential role of 
Vg1RBP/VERA in cell migration during Xenopus embryogenesis. 
ZBP1 loss-of-function inhibits the correct localization of ?-actin mRNA, which is required 
for dendritic filopodia formation, and causes defects in synaptogenesis in rat neuronal cells 
[Tiruchinapalli DM et al., 2003, Eom T et al., 2003]. Interestingly, an increase in the density 
of dendritic filopodia and the number of synapses has been observed in mouse neuronal cells, 
overexpressing constructs containing the cis-acting, 3? -untranslated region signal (zipcode 
sequence) of ? -actin mRNA. Moreover, ZBP1 regulates axon guidance in mouse, 
modulating local translation of ?-actin with the help of neitrin-1 [Welshhans K et al., 2011]. 
In Drosophila, dIMP is a part of large RNase-sensitive complex that is present in the polarized 
developing oocytes and neurons. Loss of function of dIMP causes significant defects in 
synaptic terminal growth [Boylan KL et al., 2008]. Taken together, these observations 
determinate IGF2BPs as key regulatory factors of neuronal development that modulate 
outgrowth and cell migration of neurons.  
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IGF2BP1 is the only paralog for which knockout mice have been described.       IMP1 - / - 
mouse is characterized by severely reduced viability (50% of them were alive 3 days after 
birth), dwarfism (40% smaller than wild-type) and impaired gut development [Hansen TV et 
al., 2004]. It was suspected that smaller sized organs can be caused by hypoplasia. PCNA, a 
marker of proliferating cells, was reduced and a marker of apoptosis (TUNEL staining) was 
not significantly increased compared to wildtype mice. According to this report, IGF2BP1, 
apparently, is a key factor of embryonal development and perinatal survival, promoting cell 
growth and differentiation, presumably through IGF2 regulation [Nielsen J et al., 1999].  
For the other IMPs no in vivo models were generated.  
Interestingly, there is substantial evidence, showing IGF2BPs to modulate cell adhesion, the 
formation of invadopodia, and intrinsic cell polarization. Notably, IGF2BP2 could modulate 
cell adhesion. Recent reports, including work from our laboratory, suggest that IGF2BP2 
controls the expression of critical component of the glomerular basement membrane LAMB2 
[Schaeffer V et al., 2012 ]. Moreover, IMP2 regulates PINCH-2, an important mediator of cell 
adhesion and motility ; IMP2 controls microtubule (MT) stability via MURF-3 regulation 
[Boudoukha S et al., 2010]. The inhibition of  IMP1 and IMP3 in Hela cells affects cell 
adhesion and formation of invadopodia via the regulation of CD44 mRNA [Vikesaa J et al., 
2006]. 
 
1.12. IMPs and cancer. 
Expression of IGF2BP proteins has been observed in various cancers; however, most of these 
reports refer to IMP1 an IMP3, confirming their role as ‘oncofetal’ proteins. IMP1 and IMP3 
are mainly expressed during embryogenesis, but become de novo synthesized in various 
malignancies : cancer of colon, liver, kidney, pancreas, female reproductive tissues and 
others. Although IGF2BP2 expression was detected in liposarcoma, liver cancer, and 
endometrial adenocarcinomas [Cleynen I et al., 2007 ; Zhang L et al., 2011 ; Lu M et al., 
2001], its role in cancer remains less clear.  
Pro-oncogenic role of IGF2BP1 was demonstrated by only one in vivo study, using a 
transgenic mouse model. In this study, the expression of IGF2BP1 was induced under the 
control of whey acidic promoter (WAP) upon lactation in mammary epithelial cells of adult 
female mice [Tessier CR et al., 2004]. Within the period when IGF2BP1 was highly 
expressed (the first 60 weeks), the incidence of mammary tumors was up to 95 %. In the 
period of lower relative expression of  IGF2BP1, the incidence was  around 60 %. The levels 
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of IGF2 and H19 mRNAs were significantly increased in mammary tissues, presumably 
promoting tumor growth. 
IGF2BPs are involved in the regulation of classic oncogenes, like MYC and KRAS. There are 
many observations suggesting a positive role of IGF2BP1 in MYC expression in various 
tumors in vitro (in mammary carcinomas [Ioannidis P et al., 2005]; in ovarian carcinomas 
[Kobel M et al., 2007]; in colorectal carcinomas [Mongroo PS et al., 2011]).  
As described above, IGF2BP1 regulates the stability of MYC mRNA by preventing its 
endonucleolytic cleavage  within coding region [Weidensdorfer D et al., 2009 ; Lemm I et al., 
2002 ; Sparanese D et al., 2007 ; Bergstrom K et al., 2006]. MYC as well as KRAS are well 
known targets of let-7 miRNA family. IGF2BP1 can also interfere with let-7 microRNA, 
which targets the 3-UTRs of both transcripts. IGF2BP1 enhances KRAS expression.  This 
fact is presented in only one study, but the mechanism remains elusive [Mongroo PS et al., 
2011].  
The role of IMP1 in metastatic process is poorly understood due to lack of correlation 
between in vitro and in vivo studies. The question about pro-metastatic role of IMP1 remains 
open. Numerous observations suggest that IMP1 promotes cell migration [Vikesaa J et al., 
2006]. There is also a positive correlation between IMP1 expression and metastasis of 
colorectal carcinomas [Vainer G et al., 2008]. Moreover, the expression levels of IMP1 is in 
direct correlation with the metastatic process in rat adenocarcinoma (MTLn3). There is a 
strong evidence for a pro-metastatic role of IGF2BP1 in vivo, since transgenic expression of 
the protein in mice induced primary breast cancer lesions as well as metastasis [Tessier CR et 
al., 2004]. However, in human breast cancer cell lines T47D and MDA231, it was shown that 
IMP1 inhibits the invasive capacity of the cells by controlling the localized expression of 
various mRNAs involved in cell adhesion and motility. Thus, IMP1 is important for localized 
expression of E-cadherin and ?-actin [Gu W et al., 2012].  
IMP3, in contrast to IMP1, is not well studied in vivo, but recent observations implicate IMP3 
as an important marker of tumorigenesis [Kapoor S, 2008 ; Findeis-Hosey JJ et al., 2010] and 
a general indicator of malignancy [Wagner et al., 2003]. Over 40 studies have shown elevated 
expression levels of IMP3 in different types of cancer [Bell JL et al., 2013]. The role of 
IGF2BP3 in the regulation of IGF2 mRNA translation remains contradictory, but recent in 
vitro studies in different human cancers indicate that elevated expression levels of IGF2BP3 
might promote IGF2 translation, enhancing tumor growth [Suvasini R et al., 2011]. It has 
been shown that IMP3 promotes cell growth, proliferation, and the resistance to ionic 
radiation via IGF2 regulation [Liao B et al., 2011]. Moreover, it is interesting to note that 
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there is a correlation between IMP3 and increased in vitro invasive and metastatic ability of 
gliomas [Vikesaa J et al., 2006 ; Suvasini R et al., 2011 ; Samanta S et al., 2012]. Regulation 
of CD44, one of the validated targets of IMP3, may explain this correlation. Indeed, IMP1 and 
IMP3 promote the formation of invadopodia, stabilizing CD44 mRNA [Vikesaa J et al., 
2006]. 
Our group has shown that IMP3, with the help of HNRNPM, enters the nucleus and binds the 
mRNAs of cyclins D1, D3, and G1, positively regulating their expression, and promoting 
tumor cell proliferation [Rivera Vargas T et al., 2013]. IGF2BP3 was identified as one of the 
most severely upregulated RBPs in HCCs [Chen CL et al., 2013 ; Jeng YM et al., 2008 ; 
Gutschner T et al., 2014]. Recently it was shown, that IGF2BP3 protects HMGA2 (the 
architectural transcription factor) from let-7 family miRNA-dependent repression [Jonson L et 
al., 2014]. Consistently, IGF2BP3 expression was strongly correlated with an enhancement of 
HMGA2 expression in hepatocellular carcinomas (HCCs). IGF2BP3 was proposed to enhance 
tumor cell aggressiveness through HMGA2 upregulation in lung carcinoma cells, as well 
[Kumar MS et al., 2014]. The oncogenic role of IGF2BP3 is also supported by an in vitro 
study, where it stabilizes the ABCG2 mRNA, resulting in enhancement of chemo-resistance 
of breast cancer-derived cells [Samanta S et al., 2013]. Via stabilization of CD44, MMP9 and 
PDPN mRNAs, IGF2BP3 promotes the invasive potential of tumor cells. IMP1 and IMP3 are 
also involved in resistance to chemotherapy and radiotherapy treatments [Boyerinas B et al., 
2012]. 
Based on the above-mentioned reports, we can conclude, that IGF2BP in cancer can be 
involved in regulation of growth, migration/metastasis, survival, chemo-resistance of cancer 
cells, via the control of subcellular trafficking, translational regulation and stability of their 
RNA targets. 
1.13. Regulation of cyclin D1 and D3 expression. 
Cyclins, key coordinators of cell cycle, are highly regulated at all levels (Fig.3). In mammals, 
many metabolic and mitogenic signals are capable to influence the cell cycle. Wnts, ErbBs, 
JAKs and STATs pathways are known to activate transcription of CCND1 and CCND3. In 
addition to promoting transcription and translation, mitogen signals promote the assembly of 
cyclins with their catalytic subunits CDK4 and CDK6, and a translocation of these complexes 
to the nucleus [Sherr CJ et al., 1999]. 
Cyclins D1 and D3 can be regulated on the level of transcription. E2F1 binds to the cyclin D3 
promoter in vivo and activates it [Ma Y et al., 2003]. E1AF transcription factor, that plays an 
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important metastatic role, upregulates Cyclin D3 transcription, increasing cell cycle 
progression [Jianhai Jiang et al., 2007]. The transition from G0 to S is controlled by Ras 
[Mulcahy LS et al., 1985] which stimulates transcription of CCND1 [Albanese C et al., 1995]. 
A study of the proliferating NIH3T3 cell line shows that CCND1 is weakly expressed in S 
phase. During S/G2 progressing, CCND1 is induced by Ras and reaches the peak of its 
expression. This high level expression is maintained before the next G1 phase [Hitomi M et 
al., 1999]. Indeed, the level of CCND1 in G2 is assured by post-transcriptional mechanisms 
[Guo Y et al., 2002]. In cell culture, the absence of growth factors reduces CCND1 protein 
synthesis with insignificant changes on its mRNA levels [Brewer JW et al., 2000 ; Mettouchi 
A et al., 2001 ; Pervin S et al., 2001]. This post-transcriptional regulation of CCND1 remains 
necessary for cell cycle control.  
 
 
 
 
Figure 3. Cell cycle transitions are driven by activities of cyclin/cyclin-dependent kinase 
(Cdk) complexes [from Bioinformatics Resource Portal]. 
 
The CCND1 expression can also be regulated by alternative splicing, resulting in generation 
of two isoforms : D1a and D1b [Alao JP, 2007]. D1b transcript produces a protein lacking the 
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PEST domain, suggesting its constitutively nuclear localization and activation [Lu F et al., 
2003]. The expression of the cyclins with their rapidly changing levels throughout the cell 
cycle, is regulated not only at the level of gene transcription, but also by proteolytic 
degradation [Hershko A, 1997 ; Lania L et al., 1999]. p38SAPK2 has been shown to 
phosphorylate cyclin D1 on threonine residue 286 (T286) and induce its proteasomal 
degradation [Alao JP, 2007]. Cyclin D3 is degraded via proteasome, through a specific site 
phosphorylation (Thr-283) by  serine-threonine kinases [Casanovas O et al., 2004]. In 
addition to all these and other regulatory mechanisms, the recent years have seen an 
increasing number of studies of translational regulation of the cyclins. As these proteins have 
an extremely short half-life (30-45 min), and their mRNAs are much more stable and 
abundantly expressed, translational regulation coupled to protein degradation provides 
flexible and dynamic mechanisms that control the cyclins’ protein levels. 
CCND1 can be regulated by miRNAs. In human breast tumors, a negative correlation 
between the levels of miR-17-5p/20a cluster and cyclin D1 was observed [Yu Z et al., 2008]. 
Interestingly, cyclin D1 can bind the promoter of miR-17/92 cluster and up-regulate its 
transcription. In turn, miR-17/20 limits the proliferative function of cyclin D1 [Zuoren Yuet 
al., 2008]. This estimated feedback loop possibly allows the cell to maintain the required level 
of CCND1. Cyclin D1 can also be regulated by miR-193b in melanoma [Chen J et al., 2010]. 
A negative correlation between miR-138 and CCND3 mRNA expression was observed in 
HCC tissues  [Huang B et al., 2015]. MicroRNA-503 was reported to downregulate cyclin 
D3, which results in inhibition of G1/S transition in hepatocellular carcinoma [Xiao F et al., 
2013]. 
An interesting study reports that a cis-acting element, located at the 5' UTR of mammalian 
CCND3, forms a stable G-quadruplex structure and represses the translation of a reporter 
gene and the CCND3 gene in human cell lines [Weng HY et al., 2012].  
Indeed, post-transcriptional regulation events are particularly important for the control of 
mRNA amounts, that must be translated rapidly, like the mRNAs involved in cell cycle or 
inflammatory responses [Mitchell P et al., 2000 ; Gao M et al., 2001]. 
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2. RNA interference. siRNA, miRNA. 
The following part of literature review presents an up-to-date point of view on the 
mechanisms of inhibition of gene expression, transposable elements and viruses by various 
types of short non-coding RNAs. Observations focus on the data obtained in C. elegans, 
Drosophila and mammals, which are the principal models in the majority of RNAi studies. 
 
2.1.  General characteristics of RNA interference. 
The phenomenon of RNA interference (RNAi) is a key mechanism of suppression of gene 
expression, as well as of genomic repetitive elements and of viral nucleic acids, by means of  
homologous short RNAs. The detection of RNAi phenomenon in experiments with nematodes 
[Fire A et al., 1998] revealed a new layer of regulatory processes that are involved in the 
regulation of gene expression in the majority of eukaryotes. According to some estimates, up 
to the half of human genes may be regulated by RNAi [Bartel DP, 2009], and without an 
understanding of this process, it is impossible to receive a complete picture of the cell life. 
The functioning of repressive effector complexes RISC (RNA induced silencing complex), 
containing short RNAs guide systems for silencing of complementary targets, lays at the base 
of RNAi mechanism. Three main classes of repressive short RNA are recognized currently in 
mammals: siRNA (short interfering RNA), miRNA (microRNA) and piRNA (PIWI 
interacting RNA) [Rana TM, 2007]. siRNA take part in cell protection against the viruses and 
transpositions of mobile elements, and in rare cases can regulate the genes expression of an 
organism [Carthew RW et al., 2009; Ding SW et al., 2007; Golden DE et al., 2008]. miRNA 
is the widespread regulator of gene expression, probably involved in the regulation of 
practically every cellular process [Bartel DP, 2009]. piRNA function as part of an 
evolutionarily conservative system which is directed to the repression of mobile elements in 
germ cells of Drosophila and vertebrates, and disturbance of their function leads to the 
transpositional ‘explosion’ and, consequently, to the loss of fertility [Hartig JV et al., 2007]. 
After the biogenesis, short RNAs incorporate in RISC complex. A key component of this 
complex is the protein Argonaute (Ago), which specifically binds to a short RNA. Ago 
protein family includes two subfamilies: Ago and Piwi [Hutvagner G et al., 2008]. siRNA and 
miRNA are bound by Ago-subfamily proteins. If siRNA or miRNA, as a part of RISC, are 
fully complementary to the target RNA, Ago produces its endonuclease cleavage (‘slicer 
activity’ of Ago). In case of partial complementarity, RISC promotes the translational 
repression or slicer-independent miRNA degradation. In some cases, effector complexes in 
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the nucleus can bind to the newly formed transcripts and promote heterochromatinisation        
[Verdel A et al., 2004]. piRNAs are bound by the proteins of Piwi subfamily, and mechanism 
of repression in this case is not well studied. The existing data show the possibility of 
degradation of mobile elements, as well as their transcriptional silencing by piRNAs. 
 
2.2. siRNA. 
In plants, fungi and animals, siRNA take part in protection against viruses and transposition 
of mobile elements. They are necessary for the support of the correct structure of the 
centromere (S.pombe) and are possibly involved in the regulation of gene expression 
(Drosophila) [Carthew RW et al., 2009; Ding SW et al., 2007]. In the case of some vertebrates 
and Drosophila, siRNA are involved in the repression of transposons only in somatic tissues, 
and in germinal tissues this function is promoted by piRNA. 
 
2.2.1. siRNA biogenesis and loading into RISC. 
A characteristic feature distinguishing siRNA from miRNA and piRNA is the origin and the 
structure of their precursors. The siRNA precursor is a long dsRNA, resulting either from a 
RNA virus infection (in plants and mammals), or generated after bi-directional transcription 
of transposons (also shown for plants and mammals), from long RNA 'hairpins' and the 
overlapping mRNA transcripts (Drosophila, mammals), as well as a result of RNA-dependent 
polymerases activity (nematode, plants, yeast) [Carthew RW et al., 2009; Ding SW et al., 
2007; Golden DE et al., 2008]. siRNA is produced after dsRNA cutting with the help of 
cellular endoribonuclease Dicer (Fig.4). As a result of the dsRNA processing, siRNA 
duplexes are generated, consisting of two short RNAs with the size of 21-22 nt (in plants - up 
to 24 nts). Dicer belongs to a RNAseIII family and therefore performs cleavage in a manner 
specific for this family - each end of the duplex comprises two protrusive unpaired 
nucleotides at the 3 'end as well as a phosphate at the 5' end. 
The resulting siRNA duplexes are included in the effector RISC complex, interacting with 
key component of this complex, i.e. protein of Argonaute family (Ago). Apart form Ago, the 
complex RISC, contains a number of additional proteins. The Dicer not only cuts dsRNA, but 
it is also a component of the intermediate protein complexes, carrying out the loading of the 
siRNA in RISC.  In Drosophila, Dicer2 acts in a complex with a helper protein R2D2, 
comprising two domains for dsRNA binding (in mammals, a similar function is performed by 
TRBP) [Chendrimada TP et al., 2005; Liu J et al., 2003]. R2D2 is not involved in dsRNA 
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cleavage, but plays an important role in siRNA loading to RISC. In active RISC, which can 
promote silencing, there is only one strand of the siRNA duplex (guide strand). Another 
strand (passenger strand) is cleaved by Ago protein and in most cases dissociated (slicer 
Activity of Ago) [Matranga C et al., 2005; Miyoshi K et al., 2005; Rand TA et al., 2005]. The 
Dicer2 / R2D2 complex determines which one of the duplex strands will be guide. 
The thermodynamically stable end of the siRNA duplex binds to R2D2, and a low melting 
end binds to Dicer2 [Tomari Y et al., 2004b]. The strand which is incorporated in the active 
RISC and becomes a guide one, has the 3'-end directed to R2D2. This "thermodynamic rule" 
is confirmed by many experiments [Hutvagner G et al., 2005; Khvorova A et al., 2003; 
Schwarz SP et al., 2003]. Although siRNA which is loaded in RISC is a double-strand one 
[Rand TA et al., 2005], the Ago protein binds only the guide strand and does not form a stable 
contact with passenger strand [Hutvagner G et al., 2008], which allows its excluding during 
the formation of an active RISC. 
 
 
 
Figure 4. siRNA biogenesis in humans and Drosophila [from Martin Jinek et al., 2009; 
Ghildiyal et al., 2008] . 
	   31	  
2.2.2. Mechanisms of mRNA repression by siRNA.  
Degradation of complementary mRNA. 
In the effector  RISC complex, siRNA is bound by Ago family proteins. Ago proteins contain 
the conservative PAZ and PIWI domains [Carmell MA et al., 2002]. PAZ domain is 
composed of two subdomains separated by a pocket, which held two 3' overhanging siRNA 
nucleotides [Lingel A et al., 2004; Ma JB et al., 2004], interacting with the conservative 
aromatic and hydrophobic amino acid residues. The phosphorylated 5'-terminal nucleotide of 
siRNA is anchored inside the pocket of the PIWI domain, which is composed of basic amino 
acids [Parker JS et al., 2005]. siRNA is positioned on the surface of Ago, like one of the 
strands of double-stranded A-form RNA. Such arrangement facilitates the scanning and 
interaction between siRNA and mRNA. ‘Out-of spiral’ localization of 5' nucleotide, anchored 
inside the PIWI domain pocket, is in a good agreement with the experimental data and 
bioinformatics, according to which the pairing of 5' guide strand terminal nucleotide of 
siRNA or miRNA with mRNA is not necessary for recognition and cleavage of mRNA 
[Haley B et al., 2004]. 
PIWI domain contains a structure similar to that detected in RNaseH [Parker JS et al., 2004; 
Rivas FV et al., 2005; Song JJ et al., 2004]. In RNaseH, this structure is responsible for RNA 
strand cleavage in RNA-DNA hybrids. RNAseH contains a "catalytic triad" of amino acids 
AspAspGlu, involved in catalysis. The similar amino acid motif AspAspHis is found in many 
eukaryotic Ago PIWI domains, including human Ago2. It was shown that AspAspHis motif 
in PIWI domain of Ago2 is required for the human mRNA cleavage [Liu J et al., 2004; Rivas 
FV et al., 2005]. Recombinant Drosophila and mammalian Agos, produced in E.coli, can 
catalyze the cleavage of mRNA by siRNA without any additional proteins [Liu J et al., 2004; 
Meister G et al., 2004; Miyoshi K et al., 2005; Rivas FV et al., 2005]. Thus, siRNA directs the 
cleavage activity of Ago protein to the complementary mRNA (slicer activity of Ago). The 
cleaved phosphodiester bond is localized between mRNA nucleotides, which are 
complementary to the tenth and eleventh nucleotides from the 5' end of the siRNA [Haley B 
et al., 2004]. mRNA cleavage products contain 5' phosphate and 3' hydroxyl [Martinez and 
Tuschl, 2004]. Cellular exonucleases catalyze the degradation of miRNA fragments [Orban TI 
et al., 2005]. 
siRNAs formed by viral dsRNA cutting are completely complementary to the viral RNA. 
Therefore, these siRNA initiate degradation of viral transcripts. In order to achieve a gene 
KD, scientists typically use a dsRNA that is fully complementary to the targets and causes its 
degradation. The question arises, what is the mechanism of mRNA suppression in the case of 
	   32	  
partial complementarity  between siRNA and mRNA? The answer to this question is 
important for the determination of non-specific siRNA targets. In the presence of unpaired 
nucleotides in the middle of a short RNA-target RNA duplex, the catalytic center of Ago can 
not perform the degradation of the targets [Hutvagner G et al., 2002: Saxena S et al., 2003]. 
Imperfect complementarity is typical for miRNA – mRNA interaction with a result in mRNA 
translational repression or slicer-independent degradation. 
Some data suggest that siRNA-dependent degradation may affect the translated mRNA 
targets. In Drosophila, a protein dFMR (component of RISC), interacts with ribosomal 
proteins L5 and L11 [Caudy AA et al., 2002; Ishizuka A et al., 2002]. dFMR knockdown in 
cell culture reduces the efficiency of target repression [Caudy AA et al., 2002]. In 
trypanosomes, siRNA are found in polysomal fractions after sucrose gradient fractionation 
[Djikeng A et al., 2003]. On the other hand, some evidence suggests that the actual translation 
process is not required for efficient siRNA-dependent degradation. The inhibition of 
translation at the initiation level by IRE (iron response element) or at the elongation step using 
hygromycin B, anisomycin or cycloheximide, does not reduce the efficiency of the target 
mRNA degradation [Gu S et al., 2005; Zamore PD et al., 2000]. Inhibition of translation 
initiation even increases the efficiency of mRNA degradation, probably because the active 
ribosomes movement along the mRNA may interfere with RISC binding [Gu S et al., 2005]. 
A similar effect is observed in the miRNA-dependent translational repression. It seems that 
the interaction between translation machinery and miRNA switches it into an "open" 
conformation, available for RISC binding. According to this interpretation, the masked 
mRNA in Drosophila oocytes are resistant to miRNA-dependent degradation and start 
degrading only after unmasking and translational initiation (switching to the "open" state) 
[Kennerdell JR el al., 2002]. 
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2.3. miRNA. 
According to various estimations, miRNA may affect between a third and a half of human 
genes and, apparently, miRNAs are involved in the regulation of almost every cellular process 
[Bartel DP, 2009]. miRNA differ from siRNA by a typical structure of RNA precursors. 
miRNA, in contrast to siRNA, are specifically cut out from 'hairpin' precursors and 
correspond to one of its strands, in most cases.  
 
2.3.1. Biogenesis of miRNA. 
miR coding sequences are located within various genomic contexts. In humans, the majority 
of canonical miRNA genes are located in introns of noncoding or coding transcripts, but some 
miRNAs are encoded by exonic regions [Minju Ha et al., 2014 ; Cai X et al., 2004; Lee Y et 
al., 2004a]. miRNA genes are transcribed by RNA polymerase II, to form a pri-miRNA 
(primary miRNA) with the size of up to 1000 nucleotides (Fig. 5) [Bartel DP, 2004]. Typical 
animal pri-miRNA forms a 'hairpin' containing a double-stranded region of 33 nt, a terminal 
loop and two flanking single-stranded RNA. RNaseIII Drosha in combination with dsRNA-
binding proteins Pasha in Drosophila [Denli AM el al., 2004] or a human DGCR8 [Han J et 
al., 2004] cuts out a 'hairpin' of 65-70 nucleotides in length from pri-miRNA, which is called 
pre-miRNA (precursor of miRNA). At the moment, the exact mechanism defining the 
cleavage region in pri-miRNA is not clear. According to the predominant point of view, 
DGCR8 protein binds to the base of a 'hairpin' due to dsRNA-binding domains and orients the 
catalytic site of Drosha at a distance of 11 nucleotides from the crossing of single-stranded 
RNA into double-stranded [Han J et al., 2006]. Pre-miRNA contains the characteristic 
features of RNAseIII processing, 5 'phosphate and two 3' overhanging nucleotides. 
Some of the miRNA precursors, located in introns and called mirtrones, can be processed 
without Drosha. The intron with such miRNA is cut out using the spliceosome: firstly, a 
lasso-type structure is formed, then it is linearised and folded in a 'hairpin' resembling a pre-
miRNA and containing two 3' overhanging nucleotides and 5' phosphate [Ruby JG et al., 
2007a]. Such pre-miRNA may be involved in normal miRNA pathway and provide a mature 
miRNA. 14 mirtrones were identified in Drosophila and 4 mirtrones in nematode. It is 
proposed that the first pre-miRNA, arising during evolutional process could be formed using 
the spliceosome, and only after some time Drosha has been adapted for this purpose. 
In Drosophila, exportin-5 provides the transport of pre-miRNA from the nucleus to the 
cytoplasm [Yi R et al., 2003], where the complex of Dicerl with a dsRNA-binding protein 
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Loqs cuts the miRNA duplex to the size of 21-23 nt (Fig.5) [Forstemann K et al ., 2005]. 
Dicer1 recognizes the end of pre-miRNA with two overhanging 3' nucleotides, using its PAZ 
domain. At the present moment, the role of other proteins in pre-miRNA processing is not 
well documented. The emerging examples of such proteins are the Drosophila Loqs 
[Forstemann K et al., 2005; Saito K et al., 2005] and TRBP (TAR RNA binding protein) in 
humans [Chendrimada TP et al., 2005]. There are known three isoforms of Loqs, resulting 
from an alternative splicing. Only two of them, containing two canonical and one 
noncanonical dsRBD, interact with Dicer1 and determine its specificity with regard to pre-
miRNA [Saito K et al., 2005]. 
 
 
 
Figure 5. miRNA biogenesis in Humans and Drosophila [from Martin Jinek et al., 2009]. 
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The same Dicer protein can process pre-miRNAs as well as long dsRNAs in human and 
nematode cells. In other organisms, the existence of different Dicers allows to regulate 
selectively the processes of siRNA and miRNA formation.  
Drosophila Dicer1 is involved in miRNA processing, and Dicer2 is responsible for the 
formation of siRNA [Lee YS et al., 2004b; Xie Z et al., 2004]. In Arabidopsis thaliana, four 
genes encoding Dicer-like proteins are found (Dicer like, DCL). DCL3, localized in the 
nucleus, is involved in cutting long dsRNA to siRNA with the length of 24-26 nt, thus 
allowing transcriptional retroelement silencing [Hamilton A et al., 2002]. DCL1 is required 
for the miRNA formation and, apparently, can carry out both stages of pri-miRNA processing 
without Drosha participation. 
Loading of miRNA duplex into the RISC is performed by Dicer together with other proteins. 
In humans, a Dicer / TRBP / Ago2 complex performs the processing of pre-miRNA and loads 
the resulting miRNA duplex in Ago2, which leads to the formation of an active RISC 
[Gregory RI et al., 2005; Maniataki E et al., 2005]. It is shown that the active RISC 
incorporates guide miRNA, but not passenger miRNA. It means that as in the case of miRNA 
downloading, Dicer with TRBP can ‘feel’ the more fusible end of the duplex and incorporate 
miRNA into the RISC according to the "thermodynamic" rule [Gregory RI et al., 2005]. 
Addition of the miRNA duplex to the RISC results in 10 times more slow degradation of the 
target than the addition of the equivalent amount of pre-miRNA. This may indicate a more 
efficient loading of newly miRNA duplexes in Ago2 compared with duplexes that are present 
in the solution. It seems that the complex Dicer / TRBP / Ago2 quickly provides the cutting of 
miRNA duplex from pre-miRNA, as well as determining the guide strand, and then loads it 
into Ago2, working like a highly efficient enzyme complex which catalyzes the consecutive 
modifications of the substrate. However, recent publications show a regulatory function and 
activity of passenger strand [Mah SM et al., 2010 ; Okamura K et al., 2008]. 
In Drosophila, miRNA and siRNA loading into RISC, as well as their biogenesis, is carried 
out by different systems. A Dicer2 / R2D2 complex binds the short RNA duplexes, where the 
strands are completely complementary to each other (i.e. siRNA) and loads them into Ago2 
[Tomari Y et al., 2007]. Another complex, possibly consisting of Dicerl and Loqs proteins, 
binds the duplexes with unpaired nucleotides (this is the predominant form of miRNA 
duplexes) and loads them into Agol. Participation of different Dicer and Ago proteins in 
miRNA and siRNA metabolism in Drosophila allows to avoid the competition between these 
pathways, which could lead, for example, after a viral infection with subsequent appearance 
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of an excess of siRNA, to the disruption of the  miRNA-dependent regulation of gene 
expression. 
 
2.3.2. miRNA interaction with mRNA. 
2.3.2.1. 5'- miRNA region plays a major role in the recognition of the mRNA target. 
The bioinformatics tools are widely used in searching for miRNA targets. There are many 
programs created for this purpose, such as TargetScan, PicTar, Miranda, miRBase Targets, 
PITA Top, mirWIP [Betel D et al., 2008; Friedman RC et al., 2009; Gaidatzis D et al., 2007; 
Griffiths-Jones S et al., 2008; Hammell M et al., 2008; Kertesz M et al., 2007; Lall S et al., 
2006; Ruby JG et al., 2007b]. These programs are used to predict the miRNA targets, which 
can be subsequently experimentally validated by analyzing the transcriptome (oligonucleotide 
microarray) or proteome (for example, quantitative mass spectrometry). As a result, new 
patterns of target recognition are included in subsequent versions. This systematic approach 
allows to identify the main requirements that are necessary for interaction between miRNA 
and their targets. 
Searching programs impose two basic requirements for the target sites within miRNA: these 
sites should have complementarity with "seed" miRNA region and should be evolutionally 
conserved. The seed region consists of nt 2-7 from the 5 'end of miRNA. This area is the most 
conserved part of animal miRNA [Lim LP et al., 2003]. In some experiments, it is shown that 
nucleotide changes in the seed region strongly disrupt miRNA-dependent regulation 
[Brennecke J et al., 2005; Doench JG et al., 2003; Kloosterman WP et al., 2004; Lai EC et al., 
2005; Wang B et al., 2006]. Pairing of 6-nucleotide miRNA seed region with target site is 
necessary, but not sufficient for miRISC binding. The searching algorithm, which gives the 
largest number of confirmed targets after experimental verification, requires conservation of 
one and / or two nucleotides in target site, adjacent to the 6 nucleotides (complementary to 
seed). It is necessary that the nucleotide, which is located opposite to the 1st nt in miRNA at 
the target site, is an adenine (it does not matter what nucleotide is the first one in miRNA in 
this case) and / or the nucleotide, which is opposite to 8th nt in miRNA will form a 
complementary pair with him. Thus, for each miRNA target site within mRNA, programs 
search for any of the two 7-nucleotides sites, which correspond to the above conditions. 
In simplified form, the searching of target sites for miRNA can be divided into three stages. 1) 
for each miRNA program, two 7- nucleotides target sites are determined; 2) In the available 
genome sequences of different species, the orthologous 3 ' UTRs are identified; 3) Within 
these 3 'UTR 7 -nucleotides target sites are searched. The result is a hypothetic target sites. If 
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there is a small number of genomic sequences, the criterion of conservation is the presence of 
7-nucleotide site in all genomes. With more available quantity of genomic sequences, search 
programs start to include poorly conserved target sites. This is determined by individual 
settings which differ from one program to another. 
For a highly conserved miRNA, this approach reveals a significant number of  mRNA targets. 
Even after subtracting poorly conserved sites, for each family of miRNA (in the miRNA 
family all the elements contain identical nucleotides 2-8) hundreds of targets usually could be 
found. For example, mammalian miRNAs which are conserved among the vertebrates, have 
approximately 300 mRNA targets for a family [Friedman RC et al., 2009]. It is expected that 
more than a half of the human protein coding genes have the conserved target sites in 3'UTR 
[Friedman RC et al., 2009]. 
Experimental data confirm the ability of one miRNA to inhibit the expression of a large 
number of  mRNA targets. According to microarray data, miRNA transfection in HeLa cells 
causes changes in the expression of hundreds of mRNAs [Lim LP et al., 2005]. Many of these 
mRNAs contain miRNA seed region complementary sites, which indicates that the effect of 
reducing of the mRNA quantity can be a direct consequence of miRNA - dependent 
repression. miRNAs shift the gene expression pattern of HeLa cells towards the tissue which 
normally expresses this miRNA, indicating that the observed regulation may occur in the 
organism. 
 
2.3.2.2. The role of the miRNA 3 'end in target recognition. 
In theory, additional pairing of the target site with the 3' region of miRNA could increase the 
affinity between miRISC and mRNA and thereby enhance the silencing. However, 
experimental data show that additional pairing only slightly increases the efficiency of 
miRNA-dependent silencing [Grimson A et al., 2007] and in most cases does not play a 
significant role in the target recognition. In accordance with its small role in the target 
recognition, additional pairing is found out only in a small percentage of miRNA-target pairs. 
For example, in Drosophila, in the majority of  target sites, additional pairing is found out 
with a frequency corresponding to the frequency of random occurrence [Brermecke J et al., 
2005]. In mammals, 5% of target miRNAs have additional pairing with their target sites 
[Friedman RC et al., 2009]. 
One of the functions of additional pairing may be the compensation of single-nucleotide non-
complementarity in seed region, which is found out in pairs of let-7 miRNA - lin-41 mRNA 
in nematode and miR196 - Hoxb8 mRNA in mammals (so-called compensatory pairing) 
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[Vella MC et al., 2004; Yekta S et al., 2004]. Other members of the family of let-7 - miR-48, 
miR-84 and miR-241 have the same seed region but different 3 'UTR [Lau NC et al., 2001; 
Lim LP et al., 2003] and are expressed in the earlier stages of nematode development than let-
7 [Abbott AL et al., 2005; Reinhart BJ et al., 2000]. It is assumed that the absence of 
compensatory pairing in these miRNA  prevents the premature mRNA repression of lin-41, 
which could disrupt the normal development of the nematode. In general, the compensatory 
pairing is found out only in very few cases [Brennecke J et al., 2005; Friedman RC et al., 
2009; Lewis RC et al., 2005]. 
 
2.3.2.3. Non-conserved target sites of miRNA. 
The functional significance of miRNA target sites is often evaluated by their evolutionary 
conservation. At the same time, the number of non-conserved 7 nt miRNA target sites 
exceeds the number of conserved sites about 10 times [Bartel DP, 2009]. Experimental 
validation of multiple non-conserved sites using the reporter constructs showed an efficient 
miRNA-dependent repression of such constructs [Farh KK et al., 2005]. However, in the 
organism, the majority of  mRNAs which contain non-conserved sites, is not subjected to 
repression, as they are expressed in tissues where the complementary miRNA is absent [Farh 
KK et al., 2005]. This phenomenon can be explained by the "selective avoidance"- 
evolutionary pressure for highly expressed tissue-specific mRNAs to lose the target sites for 
the miRNAs present in the same tissue. In addition, in tissues and organs where a given 
miRNA is not expressed, there may occur random non-conserved complementary sites which 
will not be functionally important [Farh KK et al., 2005; Stark A et al., 2005]. Some mRNA 
with non-conserved sites are not a subject of selective avoidance, i.e. they are  expressed in 
the same tissues as the complementary miRNA, and may represent newly established targets. 
 
2.3.2.4. The influence of the mRNA context for the efficiency of miRNA-dependent 
silencing. 
It is shown that the same miRNA target sites can be repressed in some mRNAs and be 
insensitive to the repression in others [Brennecke J et al., 2005; Farh KK et al., 2005; Giraldez 
AJ et al., 2006], which indicates the influence of the surrounding sequences on the site 
efficiency. Currently, several features of the mRNA context of miRNA target sites were 
shown to increase their efficiency. 
First of all, an efficient site must be located in the 3 'UTR, with a distance more than 15 
nucleotides from the stop codon. The sites located in the 5 'UTR and ORF (Open Reading 
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Frame) can cause the repression [Kloosterman WP et al., 2004; Lytle JR et al., 2007], but 
such repression is much less efficient than for sites in the 3 'UTR [Grimson A et al., 2007]. 
Bioinformatics and genome-wide experimental analyzes indicate that some part of miRNA-
mediated silencing is directed to ORF [Baek D et al., 2008; Easow G et al., 2007; Farh KK et 
al., 2005; Grimson A et al. 2007; Lewis BP et al., 2005; Lim LP et al., 2005; Stark A et al., 
2007], but the number of sites in the 3 'UTR is ten times more. Apparently, miRISC can be 
removed from mRNA by the movement of ribosome through the 5 'UTR and ORF [Bartel DP, 
2004], so the sites in 3 'UTR appear to be more efficient. Since the ribosome during 
translation termination interacts with the first 15 nucleotides in the 3 'UTR, the sites located in 
this area are also inefficient [Grimson A et al., 2007]. 
Second, target sites in the 3 'UTR must not be made inaccessible by secondary structures of 
RNA. The most efficient are the sites at the ends of the 3 'UTR, since, as it is assumed,  there 
is higher possibility for the forming of secondary structures in the middle of a 3' UTR 
[Grimson A et al., 2007]. Even more important is the nucleotide composition near the site. It 
is shown that the sites surrounded by the sequences with high AU content are more efficient 
[Grimson A et al., 2007]. The reason for this lies in the fact that the potential secondary 
structure formed by AU  sequences is less stable and therefore more accessible to miRISC,  
than the structure which consists of GC nucleotides. 
Third, in a small number of cases, the cooperativity of miRNA effects is detected. If the target 
sites in a mRNA are located at the distance less than 40 but more than 8 nucleotides, then the 
summary effect is greater than the sum of the effects of two independent sites [Grimson A et 
al., 2007; Saetrom P et al., 2007]. In analogy with the transcription factors, it can be assumed 
that the cooperativity of miRISCs action may lead to repression that is sensitive to small 
changes in the level of miRNAs. If the complementary sites are located at a greater distance, 
then the combined effect is the sum of the effects of each site. The above-listed observations 
of the influence of site location in miRNA to the repression efficiency are included in the 
number of prediction algorithms for miRNA targets (TargetScan, PITA Thor mirWIP) 
[Friedman  RC et al., 2009; Hammell M et al., 2008; Kertesz M et al., 2007]. 
 
2.3.2.5. Limitations of existing ideas about the recognition of miRNA targets. 
Despite the significant success in understanding of the miRNA-target recognition 
mechanisms, at the moment there remain a number of non-resolved issues in this area. First, 
some functionally efficient sites do not fit the generally accepted rules of target search. For 
example, the experimentally validated miR-125 sites in the 3 'UTR of LIN28 mRNA in 
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humans contain 3’ adenosine residues that contribute to the function of the site, without being 
complementary to the target site in miR-125 [Wu L et al., 2005]. In HeLa cells, miR-16 
causes the degradation of TNF-α mRNA, though it contains only partially complementary 
miR-16 target sites [Jing Q et al., 2005]. It is assumed that the TTR protein (tristetraprolin), 
which is necessary for miR-16-dependent silencing and which interacts with the mRNA target 
site and miRISC, is providing such a non-canonical interaction. 
Second, the influence of the mRNA context on the efficiency of target site has not been 
sufficiently taken into account yet. The action of a given miRNA at identical target sites 
contained within different mRNAs differs in its repression intensity, and only 60% of this 
variability can be explained on the basis of modern ideas about the influence of context on 
repression [Grimson A et al., 2007]. 
Third, the mRNA is a target of many regulatory systems in the cell, which may affect the 
miRNA-dependent silencing. Some cases of such influence have been discovered. For 
example, mRNA can avoid miRNA-dependent silencing by alternative processing and 
polyadenylation, when the target sites are removed from it. In mice, this phenomenon is 
discovered in various proliferating cells, where the 3 'UTRs of multiple mRNAs are shorter 
than in non-proliferating cells. Such short 3 'UTRs have in average two times less conserved 
miRNA target sites than their long isoforms [Sandberg R et al., 2008]. In addition, a mRNA 
may be protected from silencing by RNA-binding regulatory proteins.  
Fourth, the vast majority of the studies of the mechanisms of miRNA targets recognition are 
performed using highly expressed miRNA. The low-level miRNAs may require special 
conditions for binding to the targets. The rare miRNAs may involve mechanisms which 
increase the affinity of the interaction with target mRNA, i.e. they may use miRISC-
associated mRNA-binding proteins or form a strong 3'-pairing. There is no doubt that in 
future, more interactions of miRNA pathways with other regulatory pathways of gene 
expression will be found, thus highlighting the exact place of miRNA-dependent repression in 
the overall network of intracellular regulation. 
 
2.3.3. The mechanisms of miRNA-dependent translational repression. 
miRNA, as well as siRNA, can be completely complementary to a site in mRNA that causes 
cleavage of the phosphodiester bond in mRNA, performed by Piwi domain of Ago (slicer 
activity). In animals, the majority of miRNAs are partially complementary to the sites within 
mRNAs. If the mRNA nucleotides, between which the cleavable phosphodiester bond is 
situated, do not form a complementary pair with the miRNA, the catalytic center in Piwi 
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domain can not perform the cleavage [Hutvagner G, 2002; Saxena S et al., 2003]. In this case, 
the miRISC binding to mRNA causes its translational repression and / or degradation by 
slicer-independent mechanisms. While it is sufficient to have only one complementary mRNA 
site for the effective degradation with Ago, an effective translational repression and slicer-
independent degradation usually requires several partially complementary sites, typically 
located in the 3 'UTR. In some cases, instead of mRNA repression, miRNA may cause the 
activation of translation [Vasudevan S et al., 2007; Vasudevan S et al., 2007] by mechanisms 
that will be discussed below. 
 
2.3.3.1. Slicer-dependent degradation of mRNA. 
As in the case of siRNA, when a miRNA is fully complementary to the target mRNA, the 
catalytic site in Piwi domain of Ago cleaves the phosphodiester bond between mRNA 
nucleotides, which are complementary to nucleotides 10 and 11 in miRNA. This mechanism 
of repression is widespread in plants, but in animals it occurs rarely [Bartel DP, 2004]. 
 
2.3.3.2. Suppression of translation initiation. 
If there is no complementarity between nucleotides 10-11 within miRNA and the 
corresponding nucleotides in mRNA, then miRISC activates a translational inhibition. 
Currently, the majority of studies concentrate on two possible mechanisms of translational 
suppression via miRNA. One series of studies indicates a suppression of translational 
initiation [Bhattacharyya SN et al., 2006; Humphreys DT et al., 2005; Mathonnet G et al., 
2007; Pillai RS et al., 2005; Wakiyama M et al., 2007; Wang B et al., 2006], and other groups 
show that repression happens at post-initiation step [Nottrott S et al., 2006; Olsen PH et al., 
1999; Petersen CP et al., 2006; Seggerson K et al., 2002]. In the experiments described below 
(sometimes they are very similar), the authors have somehow obtained differing data, 
implicating either the initiation or the post-initiation stage of translation as principal 
mechanisms of repression. The attempts of many authors to combine these mechanisms in a 
common regulatory pathway are not yet successful. The working hypothesis for the moment 
is that the translation of any mRNA can be inhibited by different mechanisms, and the choice 
between them is determined by specific proteins associated with the mRNA, or by the RISC 
complex composition.  
 
 
 
	   42	  
The data in favor of miRNA-dependent repression of translation initiation. 
In cell culture, exogenous target mRNA, synthesized in vitro, leaves the polysomal fractions 
of sucrose gradient as a result of miRNA-dependent repression [Pillai RS et al., 2005]. This 
indicates that miRNA interferes with ribosomes binding and inhibits translation initiation. 
Several studies have shown that the reporter mRNAs which use the alternative translation 
initiation mechanism, such as viral IRES (Internal Ribosome Entry Site), are not subject to 
miRNA-dependent silencing, which indicates that repression is directed on cap-dependent 
initiation machinery. IRES are highly structured RNA sequences that are able to initiate 
translation in the absence of cap structure [Filbin ME et al., 2009]. In [Humphreys DT et al., 
2005], a culture of mammalian cells was transfected with in vitro synthesized bicistronic 
mRNA, where the second cistron translation was directed by the IRES of CrPV (cricket 
paralysis virus) or EMCV (encephalomiocarditis virus).   It was found that the same reporter 
mRNA was resistant to miRNA-dependent repression when containing the CrPV IRES, and  
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Figure 6. Mechanisms of miRNA-mediated gene silencing [Eulalio and al., 2008a]. 
was only partially repressed when containing the IRES of EMCV. In a complementary study, 
using slightly differing methodology, cells were transfected with in vitro-synthesized mRNA 
containing the IRES of EMCV or HCV (hepatitis C virus) [Pillai RS et al., 2005]. The 
mRNAs with both IRES were completely resistant to repression using miRNA let-7a. These 
studies suggested that only cap-dependent, but not IRES-dependent translation is sensitive to 
miRNA-dependent repression, probably via the initiation factor eIF4E, and that miRISC may 
disrupt the binding between the  initiation complex and the capped mRNA. 
The m7Gppp Cap structure cotranscriptionally hinges at the 5 'end of the mRNA in the 
nucleus and is required for efficient translation of the mRNA in the cytoplasm [Spirin A., 
2000]. Cap is bound by the translation initiation factor eIF4E, which is a component of the 
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eIF4F complex, participating in the small subunit ribosomal recruitment to the 5 'end. In some 
cases, m7Gppp cap replacement by a nonfunctional ApppN cap as well as IRES element 
introduction in 5 'UTR (discussed above) can suppress the miRNA-dependent translational 
repression [Humphreys DT et al., 2005; Mathonnet G et al., 2007; Pillai RS et al., 2005; 
Wakiyama M et al., 2007; Wang B et al., 2006]. In humans, the protein Ago2 contains a motif 
similar to the cap-binding motif of eIF4E [Kiriakidou M et al., 2007]. Two conserved 
tryptophans of eIF4E ‘enfold’ both sides of methylated guanine base of the cap, forming a 
stacking interactions. Ago2 has two phenylalanine in a positions equivalent to tryptophans. 
Ago2 binds m7GTP on the surface of sepharose beads , and the cap-analogue (m7GpppG) 
competitively inhibits this binding [Kiriakidou M et al., 2007]. Replacement of one or both of 
phenylalanines by valine disrupts the m7GTP binding and as a consequence, disrupts  the 
Ago2 repressor effect too. It is expected, that after miRISC binding on mRNA, Ago can bind 
a cap structure, disrupting the eIF4F complex binding to mRNA (Fig. 6C). 
Unlike the situation in mammals, the Drosophila Ago proteins do not bind directly to the cap 
[Eulalio A et al., 2008b; Iwasaki S et al., 2009]. In Drosophila, the protein Ago1 is the main 
protein involved in miRNA-dependent repression, but in the cases where miRNA duplex has 
a complete complementarity, Ago2 may participate in silencing too [Forstemann K et al., 
2007; Tomari Y et al., 2007]. Ago1 and Ago2 in Drosophila suppress the translation by a 
variety of mechanisms. Ago1 promotes a mRNA deadenylation, and Ago2 breaks the 
interaction between eIF4E and eIF4G, which are the members of the initiation complex 
eIF4F, thereby not allowing the small subunit of the ribosome to bind to target mRNA 
[Iwasaki S et al., 2009]. 
2.3.3.3. miRISC may disrupt ribosome recruitment by attracting eIF6 factor. 
EIF6 initiation factor binds to the 60S ribosomal subunit and prevents the assembly of the 
whole 80S ribosome [Ceci M et al., 2003]. In humans, elF6 was detected in the complex 
comprising RISC proteins, particularly Ago2, and 60S ribosomal subunits [Chendrimada TP 
et al., 2007]. The knockdown of eIF6 in human cells or in nematode releases a miRNA-
dependent repression of  both reporter and endogenous mRNAs [Chendrimada TP et al., 
2007]. It is assumed that miRISC may recruit eIF6 to the ribosomes assembly site on mRNA 
and inhibit the assembly of the whole ribosome (Fig.6D). However, in the Drosophila S2 cell 
culture, the eIF6 knockdown does not disrupt the miRNA-dependent repression [Eulalio A et 
al., 2008b]. Thus, eIF6 may participate in miRNA-dependent silencing in mammals, but it is 
not required for the silencing in Drosophila. 
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2.3.3.4. miRISC may cause deadenylation of mRNA, thereby disturbing its 
circularization and therefore reducing the efficiency of translational initiation. 
Poly(A) sequence increases the translation of mRNAs [Spirin A., 2000]. PABP (poly(A) 
binding protein) binds a poly(A) sequence of mRNA and interacts with a translation initiation 
factor eIF4G, which is a cap-recognizing eIF4F complex component [Gingras AC el al., 
1999]. This leads to the formation of the “ring” structure of mRNA, detected by the electron 
microscopy [Spirin, A., 2000]. The interaction of PABP and eIF4G enhances the translation in 
Xenopus oocytes [Wakiyama M et al., 2000]. miRNA can cause mRNA deadenylation 
[Giraldez AJ et al., 2006; Wakiyama M et al., 2007; Wu B et al., 2006] and thus reduce the 
translation efficiency (Fig. 6E) [Wakiyama M et al., 2007]. In Drosophila, miRISC, which 
contains protein Ago l, causes the deadenylation of target mRNA [Iwasaki S et al., 2009]. On 
the other hand, mRNA without poly(A) can also be subject to miRNA-dependent repression 
[Eulalio A et al., 2009b; Iwasaki S et al., 2009; Wu B et al., 2006], which indicates the 
existence of other mechanisms for translational repression. 
 
2.3.3.5. miRNA can cause mRNA association with P-bodies components, involved in 
translational repression. 
P-bodies (processing bodies) are the aggregates of translationally repressed mRNAs, 
containing proteins involved in the inhibition of translation and mRNA degradation (Fig. 6F). 
The amount of translationally repressed mRNA positively correlates with an increase in size 
and in number of P-bodies, and vice versa [Teixeira D et al., 2005]. P-bodies contain a 
number of conservative "core" proteins, which include RNA decapping enzymes Dcpl/2, 
decapping activators Dhhl / RCK / p54, Pat1, Scd6 / RAP55, Edc3, Lsml-7 and 5'-3' 
exonuclease Xrnl [Parker R et al., 2007], as well as additional proteins found only in some 
organisms (e. g. GW182 protein in Drosophila and TNRC6 in humans). The P-bodies lack the 
translational initiation factors (with a few exceptions), and 60S ribosomal subunits [Valencia-
Sanchez MA et al., 2006]. It is believed that a significant part of translational repression in the 
cell can be explained by P-bodies function [Parker R et al., 2007]. The mechanism of 
translational repression in P-bodies is still not well understood. However, it is clear that the 
association of target mRNAs and P-bodies components is required for repression 
[Bhattacharyya SN et al., 2006; Liu J et al., 2005b].  Taking in mind the absence of entire 
ribosome in P-bodies, it is believed that this repression occurs at the stage of translational 
initiation. mRNA can exit from P-bodies, enter the polysomes and be translated, and various 
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protein factors may shift this dynamic equilibrium in one or another direction [Bhattacharyya 
SN et al., 2006]. 
In most cases, the knockdown of P-bodies protein components disrupt the miRNA-dependent 
repression [Behm-Ansmant I et al., 2006; Chu CY et al., 2006; Jakymiw A et al., 2005; Liu J 
et al., 2005a]. In the composition of P-bodies Ago and miRNAs are found, which indicates the 
link between the P-bodies and miRNA-dependent silencing [Behm-Ansmant I et al., 2006; 
Bhattacharyya SN et al., 2006; Humphreys DT et al., 2005; Jakymiw A et al. 2005; Leung 
KM et al., 2006; Liu J et al., 2005b; Meister G et al., 2005]. Ago proteins interact with many 
components of P-bodies [Liu J et al., 2005a; Liu J et al., 2005b]. In Drosophila cell culture, 
the mutations that disturb the interaction between Ago1 and a key component of P-bodies (i.e. 
protein GW182), interfere with miRNA-dependent silencing [Eulalio A et al., 2009a]. Thus, 
Ago proteins can cause the translational repression, holding the mRNA in P-bodies and 
thereby associating mRNA with P-bodies components. 
MiRNA targets form the basis of P-bodies, because the general disturbance of miRNA-
dependent silencing in the cell leads to the disappearance of P-bodies [Pauley KM et al., 
2006]. mRNA association  with P-bodies components is accompanied not only with 
suppressing of its translation, but in some cases, by degradation. 
However, the role of the macroscopic P-bodies in the repression of translation remains 
controversial. Several studies have shown that a mRNA association with P-bodies is not 
sufficient for the repression. A mutated GW182 that continues to interact with Ago1, but is 
not localized to macroscopic P-bodies, leads to the disappearance of macroscopic P-bodies, 
but does not disturb miRNA-dependent silencing [Eulalio A et al., 2009a]. The knockdown of 
some P-bodies proteins, resulting in the visual dissociation of P-bodies, has no effect on 
miRNA-dependent silencing [Chu CY et al., 2006; Eulalio A et al., 2007a]. This indicates that 
for the suppression of translation, the entering of mRNA target into macroscopic P-bodies is 
not necessary, and only association with P-bodies proteins is important. 
The suppression of translation with the help of P-bodies can be the bridge that will unite, at 
least partially, the conflicting data on the mechanisms of miRNA-dependent translational 
repression. Firstly, the mechanism of repression via P-bodies is currently unknown. Secondly, 
a deadenylation of target mRNA observed in some cases as a response to the miRNA, may be 
associated with P-bodies. In Drosophila, the protein Ago1 binds to GW182 and inhibits the 
translation of mRNA through deadenylation [Iwasaki S et al., 2009]. On the other hand, the 
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protein Ago2 that does not interact with GW182, suppresses the translation by inhibiting the 
formation of initiation complex eIF4F, which indicates a non-exclusive role of P-bodies in the 
repression process [Iwasaki S et al., 2009]. 
2.3.3.6. Translational repression at the post-initiation step. 
As it was mentioned above, two studies using IRES have indicated that that only cap-
dependent, but not IRES-dependent translation is sensitive to miRNA-dependent repression, 
probably via the initiation factor eIF4E, and that miRISC may disrupt the binding between the  
initiation complex and the capped mRNA [Humphreys DT et al., 2005; Pillai RS et al., 2005]. 
However, another work using the same IRES had shown that the translation controlled by the 
same IRES was sensitive to RISC-dependent inhibition [Petersen CP et al., 2006]. As these 
IRES do not require any canonical translation initiation factors, these authors concluded that 
RISC suppresses the translation at some stage after the initiation. 
How is it possible to explain the contradictory results obtained using IRES? In the first two 
studies, a transfection of in vitro synthesized mRNA was used as a model [Humphreys DT et 
al., 2005; Pillai RS et al., 2005]. In the third work, the cell culture was transfected with a 
plasmid encoding the mRNA of interest [Petersen CP et al. , 2006]. It is assumed that the 
mechanism of translational repression may depend on proteins associated with the target 
mRNA. The contradictions in the results mentioned above can be explained by the fact that in 
vitro synthesized mRNA, in contrast to the mRNA of nuclear origin, does not carry the 
associated protein factors, defining the mechanism of repression at post-initiation steps. This 
hypothesis suggests that the mechanism of repression of mRNA translation can depend on the 
promoter, which is responsible for the transcription of this mRNA [Kong YW et al., 2008]. 
Apparently, the promoter may determine the binding of different nuclear protein factors to 
mRNA, which determine the mechanism of repression. These contradictions highlight the 
importance of appropriate experimental models while studying miRNA-dependent repression. 
Other studies revealed that repressed mRNA can stay in the polysomal fractions. In HeLa 
cells, a reporter mRNA, both repressed and non-repressed by a miRNA let-7a, is found in 
sucrose gradient polysomal fractions [Nottrott S et al., 2006], as well as, Ago2 and miRNA 
let-7a. Moreover, it was shown that in growing HeLa cells, the majority of miRNA 
colocalizes with polysomes [Maroney PA et al., 2006]. Thus, it was assumed that the 
mechanisms of miRNA-induced repression may include the degradation of newly formed 
protein or the reducing of the translation elongation speed (Fig. 6 A, B). 
	   48	  
2.3.3.7. Slicer-independent degradation of mRNA. 
In the first studies of miRNA, it was assumed that the main method of repression in animals is 
the translation repression without a noticeable decrease in the level of mRNA target. 
However, in recent years, a considerable number of observation of miRNA-dependent 
degradation of mRNA was published [Behm-Ansmant I et al., 2006; Chendrimada TP et al., 
2007; Eulalio A et al., 2007b; Giraldez AJ et al., 2006; Wu L et al., 2005; Wu L et al., 2006]. 
Much of this degradation occurs in the absence of complementarity in the middle of mRNA 
and miRNA duplex. The using of microarrays for full transcriptome search of target sites 
which cause miRNA-dependent degradation of mRNA in human cell culture, shows that the 
vast majority of these sites forms a complementary pair with only seed region, but not with 
10-11 nucleotides within miRNA [Grimson A et al., 2007]. This indicates that a slicer-
independent mRNA degradation is widespread. The existence of such degradation is 
confirmed by experiments, in which the degradation of reporter mRNA carrying boxB sites, 
could be caused by miRNA-independent binding of the transgenic protein Ago1-?N [Eulalio 
A et al., 2009b]. 
This raises a question about the mechanism of slicer-independent mRNA degradation. For 
degradation of mRNA in eukaryotic cells, there are two conservative ways; both of them 
promote the removal of the mRNA poly(A) tail as the first step [Parker JS et al., 2004]. The 
mRNA is then degraded by the exosomes in the 3’-5' direction, or undergoes decapping and 
5'-3' degradation in P-bodies. The components of P-bodies that are attracted to the mRNA by 
miRlSC inhibit the translation initiation of mRNA. In the embryos of D.rerio, of C.elegans, as 
well as in Drosophila and human cell culture, miRNA enhances the deadenylation and 
decapping of their targets [Behm-Ansmant I et al., 2006; Eulalio A et al., 2007b; Giraldez AJ 
et al., 2006; Wu L et al, 2006]. 
In the culture of Drosophila cells, the changes in the level of 6000 mRNA were studied using 
oligonucleotide microarrays, in response to the protein knockdown of Ago1, Drosha, 
deadenylating, decapping enzymes and protein GW182. It was shown that the correlation 
between the sets of mRNA, that increase after the knockdown of Ago1 and GW182, as well 
as of deadenylating enzymes CAF1 and NOT1, can be esteemed as 60-75% [Behm-Ansmant I 
et al., 2006; Eulalio A et al., 2009b]. Such level of correlation is observed after the 
knockdown of Ago1 and Drosha, belonging to the same regulatory pathway [Rehwinkel J et 
al., 2006]. Consequently, the deadenylating enzymes CAF1 and NOT1, as well as GW182 
protein, are involved in almost all cases of miRNA-dependent mRNA degradation in 
Drosophila cell culture. After the knockdown of Ago1 and of decapping enzymes Ge-1, Dcp1 
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and HPat, the correlation is only 15% [Eulalio A et al., 2007b], but the role of decapping may 
be higher, because the protein Dcp2, which is the main decapping enzyme in Drosophila, was 
not included in this study. The protein GW182, which is essential for slicer-independent 
degradation of mRNA, is a component of P-bodies [Parker R et al., 2007]. miRISC attracts 
the components of P-bodies (including GW182) to the mRNA and, taking into account that 
the decapping enzymes and 5’-3' exonuclease are present between these components, it is 
logical to assume that the slicer-independent degradation of mRNA occurs due to the 
association of mRNA with the components of P-bodies. 
In the future, it is necessary to answer a number of questions. What governs the choice 
between the suppression of translation and a slicer-independent degradation of mRNA? Is a 
slicer-independent degradation of the mRNA a side consequence of the association of 
translationally repressed mRNAs with the components of P-bodies, or it is an independent 
mechanism? Why some mRNAs are subject to such degradation, and some  are not? 
Probably, the attempts to answer these questions will reveal new roles for regulatory proteins 
that bind to specific sequences in mRNAs and defining the repression mechanism. 
2.3.3.8. miRNA-dependent activation of translation. 
The arrest of cell cycle in mammalian cell culture leads to the activation of translation of 
mRNA TNF-a, as well as of some reporter constructs, due to the miRISC complex binding, 
which contains the Ago2 and FXR1 proteins [Vasudevan S et al., 2007; Vasudevan S et al., 
2007]. The activation of translation after a cell cycle arrest is induced by miRNA let-7 and by 
CXCR4, which normally induce translational repression in the proliferating cells. It is 
assumed that a formation of two types of miRISC, repressive or activating, is possible 
depending on the intracellular conditions. However, the data on miRNA-induced translational 
activation was obtained only by one group of researchers, and more studies are needed to 
evaluate the frequency and the importance of this phenomenon. 
 
2.3.4. A comparison of miRNA and siRNA-dependent silencing. 
The gene multiplicity of Ago as well as Dicer in some cases, can allow to divide the ways of 
miRNA and siRNA-dependent repression for their differential regulation. In plants, there are 
4 genes encoding Dicer, and 10 genes encoding proteins of the Ago family; in Drosophila - 2 
and 5, in mammals - 1 and 7 (8) of genes, respectively [Siomi H et al., 2009]. In Drosophila, 
Dicer2 and Ago2 participate mainly in the siRNA pathway, whereas Dicer1 and Ago1 - in the 
miRNA pathway. Dicer2 cuts the dsRNA and Dicer2/R2D2 complex loads the newly formed 
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siRNA in Ago2 [Forstemann K et al., 2007; Tomari Y et al., 2007]. Drosha/Pasha and 
Dicer1/LOQS complexes are involved in the formation of miRNA, and the unknown complex 
loads miRNA in Ago1 [Denli AM et al., 2004; Forstemann K et al., 2007; Forstemann K et 
al., 2005; Tomari Y et al., 2007]. In the study of RNAi in « in vitro » system, there  were 
described  the properties of effector complexes containing Ago2 and Ago1, and it was shown 
that both siRISC and miRISC can cause the degradation of the complementary target mRNA 
[Okamura K et al., 2004]; however, miRISC performs this with much lower efficiency 
[Forstemann K et al., 2007; Tomari Y et al., 2007]. 
In mammals, the division of siRNA and miRNA pathways is not observed. It is shown that 
human Ago1, 2 and 3 in vivo can bind both siRNA and miRNA [Liu J et al., 2004]. The 
experiments on embryonic stem cells show that all mammalian Ago are capable for the 
miRNA-dependent inhibition of translation [Su H et al., 2009]. This may be explained by the 
presence of a single protein Dicer, which participates in biogenesis as well as in loading of the 
both types of short RNAs into RISC. The redundancy of Ago genes in mammals may serve to 
suppress the expression with various RISC through various mechanisms, i.e. the degradation 
of target mRNA, the suppression of transcription, or the translation. Indeed, only the human 
RISC, carrying Ago2, is capable to promote the degradation of target mRNA [Liu J et al., 
2004; Meister G et al., 2004]. Apparently, Ago1 and Ago4 are not able to cut the target due to 
a loss of His residue for Ago1 as well as one of Asp for Ago4 in the catalytic triad. The lack 
of Ago2 does not prevent the translational repression of a reporter gene in cell culture [Liu J 
et al., 2004]. This indicates that the proteins Ago1, Ago3 and/or Ago4 are involved only in the 
suppression of translation, but not in mRNA degradation. At the same time, the Ago1 protein 
is essential for the transcription silencing induced by siRNA, which is homologous to the 
promoter of the reporter gene [Kim DH et al., 2006]. 
 
3. The role of the 3 'UTRs of mRNA in the regulation of translation. 
The attention of researchers to the 3 'untranslated region of the mRNA has appeared relatively 
recently [Standart N et al., 1994, as one of the first review on this topic]. The role of 3 'UTR 
in a post-transcriptional regulation of gene expression is due to the effect on mRNA stability, 
its localization in the cell and/or translation efficiency. This part of the Introduction will focus 
on the participation of 3' UTRs in the regulation of translation. 
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3.1. Main steps in eukaryotic translational initiation. 
Usually, the rate-limiting translation step is initiation and as a rule, it is mostly susceptible to 
the regulation involving the 3' UTRs of mRNA. Some mRNAs can initiate translation in a 
cap-independent manner, where ribosome is recruited to the correct initiation codon by 
structural motifs in the 5’-untranslated region - internal ribosome entry sites (IRES), that is 
recognized by activated 40S initiation complex, followed by a mRNA scanning to the initiator 
codon. Cap-independent initiation requires additional proteins such as La-protein (a 
polypyrimidine-binding protein, PTB). However, the majority of eucaryotic mRNAs initiate 
translation by a mechanism that depends on the recognition of the m7G(5′)ppp(5′)N structure 
(cap) located at the 5′ end of most mRNAs. The complicated process of translation initiation 
in eukaryotes consists of several stages (Fig. 7) involving a large number of eukaryotic 
initiation factors (eIFs). The 5′cap structure is recognized by eIF4E alone (in this case, this 
event is followed by a heterotrimeric eIF4F complex formation i.e. association of eIF4E with 
scaffold protein eIF4G and the RNA helicase eIF4A) or in a composition of eIF4F preformed 
complex. Additionally, eIF4G interacts with eIF3 and with the poly(A)-binding protein 
(PABP) that is bound to the poly(A) tail of the mRNA, leading to mRNA circularisation. 
Translation initiation factor eIF4A promotes the ATP - dependent melting of secondary 
structures in the 5 'UTRs of mRNA with the help of elF4B, the eIF4A ATPase center 
activator. In the next step, the 5 'end of the mRNA joins 43S preformed preinitiation complex, 
consisting of a small 40S ribosomal subunit as well as the initiator Met-tRNAi in complex 
with eIF2 - GTP and several other translation initiation factors indicated in Fig.7. This mRNA 
binding is achieved probably via eIF3, that can interact with both eIF4G and 40S ribosomal 
subunit, and is stabilized by eIF1A. At the next step, 43S complex scans the 5 'UTRs to the 
initiation codon in an appropriate sequence context (the Kozak context), leading to the 
formation of the 48S initiation complex. At this step, eIF1 is displaced and eIF5 mediates the 
hydrolysis of eIF2-bound GTP. At the final stage of translation initiation, there is an accession 
to the 48S preinitiation complex of a large 60S ribosomal subunit resulting in 80S complex 
formation. This process is promoted by eIF5B and is accompanied by the hydrolysis of 
another GTP molecule. All above-mentioned steps can be regulated during translation 
initiation through the 3' UTRs of mRNA. Naturally, the question arises what influence has a 3 
'untranslated region, as well as its associated proteins, upon the events taking place at the 5' 
end of the mRNA molecule. The regulation models proposed in literature are based on the 
mRNA circularization. 
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Figure 7. Main steps in eukaryotic translational initiation [from Preiss and Hentze, 2003, with 
changes]. 
 
3.2. Regulation involving proteins that interact with the 3`UTR of mRNAs. 
The hypotheses about mRNA circularization during translation have been proposed long time 
ago. The most popular of them is based on the fact that the poly(A) - binding protein 
associated with the 3'-terminal poly(A) tail of a mRNA interacts with initiation factor eIF4G, 
forming the part of a translation initiation complex eIF4F, which binds to the 5 'end of the 
mRNA molecule [Tarun SZ et al., 1996; Wells SE et al., 1998]. It is believed that the 
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formation of a closed mRNA ring promotes the recycling of ribosomes and, consequently, the 
protein synthesis efficiency. This model explains many experimental data [for example, 
Sachs, 2000], but it has a number of controversies, as well [Kozak M et al., 2004]. Thus, it 
was assumed that at the basis of the stimulating effect of poly(A) - binding protein on the 
translation under the hypotheses described above, there is the interaction of RNA-recognition 
PABP motifs RRM1 and RRM2 with the initiation factor eIF4G, and the destruction of this 
interaction abolishes the stimulating effect of PABP on the translation. However, some 
experiments show that PABP with deleted RRM1 and RRM2 is unable to interact with eIF4G, 
but can nevertheless stimulate the reporter mRNA translation. In addition, PABP is able to 
activate the translation of mRNAs without a poly(A) tail, and therefore, PABP may operate 
without contacting the poly(A) tail [Otero LJ et al., 1999].  
Although these and some other facts put into question the current version of the mRNA 
circularization hypothesis, this model was very attractive for the researchers who have tried to 
explain the effect of  3'UTRs on translation of a particular mRNA, by two reasons. Firstly, 
when mRNA circularization appears, 3' UTRs becomes close to the 5' end of the mRNA, and 
proteins that interact with the 3’UTR could directly affect the initiation of translation. 
Secondly, in addition to the above-described circularization, mRNAs may form an alternate 
circular structure involving proteins associated with the 3 'UTRs and 5' UTRs of mRNA 
molecule. In this case, it is possible to obtain either activation or inhibition of translation. 
The most striking examples of such translational control are obtained in studies of early 
embryonic development. Thus, it is shown that during the maturation of Xenopus leavis 
oocytes, the synthesis of key proteins of this process, c-Mos and cyclin B1, is determined by 
polyadenylation of their mRNAs (Fig. 8) [Sheets MD et al., 1994]. The mRNAs of these 
proteins have a short poly(A) tail and are found in masked state in immature oocytes. There 
are two regulatory sequences in their 3 'UTRs, such as CPE (cytoplasmic polyadenylation 
element) which specifically interacts with the protein CPEB (CPE-binding protein), as well as 
a hexanucleotide polyadenylation signal (AAUAAA), recognizable by CPSF (cleavage and 
polyadenylation specificity factor). A complex formed on the 3' UTRs includes the other 
proteins as well. A scaffold protein Symplekin interacts with both CPEB and CPSF. The Poly 
(A) polymerase Gld-2 is included in the complex through an interaction with CPSF [Barnard 
DC et al., 2004]. CPEB in its non-phosphorylated state binds PARN deadenylase and protein 
Maskin. The colocalization of poly(A) polymerase and PARN deadenylase leads to the 
maintenance of short poly(A) tail of target mRNAs. This fact contributes to the translation 
inhibition [Kim JH et al., 2006; Kuersten S et al., 2003]. However, it is believed that the main 
	   54	  
role in the inhibition is played by Maskin. This protein has a high affinity for the cap-binding 
protein eIF4E. It replaces eIF4G in the complex containing eIF4E, which leads to the 
inhibition of translation and mRNA circularisation through Maskin (5`cap-eIF4E-Maskin-
CPEB-CPE-3 'UTRs of mRNA) [Stebbins-Boaz B et al., 1999]. 
 
 
 
Figure 8. Model for translational inhibition and activation of c-mos and cyclin B1 during 
maturation of oocytes in X. leavis [from Kim JH et al., 2006, with changes]. 
 
During maturation of oocytes after progesterone stimulation, CPEB is phosphorylated  by the 
kinase Aurora IAK1/Eg2 on Ser-174 or Thr-171, which leads to the increasing of affinity of 
CPEB to CPSF, as well as to a recruitment of the poly(A) polymerase GLD-2 and to PARN 
deadenylase dissociation [Tay J et al., 2003 ; Villalba A et al., 2011 ; Fernandez-Miranda G et 
al., 2012]. In such complex, the synthesis of poly(A) tail occurs without a subsequent 
shortening by deadenylase. The newly synthesized poly(A) sequence binds PABP, which in 
its turn interacts with eIF4G. This event increases the affinity of eIF4G to eIF4E, which leads 
to the displacement of Maskin complex from eIF4E. The displacement of Maskin is probably 
influenced by the destabilization of its interaction with CPEB after the CPEB phosphorylation 
[Sarkissian M et al., 2004]. As a result of all these events, the classic circular structure occurs 
(with PABP, eIF4G, eIF4E), which induces an efficient translation of mRNA [de Moor CH et 
al., 1999; Groisman I et al., 2002; Kim JH, 2006]. Similar regulatory system has been found 
in the translation studies of nerve cells axons. It is considered to play a key role in synaptic 
plasticity [Richter JD, 2001; Wu L et al., 1998]. The Maskin protein function in this situation 
is performed by another eIF4E-binding protein, Neuroguidin [Jung MY et al., 2006; Huang 
YS et al., 2007].  
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It is necessary to note that the translational inhibition model involving Maskin protein is not 
controversy-free. In addition to lack of certain direct experimental evidences [discussed in 
Kozak M, 2004; Kozak M, 2006], the main problem of the above-described scheme is that all 
Maskin homologs, even in species close to Xenopus laevis, lack the putative specific binding 
site to eIF4E. In addition, the role of Maskin in early embryonic development may be 
associated not only with the translation, but also with the microtubules organization in the cell 
[O'Brien LL et al., 2005].  In addition, recent studies show that in the case of CPEB-mediated 
inhibition of cyclin B1, Xp54 and Pumilio proteins can be key to the regulation of the cyclin 
mRNA translation. Xp54 is a RNA helicase, which interacts with CPEB and eIF4E, both 
directly and indirectly. These interactions, as well as the helicase activity of Xp54, are 
essential for translation inhibition [Minshall N et al., 2001]. It is interesting that after the 
polyadenylation of the cyclin B1 mRNA, the protein Xp54 is not included in the complex 
with 3 'UTRs of this mRNA, and the translation is not inhibited. How the protein Pumilio 
influences translation is even less clear, but it is believed that it contributes to the inhibition of 
translation initiation through the poly(A) tail shortening, recruiting a deadenylase complex to 
mRNA [Rouhana L et al., 2007]. However, these models are not yet sufficiently confirmed 
experimentally to describe them in more detail. At the same time, their appearance shows that 
in the near future, our understanding of the molecular mechanisms of translational regulation 
during the maturation of oocytes can become even more complicated.   
 
The Drosophila eIF4E-binding protein Cup is involved in the translational repression of 
mRNAs oskar and nanos (Fig. 9). The protein Bruno provides its interaction with the 3 'end of 
the mRNA molecule in the case of oskar, [Kim-Ha J et al., 1995; Wilhelm JE et al., 2003] and 
protein Smaug does the same thing in the case of nanos mRNA [Dahanukar A et al., 1999; 
Nelson MR et al., 2004]. It is believed that in this way, the formed circular structures can 
interfere the interaction between eIF4E and other components of eIF4F initiation complex, 
and this provides a translational repression of oskar and nanos mRNAs (Fig. 9).  
It was assumed that a Drosophila protein Bicoid, which contains the eIF4E binding motif 
(same as the previously-mentioned Maskin protein), prevented an interaction between eIF4E 
and eIF4G, and thereby inhibited the translational initiation of caudal mRNA (Fig.9) 
[Niessing D et al., 2002]. In this case, the mRNA was locked in a ring structure: 5'cap-eIF4E-
Bicoid-BBR-3`. However, [Barnard DC et al., 2005] showed that the inhibitory complex 
included a protein having some structural similarity to eIF4E and named 4EHP (eIF4E-
homologous protein). Due to some differences from eIF4E, this protein has a higher affinity 
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to Bicoid, than to the initiation factor eIF4G, but can still effectively interact with mRNA cap 
structure. 
Surprisingly, mammalian 4EHP can also activate translation, for example, during hypoxia, 
illustrating the complexities of translational control [Uniacke J et al., 2012]. Being similar to 
4EHP, CPEB also does not always function as a repressor (described above). So, both 4EHP 
and CPEB are the examples of RNA-binding proteins that can function either as repressors, or 
as activations of translation, depending on the cellular context, mRNA targets and protein 
partners. 
 
 
Figure 9. Maskin-related inhibitory complexes, regulating a translation of a key proteins of 
Drosophila embryogenesis. 
 
However, translation initiation can be repressed without disrupting a classical closed-loop 
structure. The experiments performed on U937 cells have shown that 2-4 hours after 
stimulation of cells by interferon, the ceruloplasmin mRNA synthesis, and respectively the 
synthesis of the ceruloplasmin (Cp)  itself,  begins (Fig. 10A) [Mazumder B et al., 1997]. 
However, 24 hours later there comes the repression of mRNA translation of Cp [Mazumder B 
et al., 1999]. It was found  that 3 'UTRs of Cp mRNA contains a 29-nucleotide regulatory site 
- GAIT-element (interferon-activated inhibitor of translation), which is associated with 
several proteins i.e. glyceraldehyde-3-phosphate dehydrogenase, phosphorylated glutamyl-
prolyl tRNA synthetase (EPRS) and protein NSAP1 (hnRNP Q) [Mazumder B et al., 2005; 
Mazumder B et al., 2003]. This so-called pre-GAIT-complex does not interfere with normal 
flow of the translation initiation. 16-24 hours after cells stimulation with interferon, the pre-
GAIT-complex interacts with the ribosomal protein L13a, which subsequently plays a role of 
translational repressor [Mazumder B et al., 2003] 
This event is possible due to the fact that L13a is phosphorylated and leaves the 60S 
ribosomal subunit at this time (Fig. 10B). A necessary condition for repressor protein action is 
the interaction of three main elements that cause circularization of mRNA: poly(A) tail, 
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PABP and eIF4G [Mazumder B et al., 2001]. Due to the circularization of the mRNA, the 
L13a, bound to GAIT-complex, is in the close proximity to the translation initiation factor 
eIF4G. It is assumed that the formation of this contact prevents the eIF4G interaction with 
other initiation factor eIF3 (more precisely, with its eIF3e subunit). As a result, the 43S 
preinitiation complex binding to the mRNA is inhibited, leading to the transcript-specific 
translational repression without suppressing of the eIF4F complex formation (Fig. 10C) 
[Kapasi P et al., 2007]. 
In male Drosophila, the transcription complex MSL (Male Specific Lethal) participates in 
genes transcription enhancing on the single X chromosome (dosage compensation). The Msl 
genes of Drosophila females are also transcribed, but the expression of one of them, msl-2, is 
suppressed at post-transcriptional level by the repressor protein SXL (sex-lethal) (Fig. 11). 
The Protein SXL, specific to females, binds within the 5 'UTR of msl-2 mRNA with the two 
regulatory U-rich regions. Furthermore, SXL in a complex with the protein UNR interacts 
with four regulatory regions in the 3`UTRs of msl-2 mRNA. The combined effect of these 
protein complexes, bound to the 3' and 5' untranslated regions of the same mRNA, prevents 
the recruitment of 43S preinitiation complex, as well as 5' UTR scanning [Abaza I et al., 
2006; Gebauer F et al., 1999; Gebauer F et al., 2003].  
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Figure 10. Transcriptional 
regulation of ceruloplasmin 
mRNA. 
 
A. 4-8 hours after cell treatment with 
IFN-gamma. Ceruloplasmin mRNA is 
effectively translated. 
B. 8-24 hours after cell treatment with 
IFN-gamma. L13a phosphorylation 
and GAIT-complex formation. 
C. ~24 hours after cell treatment with 
IFN-gamma. GAIT-complex binds to 
ceruloplasmin mRNA. Due to the 
preserved mRNA circularization 
GAIT-complex is in close proximity 
to the translational initiation region. 
L13a protein in the composition of 
GAIT-complex inhibits the translation 
of ceruloplasmin mRNA by 
preventing eIF4G and eIF3 interaction 
[from Kapasi P et al., 2007; 
Mazumder B et al., 2003; Sampath P 
et al., 2004, with changes]. 
Figure 11. Translational inhibition of 
msl-2 mRNA [Abaza I et al., 2006; 
Gebauer F et al., 1999; Gebauer F et 
al., 2003].  
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An increasing number of RBPs is associated with multifunctional deadenylase complexes, 
leading to poly(A) tail shortening and mRNA destabilization, and/or to disruption of the 
closed-loop structure and decrease of translational efficiency. Thus, a protein complex 
(Nanos, Pumilio, Brain tumor) binds to the NRE-element (nanos response element) within the 
3 'UTR of Hunchback mRNA, inhibiting its translation (Fig. 12). The Brain tumor and 
Pumilio are homogeneously distributed throughout the whole embryo, unlike Nanos, which is 
concentrated in the posterior pole of the embryo [Kuersten S.  et al., 2003; Murata Y et al., 
1995]. To inhibit the Hunchback synthesis, all three essential proteins are needed, that is why 
an effective inhibition of hunchback mRNA translation occurs only in the posterior pole of 
the embryo. The inhibition of hunchback  mRNA translation occurs, apparently, through two 
mechanisms such as mRNA deadenylation [Wreden C et al., 1997] together with a 
mechanism similar to the inhibition of caudal mRNA (Fig. 12). Pumilio recruits the 
POP2/CCR4/NOT deadenylase complex to promote mRNA repression. It has been shown 
that the Pum/Nos/Brat complex, bound on 3’ UTR, also recruits 4EHP to inhibit translation at 
the 5’-end of hunchback mRNA [Barnard DC et al., 2005]. It is therefore assumed that in this 
case, a removal of eIF4F initiation complex from the mRNA cap structure also takes place. 
 
All these examples offer interesting models of the 3' untranslated regions impact on 
translation initiation. There are many examples where the regulation takes place after closed-
loop formation, targeting the step of 60S subunit binding. Thus, ZBP1 (zip-code-binding 
protein 1), which binds to the 3′UTR of β-actin mRNA and localizes it to the leading edge of 
fibroblasts or neurite growth cones, inhibits the translation of the β-actin mRNA during its 
transport. The ZBP1 blocks the 60S joining to the 43S complex [Huttelmaier S et al., 2005].  
Another example of the same mechanism was the lipoxygenase mRNA, where it was shown 
that binding of hnRNP K and hnRNP E1 to the differentiation control element (DICE) on its  
3' UTRs leads to the establishment of translational repression in the early stages of 
reticulocytes maturation (Fig. 13) [Ostareck DH et al., 1997]. In this case, the attachment of 
Figure 12. Translational inhibition of 
hunchback mRNA [Barnard DC et 
al., 2005]. 	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60S ribosomal subunit to the 48S preinitiation complex was inhibited [Ostareck DH et al., 
2001]. Later it was found that during maturation of reticulocytes, the hnRNP K protein is 
phosphorylated  by Tyr kinase c-Src and loses its affinity to the DICE regulatory element 
within the 3 'UTRs of lipoxygenase [Ostareck-Lederer DH et al., 2002]. As a result, the 
translational block is removed, and the newly synthesized lipoxygenase triggers one of the 
last stages of reticulocytes maturation, i.e. degradation of mitochondria. Despite the elegance 
of this model, significant disadvantages can be noted. In particular, there is no evidence of 
lipoxygenase mRNA circularization, which could have explained the impact of 3 'UTRs on 
the translation initiation. Additionally, the inhibition of reporter DICE-containing mRNAs 
translation may occur even in the absence of poly(A) tail, as well as during a cap-independent 
translation initiation [Ostareck DH et al., 1997]. Thus, it is not clear how the contact between 
the inhibitory complex and mRNA 5 'end is achieved. Some critical-minded researchers may 
reasonably have a doubt about an accuracy of determining the stage of translational inhibition. 
For example, the experiments do not show any 48S intermediates accumulation, which should 
be observed during the inhibition of 60S ribosomal subunit joining [Ostareck DH et al., 
2001]. 
 
 
Histone mRNAs are remarkable their absence of poly(A) tails. It is assumed that their 
function can be performed by the hairpin elements on 3 'UTRs as well as  its specifically 
associated SLBP proteins (stem-loop binding proteins). These components are necessary 
mainly for processing and stabilizing of histones mRNAs [Dominski Z et al., 2007; Dominski 
Z et al., 2003]. It is believed that they also contribute to mRNA circularization due to the 
interaction between SLBP and translation initiation factors eIF4G and eIF3, located at the 5 
'end of the mRNA molecule [Ling J et al., 2002]. This, in its turn, can contribute to more 
efficient translational initiation. However, at the moment there is no evidence of direct 
interaction between SLBP and elF4G, as well as eIF3, and besides, there are contradictions in 
the results obtained by different research groups. Thus, in one laboratory, SLBP stimulates 
Figure 13. Translational inhibition 
of lipoxygenase mRNA [Ostareck 
DH et al., 1997]. 
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only non capped reporter mRNA with histone 3 'UTR [Sanchez R et al., 2002], and according 
to the experiments of another laboratory, it stimulates only the capped mRNA [Coles LS et 
al., 2002]. These data put into question the histone mRNA circularization hypothesis. 
Although the most of RBPs have their influence on the initiation step of translation, some of 
regulators may target the elongation step. PUF family proteins (Pumilio and FBF) are 
reported to be associated with Argonaute (AGO) and the translation elongation factor eEF1A 
[Friend K, et al. 2012]. The PUF/AGO complex, bound to the 3’UTR, inhibits the eEF1A 
GTPase activity, leading to an inhibition of translation elongation. HnRNP E1 can interfere 
with different steps of translation depending on the associated factors. For example, being 
bound to eEF1A, it attenuates the elongation by blocking eEF1A dissociation from the 
ribosome [Hussey GS et al., 2011].  
 
3.3. Interplay between RNA-binding proteins and miRNAs on 3` UTR. 
3’ UTR of a mRNA, playing an important role in post-transcriptional regulation of gene 
expression, controls this expression via a cross-talk between structural components of mRNA 
(cis-elements] and trans-acting factors (miRNA or RBPs). These molecules can bind to non-
overlapping binding sites, or to common sites, in a competitive manner, within a mRNA 
target. RBPs and miRNA can regulate mRNA translation and stability in positive or negative 
manner. At the same time, they can cooperate or be antagonists in their actions, and the final 
collective result depends on many circumstances, such as their expression levels, affinity to 
the binding sites, and localization in the cell, which can be controlled by various physiological 
conditions. 
3.3.1. Cooperation between miRNA and RBPs on 3`UTR.  
RBPs actively participate in miRNA-dependent regulation of gene expression. For example, 
Pumilio proteins (PUM1 and PUM2) collaborate with several miRNAs and act as guides that 
mediate the opening of mRNA secondary structure, allowing interactions between miRNAs 
and their binding sites. A comparative study of Pumilio target sites within mRNA, using RIP-
ChIP and PAR-CLIP in human cells, showed an enrichment for miRNA recognition sites in 
the sequences surrounding Pumilio binding sites, suggesting a widespread interaction of 
human Pumilio proteins with miRNA regulatory systems [Galgano A. et al., 2008]. 
Kedde and collaborators [Kedde M et al., 2010] have demonstrated in the MCF7 breast cancer 
cell line, that Pumilio promotes the inhibitory effects of miR-221/222 on the p27Kip1 mRNA 
by opening the secondary structure of the p27Kip1 3'UTR, allowing the access of miR-
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221/222 to its binding site.  
An elegant model was proposed for the HuR and let-7 cooperative action on the c-Myc 3’ 
UTR [Kim HH et al., 2009]. HuR bind the 3’ UTR of c-Myc mRNA in a position near let-7 
binding site and reduces c-Myc expression. The activity of let-7  is dependent on HuR, and 
the activity of HuR depends on let-7. The authors discovered that HuR binding changes the 
local mRNA conformation and promotes the association of let-7 with the c-Myc mRNA, by 
unmasking let-7 recognition site.  
RBPs can directly interact with AGO and recruit RISC. 
RBPs and RISC complex can have a direct physical interaction. In an early study, Caudy and 
colleagues demonstrated that the RISC complex in Drosophila  contains proteins that 
associate with AU-rich elements, i.e. the protein FXR1 [Caudy AA et al., 2002]. Reduction of 
FXR1 in Drosophila S2 cells resulted in less efficient RNAi silencing. Further work 
confirmed that FXR1 associates with AGO2 in mammalian cells as well [Jin P et al., 2004]. 
The discovery of a functional interaction between FXR1 and Ago2 resulted in suggestions 
that either RBPs are targeted to substrates by the RNAi complex [Caudy AA et al., 2002], or 
that FXR1 scans for the G quartet, previously reported to be a recognition site for FXR1, and 
then recruits RISC.  
3.3.2. RNA-binding proteins counteract miRNA function on 3`UTR. 
The miRNA activity can also be inhibited by RBPs bound to target 3'UTRs via a ‘competition 
for binding sites’ mechanism. DND1, an RNA-binding protein that mediates germ-cell 
viability and suppresses the formation of germ-cell tumors [Kedde M et al., 2007] has been 
shown to interact with the 3' UTRs of p27Kip1 and LATS2 mRNAs. DND1 binds these 
mRNAs and interferes with the function of miRNAs, helping to maintain p27Kip1 and 
LATS2 (tumor suppressors) protein levels in a germ-cell tumor cell line and in squamous cell 
carcinoma, thus inhibiting tumorigenesis. Generally there are two mechanisms of DND1 
action: DND1 binding may result in a mRNA secondary structure formation that makes 
miRNA recognition sites inaccessible, or alternatively, binding of DND1 could change a 
subcellular localization of the transcript, making it inaccessible to the RISC complex. 
Another interesting example of antagonistic interactions between RBPs and miRNAs was 
demonstrated by Bhattacharyya SN and Filipowicz W. They performed an elegant study 
demonstrating  that the miRNA-dependent repression is a reversible process. Downregulation 
of the cationic amino acid transporter 1 (CAT-1) mRNA by miR-122 was inhibited by stress, 
and stress-triggered elevation of cellular HuR, predominantly nuclear,  allows its entrance in 
cytoplasmic P-bodies (transcript decay structures), its binding to the specific AU-rich 
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sequence on CAT-1 mRNA and to a relocalization of CAT-1 mRNA from P-bodies to 
polysomes [Bhattacharyya SN et al., 2006]. Recently, the same authors have demonstrated a 
possible mechanism of HuR action on CAT-1 3' UTR. Because HuR AREs are positioned at a 
considerable distance from the miRNA sites, HuR promotes the relief of miRNA repression 
from a distance by a process likely involving HuR oligomerization [Kundu P et al., 2012]. 
Therefore, RBPs can directly interact with RISC (RNA-induced silencing complex) complex, 
either stabilizing the binding of the latter to target mRNAs or antagonizing miRNA functions, 
depending on the mRNA-target and on the miRNA incorporated in RISC.  
 
Figure 14. miRNA/RBP interplay in the regulation of the same mRNA [from Ciafrè SA et al., 
2013, with changes]. 
A) Cooperation : on the left : RBP scan enhance miRNA function by opening a secondary 
structure, allowing the interaction between miRNA and it target site within 3`UTR. 
On the right : RBP scan recruit RISC  complex to the 3`UTR and stabilize its binding via 
direct interaction with RISC components. 
B) Competition : RBP can interfere miRNA function via competition for the same binding 
site. In the context of non-overlapping sites RBP can change local mRNA structure and 
prevent miRNA binding. 
	   64	  
RBPs, translational inhibitors or activators, can interact on mRNA in cooperative or 
antagonistic manner, regulating the rate of protein translation. Translational activators can 
bind the specific target sequences and/or secondary structures on 3`UTR of mRNA. 
Translational inhibitors can be recruited to mRNA 3`UTR via miRNAs, which bind to their 
specific sites. During our study of cyclin D1 and D3 regulation by IMP3, we observed a 
phenomenon of  IMP3-RISC competition for cyclin D1 and D3 binding and translational 
regulation. We identified regions within cyclins 3`UTRs, targeted by this regulatory 
mechanism in vitro, and we proved their functional significance in vivo. 
Previous observations show that human IMPs and their homologs from other organisms can 
« cage » their mRNAs targets, forming a cytoplasmic mRNPs with other RBPs, making these 
mRNAs inaccessible to RISC-dependent repression. Following this logic, we identified the 
exact composition of IMP3-containing mRNP complex, which can post-transcriptionally 
regulate cyclin D1 and D3 expression.  
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RESULTS 
Article N° 1 (submitted). IMP-3 protects the mRNAs of cyclins D1 and D3 from 
GW182/AGO2-dependent translational repression. 
 
Previous studies in my group have shown that all three IMP proteins can directly bind the 
mRNAs of cyclins D1, D3 in vitro, but only IMP-3 regulates the expression of these cyclins 
in a significant manner in vivo. In this study we tried to determine the molecular mechanisms 
of the regulation of the expression of cyclins D1 and D3 by the RNA-binding protein 
IMP3/IGF2BP3 in human cancer cells.  
We have shown, that IMP-3 KD promotes decrease in cyclin D1 and D3 protein levels, 
whereas their mRNA levels do not change. In the absence of IMP3, Cyclin D1 and D3 
mRNAs  are exported to the cytoplasm and are observed within polyribosomal fractions, but 
not translated. Previous observation in my group have shown that IMP3 interact with a 
multiple RNA-binding proteins in human cancer cells. We found that some of them (HuR, 
PTBP1 and NF90) influence cyclin D1 and D3 protein levels and co-interact with cyclin D1 
and D3 mRNAs, suggesting a formation of IMP3-containing complex on 3`UTRs of the 
cyclins. This complex can protect cyclin D1 and D3 from miRISC-dependent translational 
repression. Consistent with this hypothesis, we found that decrease of cyclin D1 and D3 
protein levels after the inhibition of IMP3, NF90 or PTBP1 can be fully reversed after the 
simultaneous inhibition of two key components of miRISC : Ago2 and GW182/TNRC6. We 
concluded that IMP3 and RISC complexes can compete for cyclin D1 and D3 translational 
regulation. We proved that this regulation is direct by luciferase assays. Finally, we identified 
a functional regions within 3`UTRs of the cyclins, where a competition between IMP3 and 
miRISC complexes occurs. 
In summary, our findings indicate that IMP3 and its protein partners NF90, PTBP1 form a 
complex on 3`UTRs of the cyclins D1 and D3, protecting them from miRISC-dependent 
translational repression. 	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Abstract 
 
IGF-2 mRNA binding protein 3 (IGF2BP3, IMP-3) is a well-known post-transcriptional 
regulatory factor of gene expression, mainly involved in embryonic development and 
oncogenesis. We have previously demonstrated that a subset of IMP-3 targets, such as the 
mRNAs of cyclins D1, D3, and G1, are positively regulated by IMP-3, and that this regulation 
depends on nuclear localization of IMP-3. In this study, we show that as a first step following 
a knock-down of IMP-3, the protein levels of the cyclins rapidly decrease, while their mRNAs 
remain stable and associated with the polyribosomes, though not translated. We have 
elucidated the molecular mechanisms of this regulation, demonstrating that IMP-3 and its 
protein partners ILF3/NF90 and PTBP1 bind to the 3’UTRs of the cyclins mRNAs and 
protect them from the translational repression induced by miRNA-dependent recruitment of 
AGO2/GW182 complex in human cancer cells.  
 
Introduction 
 
Post-transcriptional regulation of gene expression plays a very important role at all stages 
of normal development, maintenance and/or pathology of cells, tissues, and organs. Post-
transcriptional regulation depends on various RNA-binding proteins (RBPs) that determine 
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the translational status of mRNAs, their structure, localizaton, and degradation rate. 
Regulatory RBPs can be recruited to their target mRNAs via specific recognition sequences 
(such as AU-rich sequences for HuR protein, or CPE sequence for CPEB family (Brennan 
and Steitz 2001; Richter 2007)). Alternatively, RBPs have been shown to bind to specifically 
structured elements within target RNAs, regardless of their nucleotide sequence. The 
IMPs/IGF2BPs (IGF-2 mRNA-binding proteins 1-3) are likely to belong to this latter group. 
IMP target sequences within RNAs vary to a large extent in different experimental models 
(Munro, Kwon et al. 2006; Jonson, Vikesaa et al. 2007; Chao, Patskovsky et al. 2010; Hafner, 
Landthaler et al. 2010). In addition, the ability of IMPs to form homo- and heterodimers 
further complicates the target sites identification and/or prediction, which is already extremely 
complex for the structure-recognizing RBPs (Nielsen, Nielsen et al. 2002). Finally, a large 
number of RNA-binding regulatory proteins are recruited to their target mRNAs via short 
non-coding RNAs, such as miRNAs (reviewed in (Filipowicz et al., 2008)). Cooperation or 
competition between different RNA-binding protein complexes determines the rate of protein 
expression from a large number of mRNAs (Ciafre and Galardi 2013) 
Post-transcriptional regulation of gene expression is particularly important in the case 
of proteins characterized by a short half-life, which are often critical for the control of cell 
cycle, signal transduction pathways, circadian rhythm, antigen processing and other processes 
(Glickman and Ciechanover 2002). We have recently shown that IMP-3/IGF2BP3 protein 
binds to and positively regulates the expression of cyclins D1, D3 and G1 in a number of 
human cancer cell lines (Rivera Vargas, Boudoukha et al. 2014). This regulatory mechanism 
controls the cell cycle and proliferation. In the current study, we explore the molecular 
mechanisms underlying the regulation of the cyclins’ expression by IMP-3 in human 
rhabdomyosarcoma cells.   
 
Results and Discussion 
The expression of CCND1 and D3 is regulated on post-transcriptional level in IMP-3 
KD cells. 
To elucidate the molecular mechanisms of the regulation of expression of the cyclins 
by IMP-3, we started by comparing the levels of CCND1 and D3 mRNA and protein in IMP-
3 KD cells, compared to control. The short half-life of  CCND1 and D3 proteins (30-40 min) 
allows to perform these studies on endogenous proteins. We have not included CCNG1 in this 
study, because although its expression is regulated by IMP-3, this atypical cyclin is very 
stable (with a half-life of over 48h). A clear decrease of the levels of CCND1 and D3 proteins 
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becomes visible as early as 24-32 h post-transfection of IMP-3 siRNA, whereas the 
corresponding mRNAs do not vary significantly at these time points (Fig. 1A, B). These 
results suggest that the expression of the cyclins is initially down-regulated by a post-
transcriptional mechanism, which does not depend on the mRNA levels. Next, we have 
addressed the question of the cyclins’ mRNA stability by blocking the transcription in IMP-3 
KD versus control cells with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB). As 
shown in Fig. 1C, the stability of mRNAs of CCND1 and D3 does not depend on the presence 
of IMP-3.  
As the IMP proteins have been previously shown to control the subcellular transport of 
some target RNAs, we have studied the efficiency of the nuclear export of the mRNAs of 
CCND1 and D3 in IMP-3 KD versus control cells, using in situ hybridization. Under both 
conditions, the CCNs mRNAs were efficiently exported to the cytoplasm, even though in 
IMP-3 KD cells they appeared to have a more perinuclear localization (Fig. 1D). 
The mRNAs of CCND1 and D3 are associated with polyribosomes in IMP-3 KD cells, 
but their translation is repressed. 
To address the translational status of the cyclins’ mRNAs in IMP-3 KD cells, we have 
performed sucrose gradient separation of polyribosomes, followed by RNA isolation from 
each fraction. Subsequently, we used RT-qPCR to evaluate the relative amounts of the 
mRNAs of CCND1 and D3 in polyribosomal versus monosomal fractions in IMP-3 KD and 
control cells. The association of the mRNAs of CCND1 and D3 with polyribosomes did not 
decrease in the absence of IMP-3 (Fig. 2A). On the contrary, a slight accumulation of these 
mRNAs in heavy polyribosomal fractions was observed for the mRNAs of CCND1 and D3, 
but not for the control mRNA of Cyclophilin A. Taken together with the decrease of protein 
levels of the cyclins in IMP-3 KD cells, these observations suggested that the translation of 
the mRNAs of CCND1 and D3 can be slowed down in the absence of IMP-3, but this event 
does not involve the dissociation of the mRNAs from the ribosomes. In agreement with this 
hypothesis, when we inhibited the protein translation in IMP-3 KD or control cells using the 
mRNA-ribosome “freezing” drug cycloheximide, we observed a strong decrease of the 
cyclins in control cells, whereas in IMP-3 KD cells, these was no further decrease of the 
cyclins’ levels when the translation was arrested by the drug. We conclude that in IMP-3 KD 
cells, the translation of the mRNAs of CCND1 and D3 is already strongly repressed by a 
mechanism that does not involve  mRNA degradation, erroneous mRNA localisation or 
disassembly of polyribosomes as an initial event. 
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 The expression of CCND1 and D3 in IMP-3 KD cells can be fully restored by 
inactivating the RISC complex. 
 The mechanisms of the rapid translational arrest occurring on the mRNAs of CCND1 
and D3 in IMP-3 KD cells were unclear. However, the observed phenomenon strongly 
resembled the translational repression caused by miRNA-dependent recruitment of Argonaute 
(AGO) proteins and/or of GW182/TNRC6A on target mRNAs (reviewed in (Carthew and 
Sontheimer 2009)). Multiple publications have earlier identified the mRNAs of CCND1 and 
D3 as miRNA targets (Jiang, Feng et al. 2009; Bandi and Vassella 2011). In addition, the 
perinuclear localization of the mRNAs of CCND1 and D3 in IMP-3 KD cells observed in our 
experiments (Fig. 1D) strongly resembled the typical subcellular localization of activated 
RISC complexes, as reported in (Stalder, Heusermann et al. 2013). Therefore, we have 
attempted to simultaneously knock-down key RISC components GW182, AGO1 or AGO2 in 
our IMP-3 KD cells, and to study the expression levels of CCND1 and D3 proteins. The 
results presented in Fig. 3A, B clearly show that a KD of GW182 and of AGO2, but not of 
AGO1, fully restored the levels of CCND1 and D3, even when IMP-3 remained 
downregulated. The KD of other GW182 family members, TNRC6B and C, which are usually 
expressed at low levels, did not rescue the expression of the cyclins in IMP-3 KD cells (Fig. 
S1). We have concluded that IMP-3 could protect the mRNAs of CCND1 and D3 from RNAi 
in human cancer cells. To find out whether this regulation was direct, we have cloned the 
3’UTRs of CCND1 and D3 into the psiCheck-2 luciferase reporter vector, and first studied 
the roles of AGO1, AGO2, GW182 and IMP-3 in the regulation of the luciferase expression. 
Consistent with the results observed on endogenous CCND1 and D3, the expression of the 
luciferase under the control of the 3’UTRs of the cyclins was dramatically down-regulated by 
a KD of IMP-3, released by a KD of GW182, and slightly increased by a KD of AGO2, but 
not of AGO1 (Fig. 3C, D). These results clearly indicated that IMP-3 and the RNAi 
machinery were competing on the 3’UTRs of CCND1 and D3, thus regulating the expression 
of the cyclins. We have subsequently co-transfected miRNAs let-7g and miR-15, known to 
regulate CCND1 and D3, respectively, and have further confirmed that while a KD of IMP-3 
increased the repressive effect of endogenous or ectopic miRNAs on the cyclins, a KD of 
GW182 fully reversed this effect.  
IMP-3 and GW182/AGO2 bind to and compete within the regions of the 3’UTRs of the 
cyclins that are critical for their expression. 
The IMP proteins do not have a universal binding motif, and were reported to bind to 
various RNA sequences depending on the cell type and experimental model used in different 
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studies. Various miRNA-binding sites, both experimentally proven and predicted, are 
numerous throughout the 3’UTR sequences of CCND1 and D3 (see Introduction for details). 
Therefore, no prediction was possible as to the functionally important binding sites of IMP-3 
protein within these mRNAs. We have decided to identify these regions by a two-step 
experimental approach (Fig. 4). First, we have synthesized a number of short, partially 
overlapping mRNA fragments covering the 3’UTRs of the cyclins (Fig. 4AB), biotinylated 
them, and used them in an in vitro pull-down assay together with total cell extracts from 
control or IMP-3 KD cells (Fig. 4C-F). In order to test our hypothesis that IMP-3 could hinder 
the binding of RISC complex to the mRNAs of CCND1 and D3, we were looking for RNA 
fragments where IMP-3 binding would compete with GW182 and/or AGO2. We used the 
HuR protein, a very well-characterized post-transcriptional regulator of the expression of 
CCND1 and D3, as an internal control for the assay, because the binding of HuR to target 
RNAs depends on the presence of AU-rich sequences, but not on IMP-3 (Brennan and Steitz 
2001; Lal, Mazan-Mamczarz et al. 2004).We were able to identify three fragments within the 
3’UTR of CCND1 where the binding of RISC complex components was increased in the 
absence of IMP-3: fragments 3, 6, and 11. In the case of CCND3, IMP-3 competed with 
GW182 and AGO2 within fragment 3 of 3’UTR.  
In the second step of the assay, we attempted to evaluate the functional importance of 
the identified binding regions of IMP-3 within the 3’UTRs of CCND1 and D3, where it 
competed with RISC in vitro. To this end, we have transfected the relevant RNA fragments, 
or the flanking regions of 3’UTRs, where no competition between IMP-3 and RISC had been 
observed, and quantified the expression of CCND1 and D3 proteins under the control of IMP-
3 KD conditions (Fig. 4G-J). If our hypothesis was correct and the depletion of IMP-3 led to 
excessive presence of RISC on the identified regions of the 3’UTRs of the cyclins, and to 
translational repression, then the transfection of the corresponding RNA fragments in molar 
excess should lead to the binding of RISC to the transfected fragments, and to a complete of 
partial release of the repression. These were the results we have observed in at least three 
independent experiments (an example of each experiments is shown on the left, and a 
quantification of three experiments is shown on the right). The transfection of the relevant 
RNA fragments, identified in Fig. 4C-F, led to a partial (Fig. 4 G, H) or complete (Fig. 4I, J) 
release of the expression of the cyclins, even in IMP-3 KD cells. Moreover, even in control 
cells, the transfection of these fragments led to a slight increase of the level of CCND1 and 
D3, respectively. Therefore, we have experimentally proven that IMP-3 can protect the 
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mRNAs of CCND1 and D3 from RISC-induced translational repression, and have identified 
the regions of 3’UTRs targeted by these regulatory mechanisms.  
 The expression of CCND1 and D3 is co-regulated by IMP-3 protein partners. 
 A competition between IMP-3 and miRNA-guided GW182 or AGO2 was a novel 
finding. However, IMP proteins interact with a large amount of other proteins in the cell, both 
RNA-binding and non-RNA binding (Fig. 5A and (Boudoukha, Cuvellier et al. 2010; Rivera 
Vargas, Boudoukha et al. 2014)). Thus, it was interesting to determine the exact composition 
of the IMP-3 subcomplex that was functionally relevant to this new regulatory mechanism. In 
our previous work, we have identified IMP-3 partners that were important or not for the 
expression of CCND1, D3, and G1 (Rivera Vargas, Boudoukha et al. 2014). Among them, 
PTBP1 was a direct IMP-3 partner, and ILF3, HuR, and HNRNPA2B1 depend on the 
presence of RNA to co-precipitate with IMP-3 (Fig. 5B). Now, we have systematically tested 
for the involvement of these proteins in competition with GW182. IMP-3 partners 
PTBP1/HNRNPI and ILF3 were shown to be necessary for the expression of CCND1 and D3, 
and their KD was compensated by a simultaneous KD of GW182 (Fig. 5CD). ILF3 gene 
gives rise to two distinct RNA-binding proteins, NF110 and NF90, which are a results of 
alternative splicing and do not have similar functions in translational regulation (Castella, 
Bernard et al. 2015). Therefore, we have used isoform-specific siRNAs and have identified 
the known regulator of cell growth NF90, but not NF110, as the partner of IMP-3 that 
regulates the expression of CCND1 and D3 in GW182-dependent manner (Fig. 5EF). 
HuR/ELAVL1 interacts with IMP-3 in an RNA-dependent manner, and regulates the 
expression of CCND1, but not CCND3 (Fig. 5G). However, the majority of IMP-3 interacting 
RNA-binding proteins, such as HNRNPA2B1, do not regulate the expression of the cyclins 
(Fig. 5H and data not shown). These latter results have highlighted the specificity of our 
experiments and confirmed the existence of a distinct specific subcomplex of IMP-3 that 
contains PTBP1 and ILF3/NF90, and is critical for the protection of the mRNAs of CCND1 
and D3 from RNAi (Fig. 5I). 
 IMP proteins are known to interact with multiple other proteins and to regulate the fate 
of numerous mRNAs, most frequently by regulation of mRNA stability, but also by impacting 
on such diverse processes as mRNA translation, mRNA subcellular localization, and others 
(Nielsen, Christiansen et al. 1999; Nielsen, Nielsen et al. 2001; Nielsen, Adolph et al. 2003; 
Oleynikov and Singer 2003; Jonson, Vikesaa et al. 2007; Bell, Wachter et al. 2012; Jonson, 
Christiansen et al. 2014). These observations suggest the existence of multiple, functionally 
diverse IMP-dependent RNP complexes, and highlight the necessity to study these complexes 
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individually and target-wise. We have recently demonstrated that the mRNAs of CCNs D1, 
D3, and G1 are direct and functionally important targets of IMP-3, as these mRNAs were 
found within IMP-3 RNP complexes, and in IMP-3 KD cells the expression of these cyclins 
on protein level was sharply down-regulated. The proliferation of IMP-3 KD cells was 
arrested due to accumulation of the cells in G1 phase of the cell cycle. This function is 
specific to IMP-3, and is not al all shared by IMP-1 and IMP-2 (Rivera Vargas, Boudoukha et 
al. 2014). Now, we have identified the molecular mechanisms of this regulation, which does 
not depend on regulation of mRNA stability, but involves miRNA and RISC-dependent, 
reversible translational arrest in the absence of IMP-3 and/or its partners PTBP1 and 
ILF3/NF90. This ability to bind the cyclins mRNAs and to protect them from RISC is a novel 
function for a member of the IMP family, showing an important function for IMP-3 in rapid, 
sensitive and reversible cell cycle regulation of human cancer cells.  
  
Materials and methods 
Cell Culture, miRNAs, plasmids and constructs 
RD embryonic rhabdomyosarcoma (eRMS) were purchased from ATCC and cultured 
as indicated on the ATCC website. MiRNA precursors were purchased from Life 
Technologies and transfected at the final concentration of 50 nM using Lipofectamin 
RNAiMAX (Invitrogen), according to the manufacturer's instructions.  FLAG-HA-IMP3 
expression construct and stable cell line was described previously (Rivera Vargas, Boudoukha 
et al. 2014). psiCHECK-2 reporter constuct was purchased from Promega. 
RNA interference 
Transient transfection of siRNA was performed using Lipofectamin RNAiMAX. 
5 x 105 cells were plated in 6-well plates, siRNA duplexes were transfected at 20 nM final 
concentration for 48 h. The efficiency of the siRNA-mediated knockdown of gene expression 
was evaluated by quantitative reverse transcription PCR (qRT-PCR) and/or western blotting 
(WB). 
Transient transfection of plasmids was performed using Lipofectamin 2000 
(Invitrogen), according to the manufacturer's instructions. 2 x 105 cells were plated in 6-well 
plates; 24 h later the cells were transfected with 1 µg of plasmid for 48 h. Efficiency of 
transfection was evaluated by immunofluorescence (IF) and/or WB. 
siRNA target sequences were: IMP-3 ggauucuccuaguagcauucau; IMP-3_2 
auggaucauuccucaugua; GW182/TNRC6A gaaaugcucugguccgcuauu; GW182/TNRC6A_2 
gcagccuccagcacaaccucuu; TNRC6B caucugggacaaggugauuguagacg; TNRC6C 
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ggaauggagacacugugaacucagc ; AGO1 ggaguuacuuucauagcauuu; AGO2 
gcacggaaguccaucugaa; PTBP1 aacaaugacaagagccgugac; ILF3 ccccagaggacgacaguaaa; 
ILF3/NF110 gcggauccgacuacaacuacg; ILF3/NF90 cuuccuagagcgucuaaaagu; HuR 
gaggcuccagucaaaaacca; HNRNPA2B1 ccaggggcucauguaacugu; Control siRNA 
uagcaaugacgaaugcgua. 
Luciferase reporter assays 
 The 3’UTR of human CCND1 or CCND3 mRNA  were cloned into a psiCHECK2-
reporter vector (Promega) downstream of the reporter gene (Renilla luciferase). HeLa cells 
were seeded at 20 000 cells per well in a 96-well plate. 24h after, 10 ng of psiCHECK2-E2F5-
3’UTR was co-transfected with 50 nM of miRNA mimic and/or 20 nM siRNA.  Co-
transfection was performed with Lipofectamine 2000 (Life Technologies). 48h after 
transfection, the relative levels of Renilla versus Firefly luciferase activity (control of 
transfection efficiency) were measured with Dual-Luciferase Reporter Assay System 
(Promega) according to the manufacturer’s instructions. The luminescence signal was 
quantified on a Mithras LB 940 Multilabel Reader and analyzed with Mikrowin software 
(Berthold Technologies). 
Antibodies 
The following antibodies were used for WB. IMP-3 (N-19) sc-47893, CCND1 (DCS-
6) sc-20044, CCND3 (D-7) sc-6283, PTBP1/HNRNPI sc-16547, ILF3 sc-136197 and HuR 
sc-5261 were obtained from Santa Cruz. GW182 rabbit polyclonal (A302-329A) was 
obtained from Bethyl Laboratories. Rat anti-AGO1 (SAB4200084), AGO2 (SAB4200085), 
actin (A5441, clone AC-15), anti-goat IgG (I9140) anti-rabbit IgG (A0545) and anti-mouse 
IgG (I8765) were purchased from Sigma Aldrich. 
Quantitative real-time RT-PCR 
The qRT-PCR primers for the detection of IMP-3, CCND1, CCND3, Cyclo A were as 
described in (Boudoukha, Cuvellier et al. 2010; Rivera Vargas, Boudoukha et al. 2014). qRT-
PCR was performed using a Light Cycler (Roche). 
Cell lysis and sucrose gradients: 
RIPA lysis for WB: The cell pellets were incubated in 5 volumes of RIPA buffer 
[50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% Na Deoxycholate, 0.1% SDS, 
1 mM EDTA, protease inhibitors] for 15 min on ice followed by sonication for 7.5 min (30 
sec ON, 1min OFF) at high intensity. After centrifugation at 16,000 g for 15 min at 4°C, the 
supernatant was recovered for WB analysis. 
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Total lysate from RD cells (3x107 cells) was prepared as described in (Nielsen, 
Christiansen et al. 1999), treated or not with 10 mM puromycin for 15 min at 37°C, and 
applied to a 21 to 47% sucrose gradient in 20 mM Tris-HCl (pH 8.0); 140 mM KCl; 5 mM 
MgCl2. Centrifugation was carried out at 40,000 rpm for 2h15min using a Beckman SW41 
rotor. 0.8-ml fractions were collected, adsorbance at 260 nm was measured, and each fraction 
was ethanol-precipitated, treated with DNAse (Promega), and  RNA was extracted with 
phenol-chloroform and used for qRT-PCR analysis. 
Immunoprecipitation of IMP-3 complexes  
Protein complexes were immunoprecipitated from whole cell extracts (lysis buffer: 
10% glycerol, 20mM Tris-HCl, pH 8, 0.2 mM EDTA, 0,1% NP-40, 0.5 M KCl, protease 
inhibitors (Complete, Roche)), pre-cleared for 1h with protein A/G-agarose (Thermo 
Scientific), treated or not with 1 mg/ml protease-free RNAse A (Roche), using IMP-3 
antibody (sc-47893, Santa Cruz) or goat IgG (Sigma) and protein A/G-agarose. Complexes 
were separated on a 4-12% polyacrylamide gel (Invitrogen), and stained using the Silver 
Quest kit from Invitrogen, according to manufacturer’s instructions. Mass-spectrometry 
identification of proteins was carried out by Dr. R.Tomaino, Harvard Medical School. 
Drug treatment 
DRB treatment: 4 x 105 RD Cells were plated in 6-well plates and transfected with 
control or IMP-3 siRNAs; DRB  (Sigma D1916) was added to a final concentration of 
100 µM, and the cells were collected at indicated time points. 
Cycloheximide Treatment: 4 x 105 RD Cells were plated in 6-well plates and 
transfected with control or IMP-3 siRNAs; 48 h later, cycloheximide (Sigma C 19881G) was 
added to a final concentration of 20 µg/ml for 2h.  
In Situ hybridization  
Probes used were: 
CCND1 sense, TAATACGACTCACTATAGGGAGACCCTCGGTGTCCTACTTCAA;  
CCND1 antisense, ATTTAGGTGACACTATAGGGGATGGTCTCCTTCATCT;  
CCND3 sense, TAATACGACTCACTATAGGGAGATGGATGCTGGAGGTATGTGA 
CCND3 antisense, ATTTAGGTGACACTATAGAATGAAGGCCAGGAAATCA 
Cells were seeded on poly-Lysine-coated glass cover slides and transfected as 
previously described. Cells were fixed with 4% paraformaldehyde in PBS for 15 min at RT, 
washed with PBS, incubated with 0.3% H2O2 dissolved in methanol for 30 min at RT and 
washed with PBS. Afterwards cells were incubated with prehybridization solution (50% 
formamide, 2X SSC, 10 mM Na2HPO4) for 90°C at RT in a humidified chamber followed by 
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incubation in hybridization solution (1.5 µl salmon sperm DNA, 1.5 µl tRNA and 200-500 ng 
of DIG-labelled mRNA probes pre-heated for 2 min at 90°C and placed on ice for 2 min, then 
mixed with 15 µl of 60% formamide, 10 mM Na2HPO4 and 15 µl of 20% dextran sulphate, 
4X SSC, 0.4% BSA) in a humidified chamber at 37°C overnight. Cells were washed twice 
with 2 ml of prehybridization solution at 37°C for 30 min, then twice with 2X SSC, 
0.1%Triton at 37°-50°C for 5 min, twice with 1X SSC, 0.1%Triton at 37°C for 5 min, and 5 
times with PBS-Tween at 37°C for 5 min. Cells were incubated for 1 h in blocking buffer (2% 
sheep serum, 2 mg/ml BSA, in PBS-Tween) at RT followed by incubation with anti-DIG-
biotin antibody (Roche) (diluted 1:500 in blocking buffer) overnight in a humidified chamber 
at 4°C. To visualize the CCND1 and D3 mRNAs, the TSA BIOTIN SYSTEM (Perkin Elmer) 
and the Enhanced Liquid Substrate System (Sigma 3,3-Diaminobenzidine) were used 
according to the manufacturer's instructions. 
Protein pull-down by biotinylated RNA 
 RT reactions were performed using The SuperScript® III First-Strand Synthesis System 
(Life Technologies) and total RNA from RD cells. Phusion™ High-Fidelity DNA Polymerase 
Kit for PCR (Thermo Scientific) was used for PCR amplification of desired fragments. All 
Forward primers had a T7 promoter sequence : TAATACGACTCACTATAGGGAGA. The 
primers were:  
CCND1: 
NM_053056.2         
Name Region  Sequence Location 
1 D1 F 3'UTR  ggacgtggacatctgagggc 1082 
1 D1 R 3'UTR  ctcccccaccgctcagggtt 1362 
2 D1 F 3'UTR  taaccctgagcggtggggga 1342 
2 D1 R 3'UTR  gctttatcaggaaaagcaca 1622 
3 D1 F 3'UTR  ttgtgcttttcctgataaag 1602 
3 D1 R 3'UTR  tgctacgctggctggtgccc 1882 
4 D1 F 3'UTR  cgggcaccagccagcgtagc 1862 
4 D1 R 3'UTR  tatttcctacacctattgga 2142 
5 D1 F 3'UTR  ccaataggtgtaggaaatag 2122 
5  D1 R 3'UTR  actttcaaacaccagttggc 2402 
6 D1 F 3'UTR  tgccaactggtgtttgaaag 2382 
6  D1 R 3'UTR  aaaataaactgtattaaatc 2662 
7 D1 F 3'UTR  agatttaatacagtttattt 2642 
7 D1 R 3'UTR  cacttcctaaataaaaatta 2922 
8 D1 F 3'UTR  gtaatttttatttaggaagt 2902 
8 D1 R 3'UTR  acatggcagtatatgacaca 3182 
9 D1 F 3'UTR  caatgtcatatactgccatg 3162 
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9 D1 R 3'UTR  tctctggggacaccggcgcg 3457 
10 D1 F 3'UTR  ccgcgccggtgtccccagag 3437 
10 D1 R 3'UTR  aaacagaacactagtacata 3732 
11 D1 F 3'UTR  ttatgtactagtgttctgtt 3712 
11 D1 R 3'UTR  tggttcagacagacgccgca 4007 
12 D1 F 3'UTR  tgcggcgtctgtctgaacca 3987 
12  D1 R 3'UTR  ttaccagttttatttctaga 4282 
CCND3: 
NM_001760.3       
Name Region  Sequence Location 
6 D3 F 3'UTR  gccctctggagtggccacta 1055 
6  D3 R 3'UTR  tcccatcagcctggcccacc 1320 
7 D3 F 3'UTR  gccaggctgatgggacagaa 1305 
7 D3 R 3'UTR  tctaggagcagctgtcagca 1570 
3 D3 F 3'UTR  acagctgctcctagagggag 1555 
3 D3 R 3'UTR  tatagcagctccttggccac 1820 
4 D3 F 3'UTR  caaggagctgctatagcctg 1805 
4 D3 R 3'UTR  tttttccaagaagccaaagc 2055 
 
MEGAscript® T7 Transcription Kit (Life Technologies) was for RNA in vitro transcription, 
and RNA 3' End Biotinylation Kit (Pierce) for biotinylation of RNA fragments, all of the 
above according to the manufacturers’ instructions. 
Biotin pull down assay was performed as follows (our original protocol): 
Necessary reagents : 
RNaseOUT™ Recombinant Ribonuclease Inhibitor. 
Complete Protease Inhibitor Cocktail (Roche). 
Pierce IP Lysis Buffer is composed of 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 
1% NP-40 and 5% glycerol. 
Cell lysis in light conditions : Incubate the cell pellet with Pierce lysis buffer + protease 
inhibitor for 15 min on ice. Up and Down for 3 times at the beginning of incubation. 
Centrifugate (15 min × 13,200 rpm × 4°C) and collect the supernatant (protein lysate). 
TENT buffer (50 mM Tris-Cl [pH 8.0], 2 mM EDTA, 150 mM NaCl, 1% Triton X-100). 
1) Pull down reaction mix : 
RNaseOUT (40U/ µL) 2.5 µL 
Protease inhibitor cocktail 50x 1 µL 
Biotinylated RNA probe 10 µL 
Protein lysate 40 µg 
TENT 2x 25 µL 
H2O 7.5 µL 
Final volume 50 µL 
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Incubate pull down reaction mix on a wheel 30 min × 20 rpm at RT 
2) Beads washing and distibution. 
Utilize 30 ?L of Streptavidin-Agarose Beads per reaction. Wash and centrifugate (2 min × 
2000 rpm × 4°C) Beads briefly 3 times with 1 ml of TENT 1X. After the last wash add 1 ml 
TENT 1X + Protease Inhibitor + RNaseOUT 1000U/ml and distribute them between the 
necessary amount of tubes, centrifugate (2 min × 2000 rpm ×  4°C), remove the supernatant 
and add pull-down reaction mix.  
3) Incubate pull-down reaction mix + beads on a wheel 30 min × 20 rpm × RT. Wash beads 3 
times × 10 min × 20 rpm in 500 ?L PBS. 
Detect proteins by standard WB technique. 
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Legends to Figures  
 
Figure 1. The expression of CCND1 and D3 is regulated on post-transcriptional level in IMP-
3 KD cells. A, B. Kinetics of inhibition of CCND1 and D3 in RD cells transfected with the 
indicated siRNAs and collected at 8, 24, 32, 48, 72, and 100 h post-transfection. A, protein 
levels (western blot), B, mRNA levels (RT-qPCR). C. Relative rate of mRNA degradation in 
control versus IMP-3 KD cells under the conditions of general transcription inhibition by 
DRB. D. In situ hybridization showing the subcellular localization of CCND1 and D3 
mRNAs in RD cells transfected with the indicated siRNAs. 
 
Figure 2. The mRNAs of CCND1 and D3 are associated with polyribosomes in IMP-3 KD 
cells, but their translation is repressed. A. Sucrose gradient fractionation of cytoplasmic 
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lysates of RD cells transfected for 48h with control siRNA or with two distinct anti-IMP-3 
siRNAs. The mRNAs of CCND1 and D3 and cyclophilin A (cycloA) were quantified in each 
fraction using RT-qPCR.  B, C. RD cells were transfected with control or IMP-3 siRNA, and 
treated at 48h post-transfection with 20 mg/ml cycloheximide or ethanol for 2h. Expression of 
CCN D1 and D3 was evaluated by WB and quantified using ChemiCapt (Vilber Lourmat). 
Shown are typical results (B) or a mean (A, C) of 3 independent experiments. 
 
Figure 3. The expression of CCND1 and D3 in IMP-3 KD cells can be fully restored by 
inactivating the RISC complex. A. A WB analysis shows a rescue of CCND1 and D3 
expression in IMP-3 KD cells when GW182 is knocked-down. B. The expression of CCND1 
and D3 in IMP-3 cells can be rescued by a KD of AGO2, but not of AGO1 (lanes 1-5). In 
control cells, the KD of AGO1, AGO2 or GW182 has no effect on the levels of CCND1 and 
D3 (lanes 5-9). C-E. The regulation of luciferase expression (psiCHECK-2 reporter vector) 
under the control of 3’UTRs of CCND1 (C, E) and CCND3 (D, F) depends on IMP-3, 
GW182, AGO2 and miRNAs let-7g (CCND1) and miR-15 (CCND3). The luciferase 
expression of each vector co-transfected with control siRNA used was set to 1 and used for 
normalization of all the respective assays. Error bars represent SEM from 3 independent 
experiments. p values (above each bar) were calculated using a paired t test comparison of the 
condition with the control siRNA condition: *p < .05; **p < .01; ***p < .001. 
 
Figure 4. IMP-3 and GW182/AGO2 bind to and compete within the regions of the 3’UTRs of 
the cyclins that are critical for their expression. A, B. A schematic representation of the 
3’UTRs of CCND1 (A) and D3 (B) with the coordinates of the fragments used for pull-down 
experiments. C-E. Indicated fragments of the 3’UTRs of CCND1 and D3 were transcribed in 
vitro, biotinylated, and incubated with total cell extracts from control of IMP-3 KD cells. The 
proteins bound to the RNA fragments were revealed using western blot. G-H. RNA fragments 
characterized by IMP-3-RISC competitive binding, or control fragments form the CCNs 
3’UTRs (identified in C-E) were transfected into control or IMP-3 KD RD cells, and the 
expression of CCND1 and D3 proteins was quantified by western blot in three independent 
experiments. Left, a representative experiment out of three, right, quantification of three 
experiments. 
  
Figure 5. The expression of CCND1 and D3 is co-regulated by IMP-3 protein partners. A. 
Silver staining of IMP-3 protein complexes immunopurified from RD cells, untreated or 
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treated with RNase A. Mock, IgG. B. Co-immunoprecipitation analysis of endogenous IMP-3 
interaction with the indicated partners. C-G. A WB analysis shows the rescue levels of 
CCND1 and D3 expression in cells depleted of IMP-3 protein partners PTBP1 (C), ILF3 (D), 
ILF3/NF90 (E), ILF3/NF110 (F), and HuR (G) when GW182 (lower band on the WB) is 
knocked-down. H. An IMP-3 protein partner HNRNPA2B1 does not influence the expression 
of CCND1 and D3. I. A model of action for IMP-3/NF90/PTBP1 complex in the inhibition of 
RISC-dependent translational repression. Antagonistic interactions between IMP-
3/NF90/PTBP1 and RISC complexes: IMP-3 complex can interfere with miRNA function via 
competition for the same binding site (on the right). In the context of non-overlapping binding 
sites IMP-3 complex can change local mRNA structure and prevent RISC binding (on the 
left). 
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Article N°2 (submitted). The WEE1 regulators CPEB1 and miR-15b switch from inhibitors to 
activators at G2/M. 
 
During my PhD work I contributed to the research project of Irina Groisman, researcher in 
our laboratory. She demonstrated that a known RNA-binding protein CPEB1 works in 
cooperation with miR-15b to repress WEE1 mRNA (key mammalian cell cycle regulator) 
translation during G1 and S-phase. But at G2/M transition CPEB1 and miR-15b switch their 
activity and promote translation of WEE1 mRNA. 
In this project, I have studied the interaction between CPEB1 and miR-15b/RISC. With a help 
of co-immunoprecipitation experiments I demonstrated that these two complexes can bind to 
common RNA targets and interact in RNA-dependent manner. I also detected the helicase 
DDX6 immunoprecipitated with CPEB1 and AGO2/RISC and demonstrated that a KD of 
DDX6 or using of DDX6 mutant with lost activity disrupt interaction between Ago2/RISC 
and CPEB1. 
These results were included in the following article. 	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Summary 
MicroRNAs (miRNAs) in the AGO-containing RISC complex control messenger RNA 
(mRNA) translation by binding to mRNA 3’ untranslated region (3’UTR). The relationship 
between miRNAs and other regulatory factors that also bind to mRNA 3’UTR, such as 
CPEB1 (cytoplasmic polyadenylation element-binding protein), remains elusive. We found 
that both CPEB1 and miR-15b control the expression of WEE1, a key mammalian cell 
cycle regulator. Together, they repress WEE1 protein expression during G1 and S-phase. 
Interestingly, the two factors lose their inhibitory activity at the G2/M transition, at the time 
of the cell cycle when WEE1 expression is maximal, and, moreover, rather activate WEE1 
translation in a synergistic manner. Our data show that translational regulation by RISC and 
CPEB1 is essential in cell cycle control and, most importantly, is coordinated, and can be 
switched from inhibition to activation during the cell cycle.  
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Introduction 
 
The importance of 3’UTR (3’ untranslated region) in the control of translation and mRNA 
stability has been known for many years. One of the best-studied RNA regulatory 
sequences located in 3’UTRs is the CPE (cytoplasmic polyadenylation element). CPE is 
bound by CPEB1 (cytoplasmic polyadenylation element binding protein), a four-member 
protein family. 
CPEB1 was initially found to be important for Xenopus oocyte maturation 1. It was later 
seen to be involved in learning and memory 2, 3 and in the regulation of the mammalian cell 
cycle 4-7. During Xenopus oocyte maturation, CPEB1 controls meiosis progression from 
prophase I to metaphase II, triggering tightly controlled waves of polyadenylation at 
various phases of meiosis 8, as well as during the embryonic cell-cycle 5. In mammals, 
CPEB1 is also implicated in senescence 4, 6 and in controlling the translation of proteins 
involved in cell-cycle checkpoints 7. CPEB1 is a conserved, sequence-specific RNA-
binding protein containing a zinc finger and two RNA recognition motifs (RRMs) 1, 8-10. 
Xenopus studies show that CPEB1 can both promote and inhibit RNA translation by 
respectively elongating or shortening mRNA poly(A) tails since CPEB1 recruits 
adenylating and/or de-adenylating protein complexes. This dual action of CPEB1 changes 
over the course of the cell cycle, depending on CPEB1 post-transcriptional modifications 
and on the number and location of the CPEs to which CPEB1 binds. The CPEB1-
containing complex in Xenopus includes: symplekin, which may be a platform protein 
upon which multi-component complexes are assembled; poly(A) ribonuclease (PARN), 
which is a deadenylating enzyme, and germ-line-development factor 2 (Gld2), which is a 
poly(A) polymerase 11, 12. Induction of cytoplasmic polyadenylation is mediated by 
	   5	  
activation of the serine/threonine kinase Aurora A/Eg2, possibly via repression of glycogen 
synthase kinase 3 10, 13. When phosphorylated on either S174 or T171 (which is species-
dependent), CPEB1 promotes polyadenylation by stimulating the activity of Gld-2 11, an 
atypical poly(A) polymerase 14. The newly elongated tail is then bound by the poly(A)-
binding protein (PABP), which promotes translation by facilitating assembly of the eIF4F 
initiation complex 15. 
The miRNA (microRNA) system is another well-known regulator of mRNA translation. 
MicroRNAs are single-stranded RNA molecules of about 21-23 nucleotides in length, 
which are transcribed as 70-90 nt precursors and further processed to short double-stranded 
sequences by the endonuclease DICER. MiRNAs regulate gene expression by forming 
miRNA-induced silencing complexes (miRISCs). MiRISCs inhibit translation by binding 
through the microRNA strand to imperfectly matched sequences in the 3’UTR of target 
mRNAs. The MiRNA mode of action is a much-debated issue. However, there are exist 
experimental proofs supporting collaboration between the RISC complex, which contains 
the proteins argonaute 1 & 2 (AGO1 and AGO2), and the deadenylation complex 16, 17. The 
mRNA targets of miRNAs are frequently subject to deadenylation 18, 19, further supporting 
the idea that the length of the poly(A) tail is a key element in the control of translation by 
miRNAs. Thus, both miRNAs and CPEB1 control the length of mRNA poly(A) tails, 
raising the possibility that they may cooperate to regulate common targets.  
CPEB1 and RISC complexes have been found in processing bodies (P-bodies), which are 
sites of mRNA degradation and storage, as well as in stress granules, where translation 
initiation complexes are stored under various stress conditions. It is worth mentioning that 
DDX6 (rck/p54), a DEAD-box helicase that interacts with AGO1 and AGO2 in cells and is 
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essential in P-bodies 20 and stress granules, associates with CPEB1 in both Spisula (clam 
p47) and Xenopus 21 and could therefore constitute a link between CPEB1 and the RISC 
complex.  
 
All these observations suggest that CPEB1 and RISC cooperate. Here, we address this issue 
by investigating the functional interaction between CPEB1 and a nearby miRNA-binding 
site on the 3’UTR of WEE1 mRNA. WEE1 is a kinase component of the G2/M cell-cycle 
checkpoint. WEE1 determines the time of entry into mitosis, thereby influencing the size of 
daughter cells. Loss of WEE1 results in smaller than normal daughter cells, due to 
premature cell division. Although WEE1 kinase has long been characterized as a key 
inhibitor of cyclin-dependent kinase 1 (Cdk1) and of mitotic entry in eukaryotes, the 
regulation of WEE1 expression and activity is still not fully understood. WEE1 is regulated 
at the post-translational level by phosphorylation 22. During Xenopus oocyte maturation, 
WEE1 mRNA translation is regulated by a CPE sequence located in its 3’UTR 23. WEE1 
mRNA CPE is conserved in the human. In addition, the 3’UTR of human WEE1 mRNA 
contains a miR-15b binding site, and WEE1 is one of the high-score predicted targets for 
miR-15b (using two algorithms, Targetscan and Microcosm). And it was indeed proved 
that WEE1 could be a target of miR-15b under a certain physiological condition 24. We 
therefore explored how each of these two elements of WEE1 3’UTR, the CPE and miR-15b 
binding sites, function during the mammalian cell cycle.  
We found that the CPE and miR-15b sequences in WEE1 3’UTR are both important for 
WEE1 expression, being independent inhibitors of WEE1 3’UTR-dependent translation in 
G1 and S cells. CPEB1 and AGO2 (RISC) complexes interacted in an RNA- and DDX6 
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(rck/p54)-dependent manner. Importantly, we observed that the inhibitory effects of miR-
15/RISC and CPEB1 were abolished during G2/M transition. Moreover, the two sequences 
together had an activating effect at this stage of the cell cycle when WEE1 protein is 
maximal, as documented by luciferase assays or polysomal profiles of reporter mRNAs, as 
well by analyzing WEE1 endogenous protein in CPEB1- and/or miR-15b-depleted cells.  
Our data demonstrate that WEE1 expression is regulated at the translational level in a cell-
cycle-dependent manner. Moreover, they show that the regulatory activities of two RNA 
binding complexes are modified in a coordinated manner, switching from being activators 
to inhibitors during the cell cycle.  
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Results 
 
WEE1 is regulated at the prost-transcriptional level in a 3’UTR-dependent manner 
 
WEE1 expression is regulated at the level of translation during Xenopus oocyte maturation 
23. In HeLa cells synchronized by a double thymidine block, WEE1 protein expression was 
regulated in a cell-cycle dependent manner (Figure 1A, B), increasing at the G2/M 
transition. This regulation occurred mostly at the post-transcriptional level, since WEE1 
mRNA did not vary significantly during cell-cycle progression (Figure 1C).  
In Xenopus oocyte, Wee1 3’UTR includes three CPEs, and Wee1 mRNA translation is 
controlled by CPEB1 (Charlesworth et al., 2000). Human WEE1 mRNA contains 2 CPEs. 
Interestingly, an miR-15b binding site is located 180 nucleotides upstream of the first CPE-
site (Figure 1D). In order to explore the role of these elements in WEE1 regulation, we 
generated Renilla-luciferase reporter constructs containing, either wild type or mutated 
WEE1 3’UTR in the first CPE or the miR-15b sites, alone or in combination (Figure 1D). 
We focused our attention on the first CPE, because of its close location to the miR-15b site. 
In HeLa cells, reporter activity was stimulated by mutations in the CPE or miR-15b site 
(Figure 1E). Mutating the two sites led to higher expression than mutating each one alone, 
and the effects were additive. These data suggest that both CPEB1 and miR-15b control 
WEE1 expression in an independent manner. To further confirm this hypothesis, we used 
CPEB1 25 and/or miR-15b 26 loss-of-function assays. First, we confirmed the activity of the 
inhibitors by Western blot analysis and QRT-PCR, respectively (Figure. 2A, B). Treating 
the cells with either one of the inhibitors increased the activity of the wild-type WEE1 
3’UTR reporter, while simultaneous depletion of CPEB1 and inhibition of miR-15b was 
even more effective (Figure 2C), well correlated with the results obtained by mutating 
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CPEB1 and miR-15b binding sites (Figure 2C and 1D). It is important to note that 
depletion of CPEB1 did not affect luciferase activity in the absence of the CPE sequence, 
nor did inhibition of miR-15b affect luciferase in the absence of the miR-15b binding site 
(Figure 2C), underscoring the specificity of the inhibition. Thus both CPEB1 and the RISC 
complexes appear to regulate WEE1 mRNA through their respective binding sites. This 
hypothesis was further supported by the subcellular localization of WEE1 reporter mRNA, 
CPEB1, and miR-15b (Figure 2D).  The three components were observed in dots that are 
likely to be P-bodies or stress granules, since they contain DDX6/p54 or TIA1 (Figure S1 
A, B, C). Some granules containing the reporter mRNA also contained both miR-15b and 
CPEB1. Mutation of each binding site alone did not reduce the presence of the reporter 
mRNA in dots containing the other partner, but mutation of the two sites did abolish the 
recruitment of the reporter mRNA into granules (Figure 2D and S2 A, B). 
We next tested whether endogenous WEE1 protein was affected by modulating CPEB1 
and/or miR-15b levels. When CPEB1 and/or miR-15b were down-regulated or inhibited   
(Figure 2A, B, S3A), endogenous WEE1 protein was increased (Figure 2E, S3B).  
Importantly, depletion of CPEB1 and/or miR-15b had little effect on WEE1 mRNA levels 
(Figure S3C). Conversely, overexpressing CPEB1 (Figure 2G) reduced WEE1 protein 
expression (Figure 2E). Overexpressing miR-15b (Figure 2F) did not impact on WEE1 
protein, possibly due to the fact that this miRNA is already highly expressed in HeLa cells.  
 
Interaction between CPEB1 and miR-15b/RISC 
Since the CPE and miR-15b binding sites are in close proximity, next we used co-
immunoprecipitation experiments to investigate whether CPEB1 and RISC could 
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physically interact. AGO2 co-immunoprecipitated with overexpressed FLAG-Myc-CPEB1, 
but this interaction was RNA-dependent (Figure 3A). Conversely, CPEB1 co-
immunoprecipitated with exogenous FLAG-HA-AGO2, and this was also dependent on the 
presence of RNA (Figure 3B). Thus, the two complexes may bind to common mRNA 
targets.  
As previously published 20, 21, we detected the helicase DDX6 in both CPEB1 and AGO2 
FLAG-tag immunoprecipitated complexes (Figure 3C, E).  Knocking-down DDX6 (with an 
siRNA) or inhibiting its activity with a helicase-dead transdominant mutant 27 abolished 
interaction between CPEB1 and AGO2 (Figure 3C-E).  
 
The activity of CPEB1 and miR-15/RISC is coordinated during the cell cycle   
 
WEE1 is regulated in a cell-cycle-dependent manner (Figure 1A), and the activity of 
CPEB1 is also cell cycle dependent in Xenopus embryo, CPEB1 acting alternatively as a 
repressor and an activator of gene translation  (Groisman et al., 2002). We therefore 
investigated the importance of CPEB1 and miR-15b for WEE1 expression during the cell 
cycle, after releasing HeLa cells from a double thymidine block (Figure 4A).  Surprisingly, 
we observed that when cells progressed toward G2/M, not only the CPE, but also the miR-
15b sites lost their inhibitory activity (Figure 4B). Coincidentally, silencing granules that 
contained WEE1 mRNA disappeared in G2/M cells (Figure S4A), implying that WEE1 
mRNA is released into the cytoplasm and may be actively translated. 
Moreover, WEE1 protein expression was maximal upon entering G2/M (Figure 4C). Both 
sites tend to have an opposite effect, which is to stimulate translation. Note that in this case, 
the activities of the two sites were synergistic rather than additive, both sites being required 
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for activation. A more detailed time-course analysis (hourly, beginning 28 hours after 
transfection, supplementary Figure S4B) showed that during G2/M, the CPE and miR-15b 
sequences in WEE1 3’UTR sequentially lost their inhibitory activity, then, when most of 
the cells had progressed into G2/M, together they became slightly stimulating for luciferase 
expression (Figure S4C). When the cells returned to the G0/G1 cell-cycle stage, the 
inhibitory functions of CPE and miR-15b binding sites were restored (Figure S4C).  
Thus, CPEB1 and miR-15b seem to lose their inhibitory activity at the G2/M phase of the 
cell cycle. CPEB1 protein was down regulated during G2/M, but CPEB1 mRNA level was 
stable (Figure S4D, E), similar to what was observed during Xenopus oocyte maturation. 
MiR-15b, were constitutively expressed throughout the cell cycle (Figure S4F). 
Importantly, the WEE1 mRNA level did not change throughout the cell cycle (Figure S4G), 
as observed earlier (Figure 1C).    
Our results support the hypothesis that WEE1 translation is regulated in a cell-cycle-
dependent manner. In order to further explore this hypothesis, we monitored WEE1 
reporter translation throughout the cell cycle. Active translation of mRNAs can be 
monitored by their presence in the heavy fractions of a sucrose gradient, which is 
interpreted as association of mRNA with multiple ribosomes in polysomes. In a population 
of predominantly G0/G1 cells (83%), WEE1 wild-type 3’UTR was distributed into three 
peaks, with more than half in the monosomal or light polysomal fractions (Figure 4C, 
fractions 1 to 7), implying low translational activity. When only the CPE or, alternatively, 
the miR-15b sequence was mutated, the reporter mRNA shifted toward the heavier 
polysomal fractions (fractions 5 to 8) (Figure S5A). Mutating both the miR-15b and CPE 
sites eliminated the two light peaks, and the reporter was then mostly associated with heavy 
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polysomes (fractions 9 to 12), indicating high translational activity (Figure 4D). In a 
population with at least 50% of cells in G2/M, wt WEE1 3’UTR was mostly associated 
with the heavy polysomal fractions (fractions 8 to 12). However, when the miR-15b 
binding site, the CPE site, or both were mutated, the mRNA shifted to the lighter polysomal 
fractions (fractions 5 to 8) (Figure 4D, and S5A). This result is correlates well with the 
reduced luciferase activity expressed by the same constructs in G2/M cells (Figure 4B, 
S4C).  Moreover, also in this assay, mutating one of the two sites had the same effect in 
G2/M cells as mutating both of them (Figure 4D and S5A), implying synergy between the 
two complexes. The control GAPDH mRNA was constitutively associated with heavy 
polysomal fractions in all samples (Figure 4D and S5B). These data amount to strong 
support of the idea that CPEB1 and miR-15b activity on WEE1 mRNA depends on the cell 
cycle, with both regulators being inhibitors in the G1 and/or S phases and activators at 
G2/M.  
This idea was further supported by analysis of WEE1 protein accumulation during the cell 
cycle, since WEE1 protein was deregulated by CPEB1 and/or miRNA depletion (Figure 
5A, B). In control cells, WEE1 protein was low in G1 or S cells (1h post-release) and 
increased at G2/M (5h post-release), whereas WEE1 mRNA levels remained quite stable 
throughout the cell cycle (Figure 5C). When both CPEB1 and miR-15b were depleted, 
WEE1 protein and, coincidently, Cyclin B1, used here as a cell-cycle marker, were 
deregulated, showing little variation in the time frame of the experiment (Figure 5A). Most 
interestingly, when miR-15b, CPEB1, or both were depleted, WEE1 protein was higher in 
G1/S cells than in control cells (Figure 5B), as expected if the two regulators are inhibitors. 
In sharp contrast, in G2/M cells (5h post-release) depletion of CPEB1, miR-15b, or both 
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resulted in reduced WEE1 expression, as expected for activators. Even though Western blot 
is not a fully quantitative technique, these data clearly indicate a tendency. Thus, the 
expression of endogenous WEE1 protein appears to be dependent on miR-15b and CPEB1 
in G2/M cells, consistent with the data obtained using the WEE1 reporter construct (Figure 
4). Depletion of DDX6 also affected the expression of WEE1 and Cyclin B1 (Figure S6). 
Together, these data indicate that CPEB1 and miR-15b/RISC are required for proper 
expression of WEE1 protein during the cell cycle.  
Since WEE1 regulates the temporality of cell-cycle progression, affecting WEE1 
expression, it should also impact cell-cycle progression and cell proliferation.  
A significant change was observed in cell distribution during the cell cycle in CPEB1-
depleted cells, indicating a delayed exit from the G2/M phase (Figure 5D). This effect was 
enhanced when CPEB1 and miR-15b were depleted simultaneously (Figure 5D). This 
result is consistent with the observation that depletion of WEE1 accelerates the G2/M phase 
in Xenopus. Here, depletion of CPEB1 and miR-15b increased WEE1 expression and 
resulted in delayed exit from G2/M.  
Cell growth was also affected by CPEB1 depletion (Figure 5E), as documented by the 
decreased number of cells; however, inhibiting miR-15b had little effect on cell counts. 
Taken together, these data show that WEE1 is regulated at the translational level by CPEB1 
and miR-15b in a coordinated and cell-cycle-dependent manner.  
Discussion 
We have analyzed the regulation of WEE1, an oncogenic cell-cycle regulator, by the RNA 
binding complexes CPEB1 and miR-15b/RISC.  We show that miR-15b/RISC and CPEB1 
have a coordinated impact on WEE1 translation. There are few examples of coordination 
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between RISC and other RNA binding proteins. Under stress conditions, the inactivation, 
storage, and reactivation of CAT-1 mRNA depend on the binding of both miR-122 and 
HuR, an AU-rich-element-binding protein, to the 3’UTR of CAT-1 mRNA 28. Cooperation 
between miR-16 (a member of the miR-15/16 family of miRNPs) and an ARE-binding 
protein called TTP (tristetraprolin) was shown to occur through the association of TTP with 
AGO/eIF2C family members. MiR-16 assists TTP in targeting ARE, which appears to be 
an essential step in ARE-mediated mRNA degradation 29. Our data not only constitute an 
additional example of such a coordinated action, but also demonstrate that such a 
coordinated action can be cell-cycle-dependent, the two sites being inhibitors during G1 
and S and activators during G2/M. In G1/S, the two regulators are at least in part 
colocalized in cytoplasmic granules (Figure 2D), which may be silencing granules (since 
they include DDX6/p54, Figure S2). These granules disappear at G2/M 30 and  Figure S4A. 
This could at least in part account for decreased inhibition by CPEB1 and miR-15b at 
G2/M. However, we observed that at G2/M the two sites not only lost their inhibitory 
activity, but also had a tendency to activate WEE1 mRNA translation, since their deletion 
decreased both the activity of a reporter construct (Figure 4B and Figure S4C) and the 
ribosome loading of the reporter mRNAs, as monitored by their distribution in heavy 
polysomal fractions (Figure 4D). Moreover, depletion of CPEB1 and miR-15b affected the 
expression of the endogenous protein in an opposite manner in G1/S or G2/M cells (Figure 
5A, B). CPEB1 is known to act as a cell-cycle-dependent activator of translation by 
elongating mRNA poly(A) tails during Xenopus oocyte maturation and during the 
transition to M phase in Xenopus embryo 9, 31. But such a cell-cycle-dependent switch is 
much less expected for the RISC complex, and translational activation by RISC complexes 
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is a rather controversial issue. There are, however, examples of such switches in the RISC 
complex in the literature. It has been shown that upon cell-cycle arrest, the ARE (AU-rich 
element) in tumor necrosis factor-α (TNFα) mRNA is transformed into a translation 
activation signal, recruiting AGO and fragile X mental retardation-related protein 1 
(FXR1), factors associated with miRNPs. Human miRNA miR-369-3 directs the 
association of these proteins with the AREs, leading to translation activation (Vasudevan et 
al., 2008). Moreover, two well-studied miRNAs – let-7 and the synthetic miRNA miRcxcr4 
– likewise induced translational up-regulation of target mRNAs upon cell-cycle arrest, yet 
they repressed translation in proliferating cells. It has been proposed that translation 
regulation by miRNPs oscillates between repression and activation during the cell cycle 32.  
It is quite possible that switches of activity by the RISC complex depend on the switch in 
activity of other 3’UTR-binding proteins, such as CPEB1. Indeed, here, in the absence of 
CPE, miR-15b did not activate WEE1 3’UTR in a reporter construct.  
CPEB1 activity is regulated by phosphorylation during the Xenopus embryo cell cycle 10. It 
is likely that similar phosphorylation is involved in HeLa cells.  Phosphorylation, possibly 
by the same enzyme, might also be responsible for the modification of miR-15b /RISC 
activity. In Xenopus embryo, CPEB1 phosphorylation results in the modification of the 
composition of the CPEB1 complex, which recruits a polymerase rather than a 
deadenylase. Thus, we speculate that at G2/M, CPEB1 and miR-15b/RISC recruit 
activating proteins rather than inhibitors, possibly increasing the size of the poly(A) tail of 
WEE1 mRNA. Most interestingly, whereas the inhibiting activities of the two complexes 
were acting independently of each other, activation required the integrity of each of the two 
sites, implying that the two complexes cooperate for this action. This was further supported 
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by the observation that independently mutating each site also reduced the association of 
WEE1 mRNAs with the heavy polysomal fraction at G2/M, indicative of reduced 
translation. Thus, it appears that whereas each of the complexes can independently recruit 
translation inhibitors, they need to cooperate to recruit translation activators. The 
mechanism of this cooperation is elusive. The two complexes do not appear to interact 
directly in unsynchronized cells, which are mostly in G1/S, since most of the interaction is 
sensitive to RNase (Figure 3A). It is quite possible however, that the two complexes do 
interact in G2/M cells, which would account for the residual binding observed after RNase 
treatment  (Figure 3A), since a small fraction of cells are in G2/M in the unsynchronized 
population. We will try to verify it in our future work. 
In summary, here we demonstrate a cell cycle-dependent, coordinated action of a miRNA 
(miR-15b) and an RNA-binding protein (CPEB1) to inhibit WEE1 mRNA translation in 
G1/S and activate it in G2/M, providing an example of coordination between a 
miRNA/RISC complex and another RNA binding protein, as well as, even more 
importantly, of a cell cycle-dependent switch from inhibitor to activator of the two 
complexes.    
Materials and methods 
 
Cell lines and constructs 
HeLa and HeLa S3 cells were maintained in DMEM media supplemented with 10% FCS, 
100 mg/ml streptomycin, and 100 U/ml penicillin (Gibco®) cultured at 37ºC and 5% CO2. 
The WEE1 3’UTR sequence (nt 2274-2524, [GeneBank: NM 001143976.1]) was cloned 
into XbaI/NotI sites in the pRL-TK vector (Promega). An miR-15b site substitution 
mutation was introduced by replacing the 2316-2325 sequence in the WEE1 3’UTR by 
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accacacgcga. CPE site mutation was accomplished by replacing ttttttaatt (2494-2504) with 
ggggggccgg in the WEE1 3’UTR. Double miR-15b and CPE mutations were done by 
simultaneous replacement of both sites.  
CPEB1 transcript variant 1 [GeneBank: NM_030594.3] was cloned into XhoI/EcoRI sites 
of the pmCherry-N1 expression vector. 
In transfection assays, pmCherry-N1 (632523, Clontech) was used as control.  
MiRNA precursor molecules (Applied Biosystems) used were: miR-15b (PM17100); 
MiRNA inhibitors (Applied Biosystems) used were: miR-15b (AM17000) and Negative 
Control #1 (PM17110).  
SiRNAs used were: siCPEB1 (5’ taggaggtgttccttgggata 3’, 5’cagccgaaggatgcgctgcaa 3’), 
and AllStars - negative control siRNA (Qiagen).  
 
Transfection assays and luciferase measurements 
 
All transfections were performed in triplicate in 96-well plates with 200ng (or 100ng + 
100ng) DNA and lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions. Pre- and anti-miRNAs were used at 50nM and siRNAs at 10nM. Cells were 
lysed after 20h of transfection using Passive Lysis Buffer (Promega), then Firefly and 
Renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay 
System Kit (Promega). Results are expressed as Renilla luciferase values normalized to 
Firefly, and statistical analyses performed using Student’s t test. 
 
Quantitative PCR 
 
Total RNA purification was performed using Trizol (Invitrogen) according to the 
manufacturer’s instructions. 500ng or 250ng total RNA was used for CPEB1,WEE1 mRNA 
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quantification, using QuantiTect SYBR-green RT-PCR kits (Qiagen) and a LightCycler 
Real-Time PCR System (Roche).  
For miRNA analysis, 25ng of total RNA was reverse-transcribed using the TaqMan® 
MicroRNA Reverse Transcription Kit (Applied Biosystems). QPCR was carried out in 
triplicate using the TaqMan Universal PCR Master Mix (Applied Biosystems).  
Primers used were: WEE1 forward (5’ acctcggataccacaagtgctt 3’)  
reverse (5’ ggtcttctctctggatctggatga 3’), WEE1 3’UTR forward (5’ ttggatgttacaccagcctt 3’), 
WEE1 3’UTR reverse (5’ gatatacaagtctaattcaca 3’); CPEB1 forward 
(5’ tcccagatgcaaatgacttgtgcc 3’), CPEB1 reverse (5’ aacttgtccaccaagtcagaccca 3’); 
(5’ gacgatgcgctagatgtcaa 3’); GAPDH forward (5’ ggacctgacctgccgtctagaa 3’), GAPDH 
reverse (5’ ggtgtcgctgttgaagtcagag 3’); Cyclophiline A forward (5’-
GTCAACCCCACCGTGTTCTT-3’); Cyclophilin A reverse (5’-
CTGCTGTCTTTGGGACCTTGT-3’) 
 
Immunoprecipitation assay 
Four 15-cm dishes of HeLa S3 cells were transfected with Myc-FLAG-CPEB1, HA-
FLAG-CPEB1 (or CPEB1 mutants), or HA-FLAG-AGO2 expression plasmids (OriGene). 
After 48h of incubation, cells were collected, lysed in 150ml/plate lysis buffer consisting of 
100mM KCl, 5mM MgCl2, 20mM Hepes-KOH (pH 7.8), 2mM DTT, 0.25% NP-40, and 
protease inhibitor cocktail (Roche) for 30 min on ice.  
Lysates were incubated with 100ml anti-FLAG beads (SIGMA), washed in lysis buffer, 
and incubated overnight at 4°C with rotation. The beads were washed 5 times in 0.5ml lysis 
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buffer. Then CPEB1 complexes were eluted in 120ml of lysis buffer with 100mg/ml FLAG 
peptide at 4°C for 2h with shaking. FLAG peptide elution were analyzed by Western blot.   
 
SDS-PAGE and Western Blot 
Protein extracts were prepared in 100mM KCl, 5mM MgCl2, 20mM Hepes-KOH (pH 7.8), 
2mM DTT, 0.25% NP-40, and protease inhibitor cocktail (Roche).  
20mg of protein was loaded onto NuPAGE 4-12% Bis-Tris Pre-Cast Gels and resolved 
using the NuPAGE System (Invitrogen), followed by Western blotting, using standard 
techniques. Primary antibodies and dilutions used were: CPEB1 1:1000 (NB100-1437, 
Novus Biological), b-actin 1:10000 (A5441, Sigma) and α-Tubulin 1:5000 (F2168, Sigma), 
WEE1 (sc-5285, Santa Cruz), Cyclin B1 (sc-752, Santa Cruz), Myc-tag (sc-40, Sigma), 
AGO1 (SAB4200084, SIGMA), AGO2 (SAB4200085, SIGMA). Secondary antibodies and 
dilutions used were anti-rabbit-HRP 1:25000 (A0545, Sigma), anti-mouse 1:25000 (A2304, 
Sigma), and anti-rat 1:25000 (A9037, SIGMA). 
Protein levels determined by Western blot were quantified using BioImage software. 
 
Ribosomal profile 
15-cm plates of HeLa S3 cells were transfected with pRL-TK Vector containing a fragment 
of the WEE1 3’UTR (wt, or else mutated at the miR-15b and/or CPE sites) attached to the 
luciferase coding sequence. After 24h, cells were lysed in 500ml buffer containing 20mM 
Tris-HCl (pH 8.5), 1.5mM MgCl2, 140mM KCl, 0.5mM DTT, 0.5% NP-40, 1000U of 
RNAsin (Promega) per ml, and 0.1mM cycloheximide. The lysate was centrifuged at 
10,000g for 10 min, and supernatants were applied to linear 20-47% sucrose gradients in 
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buffer containing 20mM Tris-HCl (pH 8.0), 140mM KCl, 5mM MgCl2. Centrifugation was 
carried out at 40,000 rpm for 135 min in a Beckman SW41 rotor. 1 ml fractions were 
collected using a Teledyne ISCO Model 160 system with concomitant measurement of the 
absorbance at 260nm followed by RNA precipitation by 1ml of isopropanol and Q-PCR 
analysis with primers for Luciferase (forward: 5’ atttaggtgacactatacatgacttcgaaagtttatg 3’ 
and reverse: 5’ taatacgactcactatacgcaatatcttcttcttcaatatc 3’), with GAPDH (forward: 
5’ ggacctgacctgccgtctagaa 3’and reverse: 5’ ggtgtcgctgttgaagtcagag 3’) as control.  
Cell synchronization experiments were done in a similar way, but cells were transfected 
with plasmid after release from a double thymidine block. Cells were collected 29h after 
transfection, lysed, and separated on a sucrose gradient. RNA were extracted and subjected 
to Q-PCR analysis.  
 
Cell synchronization and FACS analysis 
 
HeLa S3 cells (25-30% confluence) were incubated with 2mM thymidine for 18 hours. 
Cells were then washed in PBS and incubated in DMEM (10% FBS) for 9 hours to release 
them from the first thymidine block. 2mM thymidine was then added to DMEM for 17 
hours (second thymidine block). After removal of thymidine by washing in PBS and adding 
fresh DMEM (10% FBS), cells were transfected with luciferase reporter constructs and 24 
hours later some cells were used for the luciferase reporter assay and some were fixed in 
70% EtOH at 4°C overnight. The next day, fixed cells were subjected to propidium iodide 
(PI) labeling. Cells were washed with PBS twice, resuspended in 50mL PBS containing a 
final concentration of 1mg/mL RNAse (DNAse-free, Qiagen), incubated at 4°C for 5 min, 
then added to 45 mL PBS containing 50mg/mL PI (final concentration), incubated at 4°C 
for 30 min in the dark and subjected to FACS analysis by FACScan (Becton Dickinson).   
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In situ hybridization 
Antisense and control (sense) probes for in situ hybridization were prepared by 
incorporating fluorescein-12-UTP (11 427 857 910 Roche) into the luciferase mRNAs 
respectively transcribed in vitro from T7 and SP6 promoters, using the mMessage 
mMachine kit (Ambion); the coding sequence was obtained by PCR amplification of a 
DNA fragment using as primers:  
forward, 5’ atttaggtgacactatacatgacttcgaaagtttatg 3’; 
reverse, 5’ taatacgactcactatacgcaatatcttcttcttcaatatc 3’. 
HeLa cells were fixed for 15 min in 3.7 % PFA in PBS at RT, washed in PBT (0.1% 
Tween-20 in PBS) and stored in 70% EtOH at 4°C overnight. After rehydration in PBT, 
cells were treated for 3 min with 1mg/mL Proteinase K in PBT, washed in 2mg/mL glycine 
in PBT and post-fixed for 10 min in 3.7% PFA in PBT.  Cells were initially incubated for 1 
hour in hybridization mix (HM; 50% formamide, 5xSSC, 1x Denhardt’s solution, 200 
mg/mL yeast tRNA, 500mg/mL salmon sperm DNA, 2% blocking reagent (Roche)) at 
37°C, and then hybridized overnight with 40nM probe at 37° C. Post-hybridization washes 
were carried out for 3 x 15 min in 30% formamide/2x SSC at 50° C, 1 x 15 min in 2x SSC 
at RT, and 1 x 15 min in 0.2x SSC at RT. Cells were rinsed three times with PBS then 
rinsed once for 2-5 min with Hoechst 33258 (the 16mM stock solution was diluted 1:8000 
final concentration 2mM), mounted on glass slides with Dako mounting medium, and 
analyzed by fluorescence microscopy.  
 
 
Co-transfection of labeled molecules and confocal microscopy 
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FITC-labeled WEE1 3’UTR mRNAs were prepared by incorporation of fluorescein-12-
UTP (Roche) into the in-vitro transcript obtained from the T7 promoter using the 
mMessage mMachine kit (Ambion); the coding sequence was obtained by PCR 
amplification of a DNA fragment from Rluc-WEE1 3’UTR constructs using as primers:  
forward, 5’ taatacgactcactatacgttcgttgagcgagttctc 3’;  
reverse, 5’ atttaggtgacactatacactgcattctagttgtggt 3’.  
Mir-15b precursor (Applied Biosystems) was labeled with Cy5 (Label IT siRNA Tracker 
Cy5 Kit, Mirus) according to the company protocol.  
FITC-labeled WEE1 3’UTR (wt, CPE and/or miR-15b site mutations), Cy5-labeled miR-
15b precursor and/or CPEB1-Cherry DNA were cotransfected into HeLa cells with a 
Lipofectamin 2000 Kit (Invitrogen) according to the company protocol. Cells were fixed 
48 hours later in 4% paraformaldehyde, labeled, and visualized by confocal microscopy. 
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Figure 1. Regulation of WEE1 in HeLa cells depends on CPE and miR-15b binding sites. 
(A) Cell cycle distribution (by FACS analysis) of HeLa cells at indicated times after release 
from a double thymidine block. (B) Western blot analyses of WEE1 expression in HeLa 
cells after release from a double thymidine block; actin is used as a loading control.  (C) 
QPCR analyses of WEE1 mRNA, in the same cells; Cyclo A was used to standardize the 
data. (D) Schematic representation of R-luc WEE1 3’UTR fusions (WEE1 3’UTR was 
introduced into the 3’UTR of Renilla luciferase reporters). (E) Luciferase expression of the 
reporter constructs described in D following transfection into HeLa cells; Renilla enzymatic 
activity (LucR) was normalized to Firefly (control, LucF). 
 Statistics: Student’s t test; *:  t = 0.05.  
 
Figure 2. MiR-15b and CPEB1 control WEE1 expression. (A) Depletion of CPEB1 by 
siRNAs (Western blot). (B) Depletion of miR-15b by an antisense LNA (QPCR); (C) 
Influence of CPEB1 and/or miR-15b depletion on WEE1 3’UTR reporter luciferase activity 
transfected into HeLa cells along with inhibitors as indicated. Controls were miRNA  
(Applied Biosystems) and AllStars (Qiagen). Numbers indicate the ratio LucR/LucF for 
each sample. (D) Localization of WEE1 mRNA, CPEB1, and miR-15b in HeLa cells. HeLa 
cells were transfected with Cy5-labeled miR-15b, CPEB1-Cherry, FITC-labeled WEE1 
3’UTR (wt or mutant as indicated). Arrows point to granules with co-localized WEE1 
mRNA, CPEB1, and/or miR-15b.  (E) CPEB1 and miR-15b control WEE1 protein 
expression. For gain-of-function assays, HeLa cells were transfected with a construct 
expressing CPEB1-Cherry (or Cherry as a control), or with miR-15b precursor (or a control 
miRNA); for loss-of-function assays, cells were transfected with the inhibitors described in 
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A and B; WEE1 expression was monitored 48h later by Western blot. (F) Overexpression 
of miR-15b monitored by QPCR. (G) Overexpression of CPEB1 monitored by Western 
blot.  
  
Figure 3. Interaction between CPEB1 and AGO2 is RNAse and DDX6 dependent. (A) Co-
immunoprecipitation of endogenous AGO2 with CPEB1-Myc-FLAG; cells were 
transfected with a tagged CPEB1 (CPEB1-Myc-FLAG) expression vector or an empty 
vehicle vector as a control (vector); cell extracts were immunoprecipitated using anti-
FLAG antibodies, following RNase treatment when indicated, and monitored by Western 
blot; inp: input; IP: immunoprecipitates. (B) Cells were transfected with a tagged AGO2 
(AGO2-FLAG-HA) expression vector or an empty vehicle vector as a control (vector); cell 
extracts were immunoprecipitated using anti-FLAG antibodies, following RNase treatment 
when indicated. (C) DDX6 is required for AGO2/CPEB1 interaction. Cells treated for 48h 
with an siRNA to DDX6 (or a control siRNA) were transfected and treated as in A. (D) 
Cells were transfected with CPEB1-Myc-FLAG and AGO2-FLAG-HA expression vectors, 
along with wild type (wt) or transdominant DDX6 helicase dead mutant (mut) expression 
vectors; extracts were immunoprecipitated with anti-HA antibodies and analyzed as in A. 
(E) Cells were transfected with wild-type DDX6 (wt) or transdominant DDX6 mutant 
(mut) together with CPEB1-Myc-FLAG or AGO2-FLAG-HA expression vectors; extracts 
were immunoprecipitated with anti-FLAG antibodies and analyzed as in A and B. 
 
Figure 4. CPEB1 and miR-15b inhibitors switch to activators at G2/M. (A) Cell-cycle 
analysis (by FACS) of HeLa cells after release from a double thymidine block unsync, -
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unsynchronized cells. (B) HeLa cells analyzed in A were transfected after they were 
released from thymidine block with WEE1 3’UTR reporter constructs (described in Figure 
1D) and 20h later, cell extracts were submitted to luciferase assays. Renilla luciferase 
activity was normalized to Firefly activity; the position of the majority of the cells in the 
cell cycle in the samples is indicated above the bars; Statistics: Student’s t test; *:  t = 0.05. 
(C) WEE1 expression along the cell cycle as monitored by Western blot; cyclin B1 is 
shown to document the position of the cells in the cell cycle. (D) Distribution of WEE1 
3’UTR reporter mRNAs in polysomal gradients at the G0/G1 or G2/M phase of the cell 
cycle. Fractions 0-3 correspond to monosomal fractions, 4-7 to low polysomal fractions, 
and 8-12 to heavy polysomal fractions.  
 
Figure 5. Depletion of CPEB1 or miR-15b affects both the cell-cycle-dependent 
accumulation of WEE1 and cell-cycle progression. (A) Cells were transfected with a 
siRNA to CPEB1, an antisense to miR-15b, or control molecules as indicated and 
submitted to a double thymidine block as in Figure 4; WEE1 or Cyclin B1 expression was 
monitored by Western blot.  (B) Quantification of the Western blots shown in (A) after 
standardization to actin. (C) WEE1 mRNA expression in the same cells, monitored by Q-
RT-PCR. (D) Cell-cycle distribution (analyzed by FACS) of HeLa cells after depletion of 
CPEB1 and/or miR-15b. (E) HeLa cell-count after CPEB1 and/or miR-15b depletion.  
 
BC
FcuL/RcuL
Transfected DNA, ng
0 
2 
4 
6 
0 100 200 
Ce
ll c
ou
nt
, X
10
00
 
FL3-H 
2h 
0 
2 
4 
6 
0 100 200 
Ce
ll c
ou
nt
, X
10
00
 
FL3-H  
6h 
0 
2 
4 
6 
0 100 200 
Ce
ll c
ou
nt
, X
10
00
 
FL3-H
3h 
0 
2 
4 
6 
0 100 200 
Ce
ll c
ou
nt
, X
10
00
 
FL3-H
7h 
A
0 
2 
4 
6 
0 100 200 
Ce
ll c
ou
nt
, X
10
00
 
FL3-H
4h 
0 
2 
4 
0 100 200 
Ce
ll c
ou
nt
, X
10
00
 
FL3-H
8h 
Time post release
0 
2 
4 
6 
8 
10 
0 100 200 
FL3-H 
unsynch 
0 
2 
4 
6 
0 100 200 
FL3-H  
5h 
Ce
ll c
ou
nt
, X
10
00
 
Ce
ll c
ou
nt
, X
10
00
 
W
EE
1/
cy
clo
A 
m
RN
A
Time post release, hours
0.00 
0.01 
0.02 
0.03 
0.04 
2 3 4 5 6 7 8 
100 50 25 12 6 3 
2 
0 
4 
6 
8 
10 
WEE1 3'UTR wt 
WEE1 3'UTR CPE mut 
WEE1 3'UTR miR-15b mut
WEE1 3'UTR CPE mut,
miR-15b mut 
Time post 
release
(hours)
2 4 6 7 83 5
WEE1
Actin
D E
CPE miR-15b
miR-15b
miR-15b
miR-15b
CCACUGUGGUGGUGUGCUGCUU UUUUUUUAU
CCACUGUGGACCACACGACGAU
180 nt 
ACAUUUGGUACUACACGACGAU
UUUUUUUAU
CPE
CPE
CCACUGUGGUGGUGUGCUGCUU GGGGGGCCG
CCACUGUGGACCACACGACGAU GGGGGGCCG
CPE
ORF
ORF
ORF
ORF
Kratassiouk et al. Figure 1
D 
E G 
C HeLa
CPEB
actin
A
actin
WEE1
CPEB-Cherry 
miR-15b 
CPEB siRNA 
antimiR-15b 
Cherry 
CPEB-Cherry + 
Cherry +ctrl miRNA
+ + 
+ +  
+ +  
++
 
+
++ +  
+ +ctrl siRNA
ctrl 
 ctrl 
CPEB 
ctrl 
ctrl 
miR-15b
CPEB 
miR-15b
  WEE1 3'UTR wt  
CPE mut 
miR-15b mut
CPE and 
miR-15b mut
siRNA
antimiR
RTU’3-1EE
W
t u
m b51
M
iR
-
, EPC
merge
 RTU’3-1EE
W
t w
 RTU’3-1EE
W
tu
m EPC
miR-15b
(Cy-5 )CPEB-Cherry
luc mRNA
(FITC) merge
CPEB
actin
F 
miR-15b 0
5
10
15
+ 
m
iR
-1
5b
 
 / 
U6
 sn
RN
A
ctrl miRNA +
LNA-antimiR-15b 
m
iR
-1
5b
  /
U6
 sn
RN
A 
0
1
2
3
4B 
+
ctrl LNA +
siRNA 12ctrl
µm 0 25 
0 
1 
2 
0 
1 
2 
0 
1 
2 
0 
1 
2 
Kratassiouk et al. Figure 3
+− +−
IP: FLAG
A
CPEB-FLAG-HA vector
D
CPEB-
Myc-FLAG
AGO2-
FLAG-HA
IP: HA
DDX6 mut wt
HA
RNase
IP: FLAG
B
AGO2-FLAG-HA
IP IPinp. inp.
AGO2
DDX6
IP: FLAG
HA
CPEB-FLAG-HA
DDX6control
C
siRNA
IP: FLAG
CPEB-FLAG-HAAGO2-FLAG-HA
CPEB
DDX6wt
HA
AGO2
DDX6wt
HA
E
inp.inp.
CPEB
DDX6mut
IP
IP
HA
AGO2
DDX6mut
HA
FT FT
+− +−
inp. IPinp.
AGO2
+− +−+− +−
IPinp. IPinp.
vector
mut wt
IPinp. IP
HA
 CPEB
AB C
D
Kratassiouk et al.  Figure 4
FL3-H
 
FL3-H FL3-H
0 200 400 600 800 1000
0
200
400
600
800
FL3-H
0 200 400 600 800 1000
0
100
200
300
400
FL3-H
0 200 400 600 800 1000
0
100
200
300
0 200 400 600 800 1000
0
200
400
600
0 200 400 600 800 1000
0
200
400
600
800
1000
G0/G1 G1/S G2/M
20h 23h 26h 29hunsync
time post
release
(hours)
- 20 23 26 29
WEE1
cyclin B1
actin
ce
ll c
ou
nt
0.4 
0.8 
1.2 
20 23 26 29 
miR-15b mut
CPE, miR-15b mutCPE mut
 wt
G2/MG1/SG0/G1
time post
release
(hours)
0
0.5
1
0 1 2 3 4 5 6 7 8 9 10 11 12
0
0.5
1
0 1 2 3 4 5 6 7 8 9 10 11 12
0
0.5
1
0 1 2 3 4 5 6 7 8 9 10 11 12
0
0.5
1
0 1 2 3 4 5 6 7 8 9 10 11 12
G0/G1 WEE1-luc
G0/G1 GAPDH G2/M GAPDH
G2/M WEE1-luc
WEE1-luc wt
WEE1-luc CPE, miR-15b mut
**
* **
*
**
*
W
EE
1 
m
RN
A
, r
el
at
iv
e 
am
ou
nt
W
EE
1 
m
RN
A
, r
el
at
iv
e 
am
ou
nt
W
EE
1 
m
RN
A
, r
el
at
iv
e 
am
ou
nt
W
EE
1 
m
RN
A
, r
el
at
iv
e 
am
ou
nt
fraction number fraction number
fraction number fraction number
W
EE
1 
m
RN
A/
cy
clo
A 
m
RN
A
Kratassiouk et al. Figure 5
C
D
ctrl siRNA 
+ ctrl miRNA 
CPEB siRNA 
+ ctrl miRNA 
antimiR-15b 
+ ctrl siRNA
CPEB-siRNA
 + antimiR-15b 
FL3-H FL3-H FL3-H FL3-H
0
2
4
6
0 150 300
1h
0
50
100
150
0 150 300
5h
0
100
200
300
0 150 300
8h
0
5
10
0 150 300
unsync
0
1
2
3
0 150 300
1h
0
50
100
150
0 150 300
5h
0
100
200
0 150 300
8h
0
2
4
0 150 300
unsync
0
2
4
6
0 150 300
1h
0
50
100
150
0 150 300
5h
0
100
200
0 150 300
8h
0
5
10
0 150 300
unsync
0
1
2
3
0 150
1h
0
50
100
0 150
5h
0
50
100
150
0 150
8h
0
2
4
0 150
300
300
300
300
unsync
Ce
ll c
ou
nt
, ×
10
-3
 
0.01 
0.02 
0.03 
0.04 
0 1 2 3 4 5 6 
 
 
 
A
 
 
WEE1 
WEE1 
CyclinB1 
CyclinB1 
actin 
actin 
Time post 
release
(hours)
6 2 1 7 5 8 
Time post 
release
(hours)
6 2 1 7 5 8 
6 2 1 7 5 8 
6 2 1 7 5 8 
E
+CPEB siRNA  +
+ +antimiR-15b    
 +antimiR ctrl +
++ctrl siRNA
 0
10,000
20,000
30,000
ce
ll c
ou
nt
 +all star siRNA
B
0
0.5
1
1.5
2
0 2 4 6 8 10
W
EE
1 
pr
ot
ein
/a
cti
n 
pr
ot
ein
control siRNA, control antimiR-15b 
CPEB siRNA,  control antimiR 
control siRNA, antimiR-15b 
CPEB siRNA, antimiR-15b 
Time post-
release
(hours)
ctrl siRNA  
+ ctrl antimiR-15b 
control siRNA
+ anti-miR-15b 
CPEB siRNA
+ antimiR-15b 
CPEB siRNA  
+ control antimiR
G1+S G2/M
control siRNA, control antimiR control siRNA, antimiR-15b 
CPEB siRNA, control antimiR 
CPEB siRNA, antimiR-15b 
Time post 
release
(hours)
DDX6 merge WEE1-RNA  
DDX6 
TIA1 merge Wee1-RNA  
CPEB-cherry DDX6 merge 
TIA1 CPEB-cherry merge 
merge MiR-15b TIA1 
A
B
C
Kratassiouk et al. Figure S1
µm 0 25 µm 0 25 µm 0 25 
µm 0 25 µm 0 25 µm 0 25 
µm 0 25 µm 0 25 µm 0 25 
µm 0 25 µm 0 25 µm 0 25 
µm 0 25 µm 0 25 µm 0 25 µm 0 25 
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localized in P-bodies and stress granules.  (A) Cells transfected with FITC-
labeled WEE1 RNA fixed 24 h later and immunostained with DDX6 (P-body 
marker) and TIA (stress granule marker) antibody and subjected to confocal 
microscopy.  (B) Cells transfected with CPEB1-Cherry were immunostained with 
DDX6 and TIA antibody and subjected to confocal microscopy.  (C) Cells 
transfected with Cy5-miR-15b precursor were fixed 24 h later and immunostained 
with DDX6 (P-body marker) and TIA (stress-granule marker) and subjected to 
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Figure S2. WEE1 3’UTR-dependent distribution of R-Luc mRNA to silencing granules in 
HeLa cells. (A) Cells were transfected with CPEB1-Cherry and R-Luc WEE1 3’UTR (wt or 
mutant as indicated) DNA constructs and, after 48h of incubation, xed and used for 
in-situ hybridization with R-Luc anti-sense probe and visualized by uorescence 
microscopy (Arrows point to CPEB1-granules that co-localized with WEE1 3’UTR). (B) 
Cells were transfected with CPEB1-Cherry and R-Luc WEE1 3’UTR constructs and 
treated as in (A) (R-Luc sense probe used for control). Arrows point to CPEB1-granules.
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Figure S4. MiR-15b, WEE1 and CPEB1 mRNA, protein expression and 
localization during cell cycle in HeLa. (A) HeLa cells were synchronized by 
double thymidine block and transfected, after release, with FITC-labeled wt 
WEE1 3 UTR, CPEB1-Cherry, and Cy5-labeled miR-15b, incubated for 29 h, 
fixed, and analyzed by confocal microscopy (Leica TCS SP5 II). (B) FACS 
analyses of HeLa cells performed every hour-started 28h after release from 
double thymidine block. (C) HeLa cells were transfected with R-luc wt WEE1 
3 UTR or CPE and/or miR-15b mutant reporter constructs after release from a 
double thymidine block. Luciferase reporter assays were carried out every hour 
started 28h after transfection (D, F). CPEB1 mRNA and protein expression 
during cell cycle. QPCR and Western blot analyses of CPEB1 mRNA and protein 
performed at the same time points as in C; (E) QPCR analyses of the expression 
levels of miR-15b performed at the same time points as in C. 
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Figure S5. R-luc-WEE1 3 UTR mRNA presentation in polysomal gradient  
(A) Distribution of R-luc-WEE1 3 UTR mRNA with CPE or miR-15b binding site 
mutant in polysomal gradient during G0/G1 and G2/M phase of cell cycle. (B) 
Distribution of GAPDH mRNA (internal control) across the polysomal gradient 
during G0/G1 and G2/M phase of cell cycle. 
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Figure S6. Differential expression of WEE1 along the cell cycle is dependent on 
DDX6. HeLa cells were transfected with control SiRNA and DDX6 SiRNA, Cells 
were synchronized by double thymidin block. Western blot analyses of WEE1 
and cyclin B1 expression were performed at each hour after release from the 
double thymidine block!
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Conclusions	  
1) IMP3 regulates the expression of cyclin D1 and D3 in a significant manner in vivo. 
Inhibition of IMP3 did not significantly change the mRNA levels of cyclin D1 and D3. The 
stability of cyclin D1 and D3 mRNAs does not depend on the presence of IMP3. 
2) In the absence of IMP3 cyclin D1 and D3 mRNAs are exported to the cytoplasm and seems 
to have preferentially perinuclear localization. 
3) After IMP3 KD cyclin D1 and D3 mRNAs are associated with polyribosomes, but not 
translated. 
4) In the cytoplasm of RMS cells IMP interact with multiple RBPs, suggesting an existing of 
a RNP complex, that positively regulate cyclin D1 and D3 translation. 
5) We found that the decrease of the cyclins D1, D3 protein levels after IMP-3 or its protein 
partners (NF90 and PTBP1) KD can be reversed by KD of two key components of RISC 
complex: GW182 and Ago2. 
6) We identified miR let-7, as well as miR 15 and miR 193b (data not shown) for cyclin D1 
and miR let-7 for cyclin D3, that can be involved in miRISC-dependent translational 
repression of these cyclins. The efficiency of miRNA-dependent translational repression can 
be regulated by IMP-3 and RISC complex components. 
7) We determined functional regions within cyclin D1 and D3 3’UTRs, where IMP3 and 
miRISC complexes compete for cyclin regulation.  
 
Taken together, the results of this work show, that IMP3 and its protein partners form a 
complex on 3’UTRs of the cyclins D1 and D3 and protect them from miRISC-dependent 
translational repression. 
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DISCUSSION 
 
IMP3 regulates cyclin D1 and D3 expression at post-transcriptional level. 
RNA-binding proteins in cells associate with their target mRNAs, resulting in 
ribonucleoprotein (RNP) complexes formation. The composition of such complexes 
determines the cellular fate of mRNAs: localization, translation and decay. IMPs form stable 
protein-RNA associations that can prevent premature decay and promiscuous translation of 
specific target transcripts, as it has been shown for CD44, MYC, PTEN or BTRC [Lemm I 
and Ross J, 2002; Kobel M et al., 2007; Stohr N et al., 2012 ; Vikesaa J et al., 2006 ; Noubissi 
FK et al., 2006]. By regulating these and other mRNA targets, IMP3 was reported to promote 
tumor progression and metastasis in a number of malignancies.  
We have previously shown that IMP3 regulates the expression of cyclin D1 and D3 in a 
significant manner in vivo [Rivera Vargas, Boudoukha et al. 2014]. Cyclins are short-lived 
proteins with two- to four-fold shorter half-lives than their corresponding mRNAs, which 
makes them convenient models for mechanistic studies of post-transcriptional regulation of 
endogenous gene expression. We observed a rapid and significant decrease in cyclin protein, 
but not of mRNA levels after a knock-down (KD) of IMP3, suggesting that the regulation of 
cyclins expression by IMP3 occurred on post-transcriptional level. As the possibility of 
increased protein degradation of the cyclins in IMP3 KD cells was excluded by earlier studies 
in my laboratory, the main working hypothesis of my project was an involvement of 
translational repression as the principal regulatory mechanism. 
RBPs can bind their target mRNAs co-transcriptionally in the nucleus and regulate their 
localization and translation, as it has been shown for IMP1 and Bruno [Singer RH, 2003 ; 
Snee M et al., 2008]. Previous study performed in my group has shown that IMP3 with a help 
of nucleocytoplasmic protein HNRNP M can enter the nucleus and bind the newly 
synthesized cyclin transcripts [Rivera Vargas, Boudoukha et al. 2014]. Therefore, a KD of 
IMP3 could stop the nuclear export of the cyclins mRNAs. However, we found that the 
nuclear export did not depend on IMP3, as the mRNAs of the cyclins were exported to the 
cytoplasm and  associated with polysomes in  the cytoplasm even when IMP3 was depleted. 
However, in IMP3 KD cells the cyclins mRNAs have preferentially perinuclear localization. 
It should be noted that such localization can be a consequence of translational inhibition of 
these transcripts by RNA-induced silencing complex (RISC), which is enriched in the 
perinuclear regions of mammalian cells [Stalder L et al., 2013]. 	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IMP3 compete with RISC complex for cyclin D1 and D3 regulation. 
We hypothesized that the decrease of the cyclins protein expression, observed in the absence 
of IMP3, could be caused by miRISC action. Minimal mammalian miRISC is composed of 
two key factors : GW182 protein that serves as a molecular platform and binds a multitude of 
silencing effectors ; and AGO2 protein with associated miRNA, which directs the silencing 
complex to the complementary target mRNA. In the majority of published studies, the action 
of miRISC was attributed to inhibition of translational initiation, or to a degradation of the 
target mRNA [Humphreys et al., 2005; Mathonnet et al., 2007; Pillai et al., 2005; Wakiyama 
et al., 2007; Wang et al., 2006]. However, miRISC can also regulate protein translation at 
post-initiation steps, promoting co-translational peptide degradation [Nottrott S et al., 2006], 
premature termination of translation by ribosomal drop-off [Petersen CP et al., 2006] and 
impaired elongation [Gu S et al., 2009]. Therefore, the molecular mechanisms of miR-
mediated repression of protein expression remain extremely varied, depending on specific 
mRNA targets, miRNAs, and experimental models.  
We found that the decrease of the cyclins D1, D3 after IMP-3 KD could be reversed by a KD 
of two key components of RISC complex: GW182 and AGO2. In all cases, inactivation of the 
RNAi machinery leads to a re-expression of the cyclins even in the absence of IMP-3. IMP3 
partners PTBP1 and NF90/ILF3 act in the same way. These key findings led us to the 
conclusion that IMP3 and its protein partners, especially NF90/ILF3 and PTBP1, can protect 
their mRNA targets from RISC-dependent repression in human cancer cells.  
 
Identification of functional regions within 3’ UTRs  of the cyclins, where a competition 
between IMP-3 and RISC complexes occurs. 
The study of interaction between IMPs and their targets is very complex due to the absence of 
a unique target sequence. Furthermore, mRNA secondary structure also appears to play an 
important role in the target recognition by IMPs [Nielsen FC et al., 2002]. In this case, 
binding is based on the identification of the mRNA structures rather than on nucleotide 
sequence recognition. A large number of miRNAs are predicted to target cyclins D1 and D3, 
but are not confirmed experimentally. Therefore, we decided to experimentally map the 
functional sites within the cyclins 3’ UTRs, where the IMP-3 binding competes with the RISC 
complex. Using the RNA-protein biotin pull-down technique, we identified regions bound by 
RISC complex components (GW182 and AGO2) and IMP3. Among them, we identified 
functional regions, where the binding efficiency of RISC complex components increased after 
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IMP3 KD, or the regions where the competition occurs. Then, we showed in vivo, that  
transfection of these RNA fragments, but not of the adjacent flanking regions, into IMP3 KD 
cells led to a partial or complete « rescue » of the cyclins expression. These findings further 
confirmed our hypothesis that IMP3 complexes protect the 3’UTRs of the cyclins mRNAs 
from GW182/AGO2 dependent translational repression. 	  	  
Characterization of  IGF2BP-containing cytoplasmic complexes. 	  
IGF2BP/IMP proteins are mostly expressed in the cytoplasm, where they bind their target 
mRNAs  and form cytoplasmic ribonucleoprotein complexes (mRNPs), dispersed 
preferentially around the nucleus [Nielsen et al., 2002]. These mRNP granules regulate 
translation, stability and transport of associated mRNAs. Unlike other well-known granules, 
like neuronal hStaufen and/or fragile X mental retardation protein granules, processing bodies 
(P-bodies), and stress granules [Jønson et al., 2007], the IMP granules lack eIF4E, eIF4G, and 
60S ribosomal subunits, and contain CBP80 and exon-junction complex factors, suggesting 
that the associated mRNAs have never been translated.  
IGF2BPs start controlling their target mRNAs co-transcriptionally in the nucleus and 
modulate the distribution of associated transcripts between translational and decay 
machineries or prevent microRNA attack by recruiting regulated transcripts in cytoplasmic 
mRNPs. Thus, Vg1 RBP/Vera (human IMP3 homologue) localizes Vg1 mRNA to the vegetal 
cortex of Xenophus oocyte [Kress et al., 2004]. ZBP1 (chicken homolog of IMP1) promotes 
localization of beta-actin mRNA to the extremities of growing neuronal cells [Oleynikov Y et 
Singer SH, 2003]. During transport, ZBP1 prevents premature translation of beta-actin 
mRNA, inhibiting its translational initiation. ‘Caging’ MYC and MDR1 in mRNP complexes, 
IGF2BP1 protects them from endonucleolytic cleavage and degradation [Lemm I and Ross J, 
2002; Sparanese D and Lee CH, 2007]. IGF2BP1 also enhance BTRC1 expression  by 
protecting its transcript from microRNA-mediated degradation [Elcheva et al., 2009]. A 
similar mechanism of forming IMP1/3-containing granules and stabilizing HMGA2 mRNA 
by protecting it against let-7-dependent degradation was proposed for IMP3 [Jønson et al., 
2014]. It is interesting to note that these IMP3-containing granules lack translational initiation 
factors (eIF4E), RISC complex (Ago 1-4, miRNAs) and decay machinery (DCP1a) 
components. Besides HMGA2, IMP1/3 granules protect a variety of other miRNAs targets,  
making  them inaccessible to RISC [Jønson et al., 2014].  
The review of recent  literature suggests that IGF2BPs participate in a network of complex 
RNA-protein and protein-protein interactions, suggesting a vast number of  various IGF2BP-
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containing regulatory mRNPs. This observation is in agreement with the post-transcriptional 
RNA operon model proposed by Keene and Tenenbaum (2002), according to which any given 
RNA contains multiple binding sites for various RNA-binding proteins. A different set and 
functions of trans-acting RBPs, bound to specific sequences on a given mRNA, determines its 
different cellular fate. Therefore, mRNAs containing similar cis-elements can be regulated 
jointly in the composition of such posttranscriptional regulons [Jønson et al., 2011]. 
According to our results, IMP3 co-interact with multiple RBPs in human cancer cells to 
positively regulate cyclin D1 and D3 translation, by protecting these mRNAs from 
GW182/AGO2/miRNA-dependent repression This regulatory mechanism, specific to IMP3 
and not to its family members IMP1 and 2, remains fully reversible and very dynamic, as it 
does not change mRNA stability and does not involve de novo mRNA transcription. Two of 
IMP3 protein partners, PTBP1 and ILF3/NF90, have a strong impact on cyclin protein 
expression levels. The roles of these IMP3 partners could be elucidated by recent studies, 
which suggest that ILF3/NF90 regulates both mRNA translation and stability via cooperative 
or antagonistic interaction with miRISC action [Shim J et al., 2002 ; Xu YH et al., 2000; Xu 
YH et al., 2003]. PTBP1 binds to the 3?UTR of mRNAs, modulating miRNA-mediating 
gene regulation [Bart Engels et al., 2012]. To conclude, in the course of my PhD thesis I have 
characterized a novel RNP regulatory complex, consisting of  RNA-binding proteins IMP3, 
ILF3/NF90 and PTBP1. This complex binds to the mRNAs of cyclins D1 and D3 and protects 
these mRNAs from GW182/AGO2/miRNA dependent translational repression, thus ensuring 
continuous proliferation of human cancer cells.  
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PERSPECTIVES	  	  
1. IMP3 does not have a clearly defined binding sequence within its target RNAs, and it is 
hard to predict its binding sites. Our goal was to map the exact sites within the cyclins 3’ 
UTRs, where the IMP3 binding competes with the RISC complex. We identified the 
functional fragments of 250 nt, where IMP3 binding competes with miRISC. In perspective, 
we can continue to cut these fragments in order to get an IMP3 pattern and compare it with 
the results of other methods (PAR-CLIP and others, bioinformatic approaches). By analyzing 
predicted miRNAs sites located near experimentally determined IMP3 target sequences, we 
can hypothesize the « hot spots » of translational regulation within the 3’ UTRs of the target 
mRNAs, and then validate their functional significance by luciferase assays combined with 
mutations of miRNA sites and putative target sites of IMP3 complexes.  
2. Our results indicate that IMP3 partners ILF3/NF90 and PTBP1 are important for CCND1 
and CCND3 expression. However, NF90 is an RNA-dependent partner of IMP3, and could 
bind the mRNAs either as part of IMP3 complex, or independently, for examples after the 
RNA structure was changed by IMP3-PTBP1 binding. When the target sequence for IMP3 
complexes within the 3’ UTRs of the cyclins is characterized, it will be possible to elucidate 
these molecular events, their order and their relative importance for the competition with 
GW182. 
3. It will be interesting to see how IMP3 physically interacts with its targets, as it has been 
shown for ZBP1 (IGF2BP1/IMP1 homolog), which binds to and regulates ?-Actin mRNA. 
Especially, which domains of IMP3 and its partners are essential for initial mRNA binding 
and which ones are important for IMP3-mRNA complex stabilization in vivo. Structural 
analyses of subsequent protein–RNA co-crystals will be required for this approach. 
4. Since 2007, there were an ‘explosion’ of reports, observing upregulation of IMP3 
expression in various malignancies, correlating with tumor aggressiveness and metastasis. 
However, a pro-oncogenic role of IGF2BPs remains controversial due to the lack of 
‘classical’ in vivo studies, involving transgenic mouse models. Using these models, we can 
analyze the role of IMP3 in cancer and validate in vivo a number of in vitro studies of  its 
multiple mRNA targets regulation, among which are oncogenic factors (IGF2, MYC and 
others). 
5. We have shown that IMP3 and RISC complexes can compete for cyclin D1 and D3 
3`UTRs regulation. IMP3 can regulate cyclin 3`UTR length via alternative cleavage and 
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polyadenylation, resulting in a loss of miRISC binding sites. To test this hypothesis, we can 
perform analysis of alternative cleavage and polyadenylation of cyclin D1 and D3 mRNAs. 
IMP3 or another protein in its absence can regulate a polyA tail length. PolyA tail length 
positively correlates with miRISC association with mRNA via PABP. And to this case, it will 
be interesting to use several methods for measuring the length of the cyclin mRNA poly(A) 
tail. 
6. In the long term, it will be interesting to explore the presence of secondary structures within 
3’ UTRs of the cyclins mRNAs, and to identify all clusters of motifs consisting of 
cytoplasmic polyadenylation elements (CPEs), AU-rich elements and another elements, such 
as the IMP3 complex target sites. Our work has clearly shown that these mRNAs are a 
convenient model for studies of post-transcriptional regulation of gene expression. A full 
« post-transcriptional interactome » of the 3’ UTRs of the cyclins can serve as a blueprint of 
future studies in the filed.  	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Titre : Le complexe IMP3 protège ses ARNm cibles de la répression traductionnelle dépendante de 
Argonaute/GW182/miRNA. 
Mots clés : IMP3, miRISC, les ARNm de cyclines. 
Résumé : IMP-3 est difficilement détectable dans des 
tissus adultes normaux, mais il est surexprimée dans les 
nombreux cancers, où il a été rapporté comme un 
marqueur d’agressivité et de la croissance rapide tumorale, 
ainsi que d’un pronostic défavorable pour les patients. 
Dans notre recherche, nous avons utilisé un lignée 
cellulaire RD de rhabdomyosarcome (RMS), ou IMPs 
étaient décrits comme des protéines régulatrices de l’ARN 
de IGF-2. Nous avons essayé d’élucider le mécanisme par 
lequel IMP3 régule l’expression des cyclines D1 et D3, 
contribuant ainsi à la compréhension des processus 
oncogéniques dans RMS. 
Nous avons montré que IMP3 régule l'expression des 
cycline D1 et D3 d'une manière significative in vivo. Nous 
avons également démontré, qu'en absence de IMP3, les 
ARNm des cyclines sont exportés vers le cytoplasme et 
associés avec les polyribosomes, mais ne sont  pas traduits.  
En outre, l'inhibition d`IMP3 n'a pas d'influence à la 
stabilité des ARNm des cyclines. 
 
Nous démontrons que, dans des cellules cancéreuses 
humaines, IMP3 interagit avec plusieurs protéines liant 
l'ARN, ce qui suggère l'existence d'une complexe 
régulatrice sur les 3'UTR des cyclines D1 et D3. 
Nos résultats montrent que l'inhibition de deux protéines 
clés de RNA-induced silencing complex (Ago2 et 
TNRC6), délivrent les niveaux d'expression des cyclines 
D1 et D3, qui ont été considérablement diminué en 
abscence d’IMP3 ou de ses partenaires protéiques. Par 
conséquent, les complexes d`IMP3 et RISC peuvent 
concourir pour la régulation des ARNm des cyclines. Nous 
avons également identifié des miARNs, qui peuvent être 
impliqué dans ce processus et régions fonctionnelles dans 
les 3 'UTR des cyclines, où se passe la competition entre 
IMP-3 et RISC complexes. 
 Nos résultats sont compatibles avec l'existence de IMP3 - 
contenant complexe multiprotéique, qui est associé à 
3'UTRs des cyclines et régule leur traduction en les 
protégeant contre la répression traductionnelle par 
miRISC. 
 
 
 
Title : IMP3 complex protects its target mRNAs from Argonaute/GW182/miRNA dependent 
translational repression. 
Keywords : IMP3, miRISC, cyclin mRNA. 
Abstract : IMP-3 is hardly detectable in normal adult 
tissues, but is overexpressed in many cancers, where it has 
been reported as a marker of tumor aggressiveness, rapid 
growth, and bad prognosis for patients. In our research we 
utilized a rhabdomyosarcoma (RMS) cell line RD, where 
IMPs were first described as IGF-2 mRNA regulating 
proteins. We tried to elucidate the mechanism by which 
IMP3 regulates cyclins D1 and D3 expression, thereby 
contributing to the understanding of oncogenic processes 
in RMS. 
We have shown that IMP3 regulates the expression of 
cyclin D1 and D3 in a significant manner in vivo. We also 
demonstrated, that in the absence of IMP3, the mRNAs of 
the cyclins are exported to the cytoplasm and associated 
with polyribosomes, but not translated. Moreover, IMP3 
inhibition does not influence a stability of cyclin mRNAs.  
We demonstrate, that in human cancer cells, IMP3 
interacts with multiple RNA-binding proteins, suggesting 
the existence of regulatory RNP complex on the 3’UTR of 
the cyclin D1 and D3. 
Our results show that an inhibition of two key proteins of 
RNA-induced silencing complex 
(Ago2 and TNRC6),  rescue the cyclin D1 and D3 protein 
expression levels, which were significantly decreased in 
the absence of IMP3 or its protein partners. Therefore, 
IMP3 and RISC complexes can compete for cyclin 
mRNAs regulation. We also identified a miRNAs, that 
can be involved in this process and functional regions 
within 3’ UTRs of the cyclins, where a competition 
between IMP-3 and RISC complexes occurs. 
Our results are consistent with the existence of IMP3 - 
containing  multiprotein complex, which is associated 
with 3’UTRs of the cyclins and  regulates their translation 
by protecting them from miRISC-dependent translational 
repression. 
 
 
 
La synthese de la these en francais. 
Introduction. 
Les protéines se liant à l’ARN de la famille IMP 1, 2, et 3 (IGF2BP / IMP1-3) appartiennent à 
une famille conservée des protéines 'onco-foetales'. Leurs principales fonctions sont de 
réguler le transport, la stabilité et / ou la traduction des plusieurs ARNm. IMP sont fortement 
exprimés lors de l'embryogenèse et sont souvent régulés à la hausse dans un certain nombre 
de cancers. Selon plusieurs études, ces protéines 'onco-foetales' contrôlent la prolifération 
cellulaire, la différenciation, la migration, la polarisation et d`autres nombreux processus 
cellulaires. IMP3 est difficilement détectable dans les tissus adultes normaux, mais il est 
surexprimé dans de nombreux cancers, où il a été décrit comme un marqueur de l'agressivité 
tumorale, de la croissance rapide, et du mauvais pronostic aux patients. Des études antérieures 
effectuées par notre groupe ont montré que IMP3 lie l'ARNm des cyclines D1, D3 et régule 
positivement l'expression des cyclines sur le niveau de la protéine. Ce phénomène a été 
observé dans plusieurs lignées cancéreuses humaines. Dans cette étude, nous montrons que, 
en l'absence de IMP3, les ARNm des cyclines sont exportés vers le cytoplasme et associés 
avec polyribosomes, mais ne sont pas traduits. IMP3 inhibition n'a aucune influence sur la 
stabilité des ARNm des cyclines, et l'expression des cyclines peut être complètement inversée 
par une inactivation simultanée de GW182, une protéine essentielle pour la répression de la 
traduction par le complexe RISC. De plus, nous avons montré que dans les cellules 
cancéreuses humaines, IMP3 interagit avec des protéines liant l'ARN ILF3/NF90 et PTBP1, 
qui co-régulent l'expression des cyclines. Prises dans leur ensemble, nos résultats sont 
cohérents avec l'existence du complexe multiprotéique contenant IMP3, NF90 et PTBP1, qui 
se lie à des régions spécifiques des 3'UTRs des cyclines et les protège de la répression 
traductionnelle miRNA-dépendante. 
 
IMP3 régule l`expression des cyclines D1 et D3 au niveau post-transcriptionnel. 
Protéines se liant l'ARN dans les cellules s’associent à leurs ARNm cibles, résultant en 
formation des complexes de ribonucléoprotéine (mRNP). La composition de ces complexes 
détermine le destin cellulaire des ARNm: la localisation, la traduction et la dégradation. IMP 
forme des associations protéines-ARNm stables qui peuvent prévenir la dégradation 
prématurée et la traduction promiscuitée des transcriptes spécifiques, comme cela a été 
montré pour CD44, MYC, PTEN ou BTRC [Lemm I et J Ross, 2002; Kobel M et al., 2007; 
Stohr N et al 2012. Vikesaa J et al., 2006; Noubissi FK et al., 2006]. En réglant ces ARNm, 
IMP3 a été reporté comme un promoteur de la progression tumorale et des métastases dans un 
certain nombre des tumeurs malignes. 
Nous avons précédemment montré que IMP3 régule l'expression de la cycline D1 et D3 a la  
manière significative in vivo. Durée de la vie des cyclines est généralement courte avec de 
deux à quatre fois demi-vies plus courtes que leurs ARNm messagers, ce qui les rend les 
modèles pratiques pour des études mécanistiques de la régulation post-transcriptionnelle de 
l'expression des gènes. Par conséquent, mon projet de thèse vise à identifier les mécanismes 
moléculaires de la régulation de l'expression des cyclines par IMP3. Après une knock-down 
(KD) d`IMP3, nous avons observé une diminution rapide et significative des cyclines au 
niveau des protéines, mais pas au niveaux d'ARNm, ce qui suggère que la régulation de 
l'expression des cyclines par IMP3 se produit au niveau post-transcriptionnel. Comme la 
possibilité d'une forte dégradation des proteines des cyclines dans les cellules IMP3 KD a été 
exclue par des études antérieures dans mon laboratoire, la principale hypothèse du mon projet 
était une implication de la répression traductionnelle comme le principal mécanisme de la 
régulation des cyclines par IMP3. 
Les protéines se liant à l’ARN peuvent interagir avec leurs ARNm cibles a la manière co-
transcriptionnel dans le noyau et réguler leur localisation et la traduction, comme il a été 
montré pour IMP1 et Bruno [Chanteur RH, 2003; Snee M et al., 2008]. Une étude précédente 
réalisée dans mon groupe a montré que IMP3 avec une aide de la protéine 
nucleocytoplamique HnRNP M peut entrer dans le noyau et se lier les transcrites des cyclines 
nouvellement synthétisées [Rivera Vargas, Boudoukha et al. 2014]. Nous avons adressé une 
question si les ARNm des cyclines ont un problème avec leur export nucléaire en absence 
d`IMP3. Cependant, nous avons constaté que l'export nucléaire des cyclines ne dépend pas 
d`IMP3, et que leur ARNm ont été exportés dans le cytoplasme et sont associés avec des 
polysomes même en absence d`IMP3. Cependant, dans les cellules IMP3 KD les ARNm des 
cyclines semble avoir localisation préférentiellement périnucléaire. Il est à noter qu'une telle 
localisation peut être une conséquence de l'inhibition de la traduction de ces transcrits par un 
complexe de silençage induit par ARN (RISC), qui est enrichi dans les régions périnucléaires 
des cellules de mammifères (Stalder L et al., 2013). 
 
La interaction entre les protéines se liant à l’ARN et les miARN sur la 3` UTRs de 
l`ARN. 
La région 3'UTR de l'ARNm, en jouant un rôle important dans la régulation post-
transcriptionnelle de l'expression génique, contrôle cette expression par une diaphonie entre 
les composants structurels de l'ARNm (cis-éléments) et les facteurs agissant en trans (miRNA 
ou les protéines se liant à l’ARN). Ces molécules peuvent se lier aux sites communs ou 
distincts de la cible d'ARNm, de manière compétitive. Les protéines se liant à l’ARN et 
miARNs peuvent réguler la traduction et la stabilité de l'ARNm à la manière positive ou 
négative. En même temps, ils peuvent coopérer ou être antagonistes dans leur actions, et le 
résultat final dépend de la collective de nombreuses circonstances, telles que leur niveau 
d'expression, l'affinité pour des sites de liaison, et la localisation dans la cellule, qui peuvent 
être régulés par de différentes conditions physiologiques. 
 
La coopération entre les miARN et les protéines se liant à l’ARN sur la région 3`UTR de 
l'ARNm. 
Les protéines se liant à l’ARN participent activement à la régulation miARN-dépendante de 
l'expression génique. Par exemple, les protéines Pumilio (PUM1 et PUM2) collaborent avec 
plusieurs miARNs et agissent comme des guides qui interviennent dans l'ouverture de la 
structure secondaire d'ARNm, permettant des interactions entre miARN et leurs sites de 
liaison. Une étude comparative des sites cibles de Pumilio au sein de l'ARNm, en utilisant 
RIP-CHIP et PAR-CLIP dans les cellules humaines, a montré un enrichissement pour les sites 
de reconnaissance par miARN dans les séquences voisines des sites de liaison de Pumilio, ce 
qui suggère une interaction généralisée des protéines Pumilio humains avec les systèmes 
miRNA-dépendantes [Galgano A. et al., 2008]. 
Kedde et collaborateurs [Kedde M et al., 2010] ont mis en évidence dans la lignée cellulaire 
de cancer du sein MCF7, que Pumilio favorise les effets inhibiteurs de miR-221/222 sur le 
p27Kip1 ARNm par l'ouverture de la structure secondaire de la 3'UTR de p27Kip1, 
permettant l'accès de miR-221/222 à son site de liaison. 
Un modèle élégant a été proposé pour une action coopérative de HuR et let-7 sur la région 3 
'UTR de c-Myc [HH Kim et al., 2009]. HuR peut lier la 3 'UTR de l'ARNm de c-Myc dans 
une position proche de let-7 ce qui réduit l'expression de c-Myc. L'activité de let-7 est 
dépendante de Hur, et l'activité de Hur dépend de let-7. Les auteurs ont découvert que la 
liaison HuR modifie la conformation locale de l'ARNm et favorise l'association de let-7 avec 
l'ARNm de c-Myc, en démasquant site de reconnaissance par let-7. 
Les protéines se liant à l’ARN peuvent interagir directement avec AGO et recruter le 
RISC. 
Le complexe RISC peut avoir une interaction physique directe avec les protéines se liant à 
l’ARN. Dans une première étude, Caudy et ses collègues ont démontré que le complexe RISC 
chez la drosophile contient des protéines qui associent avec des éléments riches en AU, 
comme la protéine FXR1 [Caudy AA et al., 2002]. La réduction de FXR1 dans des cellules 
S2 de Drosophile a entraîné le silencing d’ARNi moins efficace. D'autres travaux ont 
confirmé que FXR1 associés avec Ago2 dans des cellules mammifères [Jin P et al., 2004]. La 
découverte d'une interaction fonctionnelle entre FXR1 et Ago2 conduit à des suggestions qui 
soit les protéines se liant a l’ARN sont ciblées sur leurs ARNm par l'ARNi complexe [Caudy 
AA et al., 2002], soit FXR1 scanne pour le G quartet, précédemment rapporté comme un site 
de reconnaissance par FXR1, et recrute le RISC ensuite. 
Les protéines se liant à l'ARN contre les fonction des miARN sur la 3`UTR. 
L'activité de miARN peut également être inhibée par les protéines se liant à l’ARN, par une 
mécanisme de la compétition pour les sites de liaison commune sur la région 3'UTR. DND1, 
une protéine de liaison à l'ARN qui assure la médiation la viabilité des cellules germinales et 
supprime la formation de tumeurs germinales [Kedde M et al., 2007], a été montrée pour 
interagir avec les extrémités 3 'UTR de l'ARNm p27Kip1 et de l’ARNm LATS2. DND1 lie 
ces ARNm et interfère avec la fonction des miARNs, en aidant à maintenir les niveaux des 
protéines p27Kip1 et LATS2 (les suppresseurs de tumeurs) dans une lignée cellulaire de 
tumeur des cellules germinales et dans le carcinome épidermoïde, inhibant ainsi la 
tumorigenèse. Généralement, il existe deux mécanismes d'action de DND1: liaison de DND1 
peut entraîner la formation de structure secondaire sur ARNm qui rend inaccessibles les sites 
de reconnaissance des miARN, ou encore, la liaison de DND1 peut changer une localisation 
subcellulaire de l’ARNm, en la rendant inaccessible au complexe RISC. 
Un autre exemple d'interactions antagonistes intéressant entre les protéines se liant à l’ARN et 
miARN a été démontrée par Bhattacharyya SN et Filipowicz W. Ils ont effectué une étude 
élégante qui démontre que la répression par miARN est une processus réversible. La 
régulation négative du transporteur cationique d'acides aminés 1 (CAT-1) ARNm par miR-
122 a été inhibée par le stress, qui en meme temps a favorisé l'élévation du niveau de Hur 
cellulaire, principalement nucléaire, et permet son entrée dans les P-bodies cytoplasmiques 
(structures de dégradation d’ARNm), la liaison à la séquence spécifique riche en AU de CAT-
1 et à la relocalisation de CAT1 ARNm à partir des P-bodies à polysomes [SN Bhattacharyya 
et al., 2006]. Récemment, les mêmes auteurs ont démontré un mécanisme d'action possible de 
HuR sur la région 3 'UTR de CAT-1. Comme les AREs Hur sont positionnés à une distance 
considérable des sites des miRNA, HuR favorise le soulagement de la répression par miARN 
à distance par un processus impliquant probablement HuR oligomérisation [Kundu P et al., 
2012]. 
Par conséquent, les protéines se liant à l’ARN peuvent interagir directement avec le complexe 
RISC (RNA-induced silencing complex), soit stabilisant la liaison de celui-ci avec des ARNm 
cibles, soit antagonisant les fonctions des miRNA. 
 
Fig.1. Intéractions des miRNA avec les protéines se liant à l’ARN dans la régulation de la 
même ARNm [de Ciafrè SA et al., 2013, avec les modifications]. 
A) La Coopération: coté gauche: les protéines se liant à l’ARN peuvent favoriser la fonction 
des miARN en ouvrant une structure secondaire, ce qui permet l'interaction entre miRNA et 
ce site cible au sein de la région 3`UTR. Sur la coté droite: les protéines se liant à l’ARN 
peuvent recruter les composants du complexe RISC vers la région 3`UTR et stabiliser leur 
liaison par l’interaction directe avec des composants du RISC. B) La compétition: les 
protéines se liant à l’ARN peuvent interférer avec la fonction des miARN via la concurrence 
pour le même site de liaison. Dans le contexte des sites qui ne se chevauchent les protéines se 
liant à l’ARN peuvent changer la structure locale de l'ARNm et prevenir la liaison avec 
miARN. 
 
 
IMP3 rivalise avec un complexe RISC pour la régulation des cyclines D1 et D3. 
Nous avons supposé que la répression des cyclines, observée en l'absence d`IMP3, peut être 
causé par l'action du miRISC. Le miRISC minimale des mammifère est composé de deux 
facteurs clés: de la protéine GW182/TNRC6 qui servent comme un plate-forme moléculaires 
et lient une multitude d'effecteurs de silençage, et de la protéine Ago2 associés avec miARN. 
Dans la majorité des études publiées, miRISC a été détecté comme un inhibiteur de la 
traduction au niveau de initiation et comme un promoteur de la dégradation d`ARNm cible 
[Humphreys et al., 2005; Mathonnet et al., 2007; Pillai et al., 2005; Wakiyama et al., 2007; 
Wang et al., 2006]. Cependant, miRISC peut également réguler la traduction au niveau de 
post-initiation, en promouvant la dégradation co-traductionnelle des peptides [Nottrott S et al., 
2006], la terminaison prématurée de la traduction par un drop-off ribosomique [Petersen CP et 
al., 2006] et l`élongation altérée [Gu S et al., 2009]. Nous avons constaté que la diminution 
des cyclines D1, D3 après IMP-3 KD peut être inversée par KD de deux éléments clés du 
complexe RISC: GW182 et Ago2. Dans tous les cas, l'inactivation de la machinerie d'ARNi 
conduit à une ré-expression des cyclines, même en absence d'IMP-3. Les partenaires d`IMP3, 
PTBP1 et NF90, peuvent agir de la même manière. Ces résultats clés nous ont amenés à 
conclure que IMP3 et ses partenaires protéiques, en particulier NF90 et PTBP1, peuvent 
protéger leurs ARNm cibles de la répression RISC-dépendante dans les cellules cancéreuses 
humaines. 
 
L`identification des régions fonctionnelles dans les 3 'UTRs des cyclines, où une 
concurrence entre les complexes IMP-3 et RISC a lieu. 
L'étude de l'interaction entre IMP3 et ses cibles est très complexe en raison de l'absence d'une 
séquence unique de liasion par IMP3. En outre, la structure secondaire de l'ARNm semble 
également jouer un rôle important dans la reconnaissance de ses cibles par IMP3 [FC Nielsen 
et al., 2002]. Dans ce cas, la liaison est basée sur l'identification des structures d'ARNm plutôt 
que sur la séquence nucléotidique d`ARNm. Un grand nombre de miARN sont prédits pour 
cibler les cyclines D1 et D3, mais ils ne sont pas confirmés expérimentalement. Par 
conséquent, nous avons décidé de chercher expérimentalement les sites fonctionnels dans les 
3 'UTR des cyclines, où a lieu la concurrence de liaison entre IMP-3 et le complexe RISC. En 
utilisant la technique ARN-protéine biotine pulldown, nous avons identifié les régions liées 
par des composants de complexe RISC (GW182 et Ago2) et IMP3. Parmi eux, nous avons 
identifié des régions fonctionnelles, où l'efficacité de liaison des composants du complexe 
RISC augmente après IMP3 KD et la concurrence se produit. Ensuite, nous avons montré in 
vivo, que la transfection de ces fragments d'ARN, mais pas des régions adjacentes dans les 
cellules IMP3 KD, provoque un «rescue» partiel ou complet de l'expression des cyclines. Ces 
résultats confirment notre hypothèse selon laquelle complexes IMP3 protège les 3'UTRs des 
cyclines de la répression traductionnelle,  GW182 / Ago2 dépendente. 
 
La caractérisation des IGF2BP-complexes cytoplasmiques. 
IGF2BP / IMP protéines sont principalement exprimés dans le cytoplasme, où ils se lient à 
leurs ARNm cibles en formant des complexes de ribonucléoprotéine (mRNP cytoplasmiques), 
qui sont préférentiellement dispersées autour du noyau [Nielsen et al., 2002]. Ces granules 
mRNP régulent la traduction, la stabilité et le transport des ARNm associés. Contrairement à 
d'autres granules bien connus, comme neuronale hStaufen et / ou fragiles X granules de 
protéines de l'arriération mentale, les P-bodies, et les granules de stress [Jonson et al., 2007], 
les granulés IMP manquent eIF4E, eIF4G et 60S sous-unités ribosomiques, et contiennent des 
facteurs d`exon-jonction complexes et CBP80, ce qui suggère que les ARNm associés ont 
jamais été traduits. 
IGF2BPs commencent à contrôler leurs ARNm cibles co-transcriptionnellement dans le 
noyau en modulant la distribution de transcrits associés entre les machineries de la traduction 
et de la dégradation et peuvent prévenir l`attaque des microARN en recrutant des transcrits 
régulés dans mRNP cytoplasmiques. Ainsi, Vg1 RBP / Vera (homologue de IMP3 chez 
l`Homme) regule le transport d`ARNm Vg1 pour le cortex végétal de ovocyte de Xenophus 
[Kress et al., 2004]. ZBP1 (un homologue de IMP1 chez le poulet) favorise la localisation de 
bêta-actine aux extrémités de la culture de cellules neuronales [Oleynikov Y et Singer SH, 
2003]. Pendant le transport, ZBP1 empêche la traduction prématurée de la bêta-actine, en 
inhibant son initiation traductionelle. En liant MYC et MDR1 dans les complexes de mRNP, 
IGF2BP1 les protège du clivage endonucléolytique et de la dégradation [Lemm I et J Ross, 
2002; Sparanese D et Lee CH, 2007]. IGF2BP1 améliore également l'expression de BTRC1 
en protégeant son transcript de la dégradation microARN dépendante [Elcheva et al., 2009]. 
Un mécanisme similaire qui se compose de la formation des granules IMP1/3 et de la 
stabilisation de l`ARNm HMGA2 en le protégeant contre la dégradation let-7-dépendante, a 
été proposé pour IMP3 [Jonson et al., 2014]. Il est intéressant de noter que ces granules 
contenant IMP3 manquent facteurs d'initiation de la traduction (eIF4E), complexe RISC 
(AGO 1-4, miARN) et les composants de la machine de la dégradation (DCP1a). Outre 
HMGA2, les granules IMP1/3 protégent une variété d'autres ARN cibles de miARN, les 
rendant inaccessibles au RISC [Jonson et al., 2014]. 
La revue de la littérature récente suggère que IGF2BPs participent à un réseau d'interactions 
ARN-protéine et protéine-protéine, ce qui suggère un grand nombre de diverses complexes 
réglementaires mRNP contenant IMPs. Cette observation est en accord avec le modèle 
d`ARN opéron post-transcriptionnel proposé par Keene et Tenenbaum (2002), selon lequel 
toute ARN contient multiples sites de liaison pour diverses protéines liant l'ARN. Un 
ensemble et fonctions differentes des protéines se liant à l`ARN, liés à des séquences 
spécifiques sur un ARNm, détermine leur différent destin cellulaire. Par conséquent, les 
ARNm contenant cis-éléments similaires peuvent être réglés conjointement dans la 
composition de ces régulons post-transcriptionnels [Jonson et al., 2011]. 
Selon nos résultats, IMP3 co-interagi avec des multiples protéines se liant à l`ARN dans les 
cellules cancéreuses humaines et régule positivement la traduction des cyclines D1 et D3, en 
protégeant leur ARNm du GW182 / Ago2 / miARN-dépendante répression. Ce mécanisme 
réglementaire, spécifique à IMP3 mais pas aux autres membres de sa famille, IMP1 et IMP2, 
reste entièrement réversible et très dynamique, car il ne se compose pas du changement de la 
stabilité de l'ARNm et ne comporte pas de novo transcription de l'ARNm. Deux partenaires 
protéiques d`IMP3, PTBP1 et ILF3 / NF90, ont un fort impact sur les niveaux d'expression de 
protéines des cyclines. Les rôles de ces partenaires d`IMP3 pourraient être élucidés par des 
études récentes qui suggèrent que ILF3 / NF90 régule à la fois la traduction et la stabilité des 
ARNm grâce à l'interaction coopérative ou antagoniste avec l'action du miRISC [Shim J et al., 
2002; Xu YH et al., 2000; Xu YH et al., 2003]. PTBP1 se lie à 3'UTR de l'ARNm, en 
promotant la modulation miARN-dépéndantes de la régulation des gènes [Bart Engels et al., 
2012]. Pour conclure, dans le cadre de ma thèse de doctorat, j'ai caractérisé un nouveau 
complexe régulateur RNP, constitué des protéines liant l'ARN comme IMP3, ILF3 / NF90 et 
PTBP1. Ce complexe se lie à l'ARNm des cyclines D1 et D3 et protège ces ARNm de la 
répression traductionnelle GW182 / Ago2 / miRNA dépendante, assurant la prolifération 
continue des cellules cancéreuses humaines. 
Basé sur les résultats de notre étude, nous avons proposé un modèle selon lequel IMP-3 et ses 
partenaires se lient les ARNm de CCND1 et D3 dans les cellules cancéreuses humaines, et cet 
événement rend ces transcrits compétents pour la traduction en les protégeant contre la 
répression traductionnelle par miRISC action. 
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Fig .2. Le modèle proposé pour la régulation de l’éxpression des cyclines par le mécanisme de 
la compétition entre les complexes IMP3 et RISC. 
Les perspectives. 
1. Le IMP3 n'a pas de séquence de liaison pour ses ARN cibles clairement définies, et il est 
difficile de prédire ses sites de liaison. Notre objectif était de « cartographier » les sites exacts 
des 3 'UTR des cyclines, où il y a une concurrence pour la liaison entre les complexes RISC et 
IMP3. Nous avons identifié les fragments fonctionnels de 250 nt, où IMP3 concurre avec 
miRISC. En perspective, nous pouvons continuer à réduire ces fragments afin d'obtenir un site 
de liasion d’IMP3 et la comparer avec les résultats d'autres méthodes (PAR-CLIP et d'autres, 
les approches bioinformatiques). En analysant les sites des miARN prévus près des séquences 
d'IMP3 expérimentalement déterminées, nous pouvons identifier les «points chauds» de la 
régulation de la traduction des ARNm cibles, et valider leur signification fonctionnelle par des 
essais de luciférase combinés avec des mutations des sites des miRNA et/ou  des putatifs sites 
d’IMP3 complexe. 
2. Nos résultats indiquent que les partenaires d’IMP3, ILF3/NF90 et PTBP1, sont importants 
pour l’expression des CCND1 et CCND3. Cependant, NF90 est un partenaire l'ARN-
dépendant de IMP3, et pourrait lier les ARNm soit dans la composition du complexe IMP3, 
ou indépendamment, après la modification de la structure de l'ARN par la liaison IMP3-
PTBP1. Lorsque la séquence de la liasion pour le complexe IMP3 sera caractérisée, il sera 
possible d'élucider ces événements moléculaires, leur ordre et leur importance relative pour la 
concurrence avec RISC. 
3. Il sera intéressant de voir comment IMP3 interagit physiquement avec ses ARNm, comme 
il a été montré pour ZBP1 (IGF2BP1 / homologue de IMP1), qui se lie à l’ARNm de β-actine. 
Surtout, il est intéressant de déterminer les domaines de IMP3 et ses partenaires qui sont 
essentiels pour la liaison de l'ARNm et ceux qui sont importants pour la stabilisation de 
complexe IMP3-ARNm in vivo. Les analyses structurales de protéines-ARN et des études de 
co-crystallisation seront nécessaires pour cette approche. 
4. Depuis 2007, il y avait une «explosion» des rapports, qui ont observé une régulation 
positive de l'expression d’IMP3 dans diverses tumeurs malignes, qui est en corrélation 
positive avec l'agressivité des tumeur et les métastases. Cependant, un rôle pro-oncogénique 
de IGF2BPs reste controversé en raison de l'absence des études «classiques»  in vivo, 
impliquant des modèles des souris transgéniques. En utilisant ces modèles, nous pouvons 
analyser le rôle des IMP3 dans le cancer et de valider in vivo un certain nombre d'études in 
vitro de régulations de ses multiples ARNm cibles, parmi lesquels sont des facteurs 
oncogènes (IGF2, MYC et autres). 
5. Nous avons montré que les complexes IMP3 et RISC peuvent concourir pour la régulation 
des 3`UTRs des cyclines D1 et D3. IMP3 peut régler la longueur de la région 3`UTR des 
cyclines par un clivage alternatif et une polyadénylation, résultant en une perte de sites de 
liaison avec miRISC. Pour tester cette hypothèse, on peut effectuer des analyses de clivage et 
polyadénylation alternative des ARNm des cyclines D1 et D3 en presence ou en absence 
d’IMP3. En absence d’IMP3, une autre protéine peut réguler une longueur de la queue polyA. 
La longueur de la queue PolyA est positivement corrélée avec l'association de miRISC avec 
l'ARNm via PABP. Et pour ce cas, il sera intéressant d'utiliser plusieurs méthodes pour 
mesurer la longueur de la queue poly (A) des cyclines. 
6. Dans le long terme, il sera intéressant d'explorer la présence des structures secondaires dans 
les 3 'UTR des cyclines, et d'identifier toutes les grappes de motifs constitués d'éléments de 
polyadénylation cytoplasmique (CPE), des éléments riches en AU et autres éléments , tels que 
les sites de liasion du complexe IMP3. Notre travail a clairement montré que ces ARNm 
présentent un modèle idéal pour les études de régulation post-transcriptionnelle de 
l'expression génique. Un plein «interactome post-transcriptionnelle» de 3 'UTR des cyclines 
peut servir comme un modèle des futures études dans le domaine. 
Nous aimerions trouver d'autres ARNm, régulés par IMP3 par le mécanisme que nous avons 
décrit pour CCND1 et CCND3. Des études antérieures dans mon laboratoire ont montré que 
ce mécanisme dépend de la import nucléaire d’IMP3, et à cela, il serait intéressant d'identifier 
tous les ARNm enrichis en IMP-3 complexes des fractions nucléaires purifiées, et d'analyser 
leur régulation par IMP-3. CCND1 et D3 peuvent servir comme les controles positifs dans 
cette étude. 
Par la suite, il sera intéressant d'identifier les éléments structurels au sein des ARNm, qui 
déterminent leur régulation par une concurrence entre IMP3 et RISC. En utilisant les 
techniques que j’ai mis en route au cours de mon travail de thèse, il sera possible de 
caractériser les protéines se liant à l'ARN et les miARN impliqués dans ce mécanisme de 
régulation. Ainsi, un effet général du phénomène que nous avons décrit pour l'ARNm de 
CCND1 et D3 peut être évalué dans le contexte de la prolifération cellulaire et l'oncogenèse. 
 
